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Congenital heart defects (CHDs) arise from perturbations in complex molecular and 
cellular processes underlying normal embryonic heart development. CHDs are the most 
common congenital malformation, occurring in 1 to 5% of live births, and are the leading 
cause of pediatric mortality. Adverse genetic and environmental factors can impede normal 
cardiogenesis, and increase the likelihood of CHDs. Pregestational maternal diabetes 
increases the risk of CHDs in children by more than four-fold. As the prevalence of diabetes 
rapidly rises among women of childbearing age, there is a need to investigate the 
mechanisms and potential preventative strategies for these defects. The aim of this thesis was 
to explore the pathogenesis of pregestational diabetes-induced CHDs and coronary artery 
malformations (CAMs), while testing the efficacy of two clinically relevant 
pharmacotherapies. To this end, using a mouse model of pregestational diabetes, I examined 
the impact of hyperglycemia-induced elevations in oxidative stress and miR-122 on heart 
development, concurrently determining the preventative capabilities of sapropterin or 
antimiR-122 treatment. I confirmed that pregestational diabetes results in spectrum of CHDs, 
CAMs and cardiac function deficits, and that their incidence is significantly lowered with 
either sapropterin or antimiR-122. Specifically, sapropterin treatment lowered the incidence 
of CHDs and CAMs from 59% and 50% to 27% and 21%, respectively. Similarly, antimiR-
122 therapy reduced this incidence of CHDs from 57% to 23%. These morphological 
malformations range in severity, and include septal and outflow defects (OFT), myocardium 
deficiencies, and hypoplastic coronary arteries. Lineage tracing experiments revealed a 
diminished commitment of second heart field progenitors to the OFT, endocardial cushions 




cardiogenic gene expression, enzyme activity, cell proliferation, and epicardial EMT, 
induced by pregestational diabetes, contribute to these defects, and were prevented by both 
treatments. Specifically, sapropterin treatment reestablished the functional eNOS dimer and 
restored its phosphorylation in embryonic hearts of diabetic dams, leading to normal 
cardiovascular development. Conversely, antimiR-122 attenuated the targeting and inhibition 
of key genes responsible for cardiogenesis by miR-122. These results suggest that 
sapropterin and antimiR-122 may have therapeutic potential in preventing CHDs in children 
of women with pregestational diabetes. 
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 The most common birth defects are congenital malformations of the heart, accounting 
for 1-5% of live births. Newborns with congenital heart defects have an increased risk of 
mortality, as proper function of the heart is compromised when specific development is not 
attained during gestation. Congenital heart defects can go unnoticed by doctors at birth, 
however, as the child matures and is involved in increasing amounts of physical activity, the 
congenital malformations can manifest themselves. Therefore, it is vital that research be 
conducted into how and why these malformations develop, and more significantly, what 
remedies during pregnancy can prevent their occurrence. In terms of how these defects arise, 
it has been previously shown that pregestational diabetes in the mother increases the risk for 
congenital heart defects in the child by over 50%. Studies in animal models have confirmed 
diabetes as a risk factor for newborns with malformed hearts. This connection is alarming as 
the incidence of diabetes in a younger demographic is seemingly increasing. This is also true 
for the female population, specifically in North America. More and more women are being 
diagnosed as diabetic at a younger age, and if these women have children, their offspring 
may have a serious, life-threatening medical condition. Therefore, it is beneficial not only to 
the lives of these children, but also to the health-care system to find a solution to this 
problem. This research will attempt to do just that, as we will investigate whether 
administration of sapropterin or antimiR-122 will decrease the presence of heart defects in 
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Chapter 1  
1 Introduction 
1.1 Pregestational Diabetes 
 Diabetes is a major health problem, currently affecting 451 million people 
globally. The number of diabetic patients is estimated to reach 693 million by 2040.1 In 
Canada, more than 11 million people are living with diabetes or prediabetes.2 Diabetes 
has two subtypes. Type 1 diabetes (T1D) is also called juvenile or insulin-dependent 
diabetes. In T1D, pancreatic beta cells produce little or no insulin, the hormone that 
allows glucose to enter the cells, resulting in hyperglycemia. Type 2 diabetes (T2D) is 
often associated with obesity and peripheral insulin resistance. In T2D, hyperglycemia is 
present despite elevated blood levels of insulin or hyperinsulinemia. The prevalence of 
T2D among the adolescent population in the US has increased 31% between 2001 and 
2009, with pre-diabetes rising from 9 to 23%.3 It is well known that diabetes is an 
important risk factor for cardiovascular disease, such as congenital heart disease, stroke, 
peripheral artery disease and heart failure. In fact, about 80% of people with diabetes die 
as a result of heart disease or stroke.4 
Importantly, the incidence of T2D is rapidly increasing in women at their 
childbearing age.1 It is estimated that 1 in 5 women are overweight/obese during 
pregnancy.5 Diabetes not only affects adult health but also puts developing embryos at 
risk in pregnant women as glucose can easily pass through the placenta and reach the 
fetal circulation. When these women have diabetes, not only is their own health affected, 
but their pregnancy is associated with a high risk of congenital malformations in the 
fetus. In addition, emerging longitudinal data suggests that adult metabolic and 
2 
 
cardiovascular disorders are in-part attributable to physiological insults in fetal life.6, 7 
Adverse uterine environments, including maternal obesity, diabetes, undernutrition and 
stress, can compromise embryonic development, reprogramming the epigenetic 
landscape.8  
Pregestational diabetes (PGD) is the development of diabetes prior to conception 
either by T1D or T2D. The risk of major congenital malformations in the offspring of 
women with diabetes is 3 to 10-fold higher compared to the general population.9, 10 In a 
recent population based study, similar rates of congenital malformations were reported 
between T1D and T2D (4.8.% and 4.3%, respectively).11 Although circulating insulin levels 
are elevated in T2D, maternal insulin does not cross the placenta. Thus, hyperglycaemia is 
likely the main cause of the congenital malformations in the offspring of diabetic women. 
1.2 Heart Development  
The heart is the first fully functional organ to form during embryogenesis, and its 
development is orchestrated by an interplay of conserved transcription factors that control 
growth, morphogenesis, and contractility of this ancient pump.12 Cardiac development is 
a complex and intricate process that in essence involves the harmonic combination of 3 
pools of progenitor cells, that when present in a specific spatial and temporal orientation 
together, form a self-excitable, four-chambered, vascular pump which only stops beating 
at the time of death.13 Heart development commences at week 3 of human 
embryogenesis, corresponding to embryonic day 7.5 (E7.5) in the mouse,14 with the 
formation of a cardiac crescent and subsequent heart tube from cells of the anterior lateral 
mesoderm. This first wave of cardiac progenitors has been termed the First Heart Field 
(FHF), and includes myoblasts forming the tube and endothelial cells lining the entire 
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structure.15 The primitive heart tube is elongated at its poles by the addition of 
proliferative cells coming from the adjacent splanchnic pharyngeal mesoderm. This 
consecutive wave of myoblasts has been termed the Second Heart Field (SHF), and 
contributes to the rightward looping morphogenesis of the tube, whereby primitive 
chambers of the heart can be distinguished.15 Chamber development by ballooning, 
muscularization and fusion of endocardial cushions, ventricular myocardialization and 
septation, outflow tract (OFT) and cardiac valve development are completed thereafter, 
with the addition of cardiac neural crest cells (CNCs) migrating from the dorsal neural 
tube.16 Cardiac development is therefore an extremely complex spatiotemporal process, 
and a misstep in this orchestration could lead to a congenital heart defect (CHD). The 
sections to follow will detail the nature of these cardiac heart fields, the numerous steps 
involved in heart morphogenesis, as well as the transcriptional regulation that directs this 
entire process. 
1.2.1 The First Heart Field 
              In embryology, a heart field is defined as a source of cardiac progenitor cells at a 
particular location that give rise to the heart.16 Clonal analysis has revealed that the FHF 
segregates from the SHF early in gastrulation,17 and the basic helix–loop–helix 
transcription factor MESP1 marks this nascent cardiac mesoderm.18 Following 
gastrulation, cardiac precursors of both lineages migrate to either sides of the embryo 
midline, below the head folds.19 Here, cardiogenesis begins, with the formation of a 
cardiac crescent from cells of the anterior lateral mesoderm, at E7.5 in the mouse. These 
cells are known as the FHF and contribute to the establishment of a linear heart tube, 
which is formed by the joining of the edges of the cardiac crescent at the ventral 
4 
 
midline.20 Here, the first evidence of a heart-beat is seen as calcium transients and 
peristaltic contractions commence through the heart tube at E8.0 in the mouse.21 This 
heart tube is composed of a concentric inner layer of endocardial cells and outer layer of 
myocardial cells separated with extra-cellular matrix, also known as cardiac jelly.22 The 
venous pole of this tube contains the cardiac inflow tract and the transient sinus venosus. 
This is connected via the atrioventricular canal to the primitive ventricle, which will 
develop into the left ventricle of the heart.15, 23 The FHF-derived heart tube specifically 
contributes to parts of the atria and the left ventricle of the mature heart. 
1.2.2 The Second Heart Field  
The primitive heart tube is elongated with the addition of cells from a second 
subpopulation of progenitors, originating from the pharyngeal mesoderm. This group of 
cells was discovered after the FHF and has been termed the Second Heart Field (SHF), 
and is originally situated medial to the cardiac crescent and then dorsal to the primitive 
heart tube.24 A distinct gene expression profile is noted in these cells before gastrulation 
in the early embryo. Lineage tracing experiments have revealed SHF-derived structures 
and precursors marked with the Mef2C transcription factor driven by an anterior heart 
field specific enhancer element. Activity of this enhancer is detectable as early as the late 
primitive streak stage in a subset of cells, prior to gastrulation,16 suggesting that the 
regional contributions to the heart are specified before the onset of cardiogenesis. These 
cells elongate the heart tube by migrating to its arterial and venous poles, progressively 
adding new myocardium and endocardium to the outflow and inflow tracts, respectively. 
Accordingly, the cardiac outflow tract is derived from the anterior SHF whereas, the 
cardiac inflow tract, which will become the atria of the heart, is posterior SHF-derived.15 
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Posterior SHF progenitors can be further segmented into right and left regions, forming 
the right and left atria, by early expression of Pitx2c confined to the left.25 The 
longitudinal growth of this tube brought about by the addition of the SHF is crucial for 
proper looping of heart onto itself. The linear tube undergoes a rightward looping 
morphogenesis, with the addition of the proliferative SHF progenitors between 
embryonic days 8.25 and 10.5.24 Along with Mef2C marking the anterior SHF, the 
expression of Fgf8 and Fgf10 is noted in these cells beginning at the crescent stage.26 
These growth factors are a pro-proliferative signal for these progenitors, contributing to 
proper cardiac looping leading to the formation of the primitive chambers of the heart. 
While expression of these factors is restricted more anteriorly, Isl1 expression extends 
into the posterior SHF, and is critical for both venous and arterial pole development. In 
fact, Isl1-mutant mice have defects in the atria and great arteries of the heart.27 
Additionally, ablation of Hand2 in the SHF using the Isl1-Cre transgenic mouse resulted 
in high levels of apoptosis in the pharyngeal mesoderm, suggesting that Hand2 is 
required for the survival of undifferentiated cardiac progenitors prior to their migration to 
the heart tube.28 At the time of looping, another pro-proliferative signal for the SHF 
comes from the pharyngeal endoderm via sonic hedgehog (Shh). Shh signaling promotes 
SHF proliferation, survival and regulates migration of these progenitors into SHF-derived 
structures such as the atrial septum and pulmonary trunk.29, 30 The canonical WNT 
pathway as well as Notch signaling also promote proliferation of the SHF. The 
progressive addition of the SHF to the looping heart tube contributes to the formation of 
endocardial, myocardial and smooth muscle cells of the outflow tract (OFT), the 
prospective right ventricle (RV), the atria and the interventricular septum.31  
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1.2.3 Cardiac Looping and Endocardial Cushion Formation 
Bilateral asymmetry in the early embryo is first established with the looping of 
the primitive heart tube. Left-right patterning differences of gene expression and cell 
polarity govern the asymmetric morphological formation of the heart.32, 33 Proper looping 
in a rightward fashion, commencing at E8.25, is critical for correct orientations of the 
atria and ventricles, establishing a circulatory system for the growing fetus.14 The dextral 
looping results in an helical shape with an inner curvature between the outflow and 
inflow tracts.34 Analysis of this morphogenesis using high-resolution episcopic 
microscopy has rendered a 3D computer simulated model of this morphogenesis. Le 
Garrec et al. show that the heart tube grows dorsally while remaining anchored at both 
ends. The length of the tube increases by over 4-fold, while the distance between the 
poles is fixed, resulting in a looped heart.32 The highly proliferative nature of the SHF, 
discussed in the previous section, accounts for this elongation. Looping is followed by 
formation of endocardial cushions within the OFT and atrioventricular canal (AVC) 
eventually leading to a four chambered heart.35 These OFT cushions form in the 
conotruncal region between the ventricle and aortic sac; and AVC cushions develop in 
the transition zone between the primitive atria and ventricle, both arising from the 
endocardium via epithelial-to-mesenchymal transition (EMT). The endocardial cushions 
transform into cardiac valves and aid in the septation of the mature heart, but function to 
shunt blood in the developing heart.36 
1.2.4 Chamber Formation and Septation 
 The heart chambers grow outward from the heart tube in a process known as 
ballooning beginning at E9.5. The cardiomyocytes on the outer curvature of the tube begin 
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to proliferate acquiring a distinct transcription profile that facilitates their growth22 as well as 
differentiates them into the cardiac myocardium, with an increased conduction velocity.37 
Cells along the inner curvature and AVC remain as undifferentiated myoblasts, which 
express transcriptional repressors to prevent differentiation, and resemble nodal 
myocardium.37 Concurrent with ballooning growth at proliferative zones along the ventricle 
loop forming the right and left ventricle, trabeculae develop at proliferative zones on the 
luminal myocardium by Notch, BMP10 and Neuregulin1 signals coming from the 
endocardium.38, 39 The trabeculae function to increase surface area for oxygen uptake prior 
to the establishment of the coronary vasculature. The atrial and ventricular septa are formed 
between E9.5 and E14.5 in mice. Multiple primordia contribute to a central mesenchymal 
mass, including the mesenchyme on the leading edge of the primary atrial septum, the 
atrioventricular endocardial cushions, and the cap of mesenchyme on the spina vestibule.40 
The membranous, primary atrial septum descends from the roof of the atrial segment of the 
heart tube, reaching the AV cushion. This structure is completely SHF derived, driven by 
the transcriptional activity of Gata4, initiating proliferative and cell cycle gene expression, 
such as Cyclin D2 and Cyclin-dependent kinase 4.41 The primary atrial septum does not 
fully fuse with the endocardial cushion, instead creating the foramen primum, which allows 
for blood flow between the right and left atria until its closure at E12.5. At this point the 
foramen secundum forms on the primary atrial septum through apoptosis.42 While this is 
occurring, a muscular septum, known as the septum secundum, grows downward parallel to 
the primary septum. An opening, termed the foramen ovale, exists between these two septa 
and allows for shunting of blood between the atria during gestation as oxygenated blood is 
not received from the fetal pulmonary circulation.43 Similar to the atrial septum, the 
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ventricular septum has membranous and muscular components, however, they are fused 
together as one structure. Formation of the intraventricular septum begins with the 
invagination of muscular myocardium at the apical component of the heart tube during 
chamber ballooning around E10.5.44 The muscular septum grows between the common 
ventricular superiorly toward the AV cushions located at the base of the heart.44 The 
majority of the muscular septum is derived from proliferation of cardiomyocytes as well as 
compaction of the trabeculae; however, the epicardium also contributes to progenitors via 
EMT to form this structure.45 The muscular septum fuses with the membranous component 
of the intraventricular septum that originates from the AV cushion and grows downwards. 
Lineage tracing with the anterior heart field specific Mef2c indicates that the interventricular 
septum is almost entirely SHF-derived. Moreover, experiments knocking out Tbx5 and 
Hand2 in the SHF result in atrial septal defects (ASDs) and ventricular septal defects 
(VSDs), respectively.16, 24   
1.2.5 Ventricular Myocardium Development  
 Maturation of the newly formed cardiac chambers occurs concurrently with 
ventricular septation and continues into the later stages of embryonic development, 
muscularizing the ventricles to meet the increased cardiac output demands of the embryo. 
At the onset of heart development, at E8.0, the volume of the myocardium constituting 
the linear heart tube is approximately 0.0014 mm3; by E17.5 the volume of the 
myocardium reaches 2 mm3.22 This myocardial growth is achieved by hyperplysia of 
cardiomyocytes, estimated to be 1 million cells at birth.22 About 30% of the cells forming 
the mature ventricle wall are cardiomyocytes, the rest being endothelial cells, vascular 
smooth muscle cells, fibroblasts, immune and epicardial cells.46 Primitive 
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cardiomyocytes are spherical and mononuclear and begin to mature at E13.5 when they 
elongate and assume a rod shape.33 Many signaling pathways regulate cardiomyocyte 
proliferation and maturation, including Hippo signaling.47 Proliferation and apoptosis 
during normal cardiac development will be explored in a following section. Formation of 
the mature myocardial architecture of the ventricle wall begins with trabeculation, 
followed by compaction and growth. Prior to the development of the compact 
myocardium, which is primarily governed by epicardial-derived signals, endocardial-
derived factors lead to the onset of trabecular development at E9.0.48 The interplay of 
Notch and neuregulin/ErbB signals from the endocardium leads to rapid growth at the 
proliferative centers along the ventricle wall, forming protrusions known as trabeculae.49, 
50 Individual trabecular units are formed from endocardial projections into the lumen 
resulting from Notch1-induced ECM degradation and neuregulin-induced ECM synthesis 
and rearrangement by the myocardium.48 Since these trabeculations are established prior 
to coronary circulation, the increased surface area to volume ratio they provide enables 
sufficient oxygen uptake and nutrient exchange, facilitating growth of the myocardium.51 
These sponge-like structures of cardiomyocytes are also important for ventricular 
septation and papillary muscle development.52 As the embryo develops, the muscle layer 
gradually thickens to compensate for the increased physiological load by cardiomyocyte 
proliferation and trabecular compaction, driven by FGF signaling from the epicardium. 
This process is concurrent with development of the coronary vasculature, and the spaces 
formed between compacted trabeculae become capillaries. Abnormalities in the 
formation of a multilayered myocardium, seen in cases of genetic perturbations of Notch 
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signaling components, disrupts chamber development, resulting in a noncompacted 
cardiomyopathy or ventricular hypoplasia.53, 54  
1.2.6 Outflow Tract Development  
 Concurrent with chamber development and maturation, the arterial pole of the 
heart tube undergoes several remodeling steps to form the aorta and pulmonary artery. 
Prior to looping, the outflow tube of the heart is comprised of SHF-derived myocardial 
cells with an inner lumen lined by endocardial cells. Collectively known as the outflow 
tract, both arteries begin as a common arterial trunk connected to the right ventricle after 
looping. The OFT endocardial cushions and myocardium are anterior SHF-derived,55 and 
these proliferative progenitors connect the ventricle to the aortic sac. The OFT must 
reorient and septate in order to establish proper connection of the aorta with the left 
ventricle and the pulmonary artery with the right ventricle. This re-positioning and 
counterclockwise rotation is accomplished by an asymmetric addition of SHF progenitors 
to the future pulmonary artery and primitive right ventricle regions, in a process termed 
the “pulmonary push.” This allows the pulmonary trunk and orifice to achieve a higher 
and more anterior orientation compared to the aorta.56 Septation of the OFT is 
accomplished by the contribution of the cardiac neural crest cells. These multi-potential 
cells are a part of the cranial neural crest region of the dorsal neural tube from which 
progenitors delaminate and migrate to various regions of the embryo at E9.0. In the heart, 
the addition of these cells helps to separate the OFT, form the semilunar valves, and add 
parasympathetic innervation.57, 58 Fusion of the OFT cushions with input from the CNC 
result in the formation of the aorticopulmonary septum, which is complete by E14.0.59  
Abnormalities in the convergence of SHF and CNCs cells, or the improper wedging of 
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the OFT can cause major defects such as double outlet right ventricle (DORV) and 
transposition of great arteries (TGA), which will be discussed in following sections.  
1.2.7 Cardiac Valve Development  
 The interfaces between the heart chambers and OFT house specialized structures 
that maintain unidirectional blood flow during a cardiac cycle. The semilunar valves exist at 
the junction between the ventricles and the great arteries, whereas the AV valves connect the 
atria to the ventricles. Both sets are comprised of a combination of connective tissue and 
valvular interstitial cells.60 Valvulogenesis begins with the formation of endocardial 
cushions in the OFT and AV canal, in response to BMP2 signals from the myocardium, 
around E9.0.61 These localized swellings of cardiac jelly, containing endocardial-derived 
mesenchyme and ECM components such as collagen and hyaluronic acid, initially act as 
valves in the primitive heart tube as they control the flow of blood.62-64 TGF-beta, Notch and 
the canonical Wnt signalling pathways control the proliferation and expansion of the 
mesenchyme.65 Endocardial cells then undergo endocardial-to-mesenchymal transition 
(EndMT), migrating and proliferating into the cushion causing its elongation. These 
mesenchymal cells differentiate into valvular interstitial cells, which extensively remodel the 
ECM and sculpt the valves.63 The valve leaflet becomes thin and elongated, with the ECM 
becoming stratified, rich in elastin, fibrillar collagen and proteoglycans.66 The mitral and 
tricuspid AV valves are derived from the endocardial cushion and epicardium, while the 
aortic and pulmonary semilunar valves are formed from endocardial cushion and cardiac 
neural crest cells.16, 35, 63 Genetic tracing experiments using the Wt1-Cre transgenic mouse 
confirm that epicardial-derived cells differentiate into fibroblasts and contribute specifically 
to the mural leaflets of the AV valves.67 Conversely, lineage tracing using the Cx43-lacZ, 
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Wnt1-Cre and Krox20-Cre mouse lines show a CNC contribution to the interleaflet region 
and insertion zone of the semilunar valves.68 
1.2.8 Transcriptional Regulators of Heart Development  
 Recently, single cell RNA-sequencing to map the transcriptome of the developing 
human heart revealed that cardiomyocytes can be partitioned into 4-chamber specific 
clusters based on differential gene expression signatures as early as 5 weeks into 
embryogenesis.69 A number of conserved transcription factors govern the complex 
process of cardiac development. Transcription factors are DNA binding elements that 
regulate the expression of downstream target genes. Through the use of genetic knockout 
mice, several transcriptional factors have been identified to be critical in the development of 
various cardiac structures. Mutations in GATA-4, Nkx2.5 and Tbx5 and MEF2 are 
associated with CHDs in humans.70-73 Specific spatiotemporal interaction and crosstalk 
between these factors are essential to control cardiogenic gene programs driving normal 
heart development.74  
1.2.8.1 Nkx2.5 
 Nkx2.5 (homeobox protein NKX2-5) is an early cardiomyocyte marker and 
regulator of heart morphogenesis and function, conserved from Drosophila to humans.75 
Its expression begins at the cardiac crescent stage in the FHF, SHF and adjacent 
endoderm, controlling migration and differentiation of cardiac precursors.76, 77 In the 
SHF, Nkx2.5 functions to maintain the proliferative progenitor cell pool.16 Loss of 
Nkx2.5 results in impaired cardiac development, as decreased myocardial growth and 
trabeculation are noted.78 Nkx2.5 null mice die between E9 and 10.5 due to an 
underdeveloped heart.79 Specifically, mesodermal expression of Nkx2.5 is required for 
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cardiogenesis, as its germ-layer specific deletion resulted in cardiac defects identical to 
null embryos, whereas endodermal expression is dispensable for heart formation.80 Thus, 
Nkx2.5 mutant mice have a spectrum of CHDs, including atrial septal defect (ASD), 
ventricular septal defect (VSD), tetralogy of Fallot (TOF), transposition of the great 
arteries (TGA) and double outlet right ventricle (DORV).81 Nkx2.5 is also implicated in 
familial CHDs in the human population, where a similar variety of malformations 
results.77 As Nkx2.5 is a dosage-sensitive regulator of cardiac development, 
haploinsufficiency and inherited point mutations cause CHDs in humans.82, 83 Nkx2.5 
directly associates with Gata4 early on in heart development to specify cardiac 
mesoderm.73  
1.2.8.2 Gata4 
 Three isoforms of the GATA family of zinc finger transcription factors are 
cardiomyocyte specific. Specifically, Gata4 is a master regulator of cardiac progenitor 
cell proliferation and differentiation, implicated in various facets of heart development 
and function.84 Beginning its expression at E7.5, a number of cardiac transcriptional 
targets have been identified for this factor. The expression of the cardiomyocyte 
contractility protein α-MHC, the SHF specific Mef2c and the cell cycle regulator Cyclin 
D2 are all controlled by Gata4.41, 85 In fact, a conserved enhancer element upstream of the 
Mef2c gene has two consensus GATA sites bound by Gata4, thereby dictating early OFT 
and right ventricle development in the anterior heart field.85 Gata4 also plays a pivotal, 
dose-sensitive role in cardiac septation through its interactions with Hedgehog signaling 
in the SHF.41 Loss of Gata4 is embryonically lethal in mice by E8.5 as a deregulation in 
lateral-to-ventral and rostral-to-caudal folding prevents the cardiac crescent from fusing 
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at the midline.86 In humans, defects in the atrial and ventricular septum at birth, and 
dilated cardiomyopathy later in life, have been attributed to mutations in Gata4. This 
gene is considered hyper-mutable as 110 different genetic mutations have been 
identified.87, 72 Interestingly, in a case of familial CHDs due to a Gata4 missense 
mutation, the physical interaction between Gata4 and Tbx5 was interrupted.72 It has since 
been established that both these factors synergistically cooperate to activate cardiogenic 
gene expression.88  
1.2.8.3 Tbx5 
Tbx5 (T-box 5) is another transcription factor expressed in early cardiogenesis, 
beginning around E8.0.89 Although Tbx5 marks the left ventricular myocardium, its 
expression is dynamic and even present in a subpopulation of the SHF.16, 90 As such, 
Tbx5 is involved in the formation of the interventricular septum, but also plays a major 
role in the development and maintenance of the cardiac electro-physiological conduction 
system by regulating the expression of connexin 40.91 Tbx5 mutations affect cardiac 
septation, inflow tract development and result in left ventricular hypoplasia; leading to an 
arrest of cardiogenesis in null mice by E10.5.70, 90 Holt-Oram syndrome affects patients 
with dominant mutations in Tbx5 and is characterized by septal and conduction defects in 
the heart, along with impaired anterior forelimb development.90, 92 This factor not only 
activates cardiogenic genes, but also functions to repress transcription of incompatible 
gene programs by interacting with the nucleosome remodeling deacetytlase complex 
(NuRD).93 Tbx5 also interacts physically with Mef2c early on in heart development, 





 Finally, Mef2C is a transcription factor expressed in the SHF precursors adjacent 
to the cardiac crescent and continues to the OFT and right ventricle of the mature heart 
from E7.5 to E11.5.95 It is specified to the anterior SHF through independent enhancer 
elements, and controls myocyte differentiation.85 The monocyte enhancer factor 2 
(MEF2) family regulates muscle-specific genes, and Mef2C is essential for sarcomere 
contractile element expression, like α-actin.96 Absence of Mef2C results in a cardiac 
looping impairment, lack of a right ventricle and is embryonic lethal between E9.5 and 
E10.5.96, 97 This germline knockout phenotype is recapitulated by deletion of Mef2c in 
early cardiac tissue using the Nkx2.5-cre transgenic mouse. However, deletion using the 
endothelial-specific Etv2-cre line results in viable offspring with no CHDs, suggesting 
that this factor is dispensable for endothelial progenitors, but is required for all 
myocardial cells.98 Other SHF exclusive genes that distinguish this group of progenitors 
from the FHF include the growth factors Fgf8 and Fgf10 as well as the transcription 
factors Tbx1 and Isl1.24 
1.2.9 Proliferation and Apoptosis in Cardiogenesis 
 Proliferation and apoptosis are key features of normal organ development. The 
adult heart is generally considered to be post-mitotic, as mouse cardiomyocytes lose their 
regenerative capacity after P7; unable to undergo cell division and instead increase in cell 
volume. The embryonic heart, however, depends on high amounts of proliferation. 
Multipotent cardiac progenitor cells of the FHF and SHF undergo proliferation followed 
by differentiation into cardiomyocytes, which in turn undergo further clonal expansion.50 
Specific regions of the heart tube undergo preferential proliferation resulting in chamber 
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ballooning, forming the left ventricle at E8.5.99 The highest proliferation rates are 
observed at the base of the ventricles at E11, after which the increase in cardiomyocyte 
number declines.100 Notch signaling, at the base of the trabecules, lining the ventricle 
wall, induces high rates of proliferation among less differentiated cardiomyocytes, 
resulting in trabecular elongation.39, 53 Furthermore, mesodermal cells of the SHF are also 
highly proliferative, elongating the primitive heart tube and resulting in its rightward 
looping. These progenitors remain proliferative much after the FHF, and their capacity is 
mediated by canonical Wnt signaling.100, 101 -catenin was found to be essential for 
expansion of SHF cardiac progenitors through deletion of this Wnt pathway component 
using the Ils1-cre mouse line.101 In addition, epicardial-derived growth factors induce 
myocardial proliferation, contributing to the expansion of the compact myocardium. 
These ligands include members of the Fgf, Igf and Wnt families (eg. Fgf-9, Igf-2 and 
Wnt9B), as well as retinoic acid, promoting proliferation of the myocardium.102-104 The 
hippo kinase cascade also dictates embryonic cardiomyocyte proliferation. In fact, 
ablation of Yap1, the nuclear target of the hippo pathway, in vascular SMCs of the 
embryonic heart suppressed their expansion and enhanced expression of cell cycle arrest 
genes, leading to cardiac defects associated with decreased proliferation such as DORV 
and ventricle wall hypoplasia.105 Deletion of Yap1 in fetal cardiomyocytes is embryonic 
lethal by E16.5 due to decreased ventricle chamber size and cardiac hypoplasia, resulting 
in pericardial effusion and heart failure.106 Conversely, overexpression of Yap1 in 
cardiomyocytes increases heart size through elevated proliferation.106 Furthermore, Rac1, 
a Rho GTPase and regulator of cellular structure, is required for anterior SHF progenitor 
cell proliferation and organization of the splanchnic mesoderm. Loss of Rac1 signaling 
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decreases the proliferation rate of SHF progenitors, subsequently resulting in OFT and 
cardiac valve anomalies.107 Finally, nitric oxide is intimately linked to cardiomyocyte 
proliferation. Postnatal eNOS knockout cardiomyocytes have lower levels of BrdU 
incorporation and fewer cells in culture compared to WT.108 This decrease in 
proliferation is mediated in part by an increased TIMP-3 expression, as treatment with an 
anti-TIMP3 antibody increased proliferation of eNOS-/- cardiomyocytes.109 In the 
embryonic heart eNOS deficiency decreased proliferation and growth of epicardial cells, 
by decreasing activity of cGMP-dependent protein kinase G signaling, thereby 
downregulating Gata4 and cardiac growth factor expression.110 Along with promoting 
proliferation in the embryonic heart, nitric oxide promotes survival by protecting cardiac 
progenitors against apoptosis.110  
 Apoptosis, or programmed cell death, is an intricately regulated process involving 
cellular disintegration by cell shrinkage, cytoskeletal breakdown and DNA 
fragmentation, and is a normal part of an organism’s development and life cycle. It is 
initiated and executed by the caspase family of proteinases, which systematically cleave 
proteins leading to blebbing and cell death.111 This process is an integral part of 
embryonic development as it aids in the proper integration of cells into tissues, shaping 
the structure of an organ.112 During cardiogenesis, apoptosis acts as a differentiation 
mechanism by inducing changes to nearby cells, contributing to the development of the 
OFT, cardiac valves, coronary vasculature and conduction system.113, 114 Significant 
levels of apoptosis have been identified in the mesenchyme of the AV cushions, the 
trabeculae and compact zones of the ventricles, and the OFT.115 Specifically, the 
cardiomyocytes of the OFT undergo apoptosis to facilitate shortening and rotation of the 
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myocardial conus, allowing for proper connection between the right ventricle and 
pulmonary artery.116 In addition, high levels of programmed cell death have been 
observed in the CNCs, which may be involved in the process of myocardialization of the 
OFT.55 Changes to the microenvironment induced by apoptosis of CNCs in the OFT 
cushion is thought to signal differentiation of the mesenchyme into myocardium.117 
Whole embryo knockout of FADD, the Fas-associated death domain protein, involved in 
the extrinsic pathway of programed cell death, is lethal by E11.5 with a dilated cardiac 
phenotype. Similarly, mice with a deletion of the caspase-8 gene die in utero by E12.5 
due to impaired cardiac muscle development leading to heart failure and edema.118 
Consistent with the proliferation defects, eNOS-/- hearts displayed elevated levels of 
cardiomyocyte apoptosis and myocardial cleaved caspase-3 at E12.5 and E15.5, 
compared to controls. Atrial and ventricular septal defects were found at a higher 
incidence in neonatal eNOS knockout hearts, in which increased apoptosis was 
maintained.119 Interestingly, in neonatal cardiomyocytes, iNOS-derived nitric oxide 
production mediates the apoptotic effects of TNF-α stimulation.120 Moreover, in cultured 
H9C2 myocytes, transduction of microRNA-122 increased caspase-3 activity and cell 
death.121  
1.2.10 Fetal Cardiovascular Physiology  
 Circulation in the fetus shifts after birth as it becomes independent from the 
maternal circulation. Normally, in the postpartum heart, deoxygenated blood enters the 
right atrium from the venous inflow of the superior and inferior vena cavae. This blood 
fills the right ventricle which subsequently contracts and pumps venous blood to the 
pulmonary circulation through the pulmonary artery. Gas exchange occurs in the lungs, 
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and oxygenated blood returns back to the heart via the pulmonary veins, entering the left 
atrium. Once the left ventricle fills, oxygenated blood is pumped into the aorta and travels 
through the systemic circulation, allowing arteries and arterioles to perfuse tissues of the 
body.122 In contrast, since the lungs are not functional in the fetus, gas exchange occurs 
via the placenta.  Therefore, the fetal heart has structural adaptations, known as shunts, to 
facilitate blood flow throughout development.122 The ductus arteriosus connects the 
pulmonary artery to the aorta. Oxygenated blood from the placenta flows into the inferior 
vena cava via the umbilical veins. This blood is pumped by the right ventricle, but, in this 
case, is shunted by the ductus arteriosus into the dorsal aorta because of the high-pressure 
resistance of the pulmonary artery. This shunt remains open throughout fetal 
development due to the high oxygen tension and prostaglandin secretion from the 
placenta.122 Another feature of the fetal heart is the foramen ovale, which shunts 
oxygenated blood from the right to the left atria, following a pressure gradient. At birth, 
as the newborn’s lungs inflate with air, the resistance in the pulmonary veins will 
decrease allowing for blood flow through the pulmonary circulation. This is followed by 
a closure of the foramen ovale by the septum secundum because of increased pressure in 
the left atrium.122 Finally, hours to days after birth, the decline in prostaglandin levels in 
the newborn will cause the ductus arteriosus to close, completing the separation of 
pulmonary and systemic circulatory systems.123  
1.3 Coronary Artery Development  
 The development of the coronary vasculature is distinct from the formation of the 
myocardium these vessels feed (Figure 1.1). Angiogenesis in the primitive heart begins at 
E9.5 in the proepicardial organ (PEO). The PEO is a transient structure adjacent to the 
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developing heart tube, located at the pericardial surface of the septum transversum close to 
the sinus venosus.124, 125 It contains a heterogenous population of mesothelial cells 
expressing Wt1 and Tbx18, destined to migrate to the heart.126, 127 Cells originating in the 
PEO migrate and proliferate to cover the surface of myocardium, forming an epicardium 
(Figure 1.1).16 By E12.5 this epicardial layer is fully formed.124 A subset of these 
epithelial cells undergo epithelial-to-mesenchymal transition (EMT) and become 
epicardial-derived cells (EPDCs).125 These EPDCs migrate to the subepicardial space and 
myocardium where they differentiate into vascular smooth muscle cells, adventitial 
fibroblasts and endothelial cells (Figure 1.1).36 These mesenchymal cells migrate 
throughout the developing myocardium and produce much of the coronary vasculature 
through a vasculogenic process. This immature vascular plexus initially develops without 
blood flow. The proximal ends of the coronary arteries connect to the ascending aorta 
through coronary orifices at the level of the left and right sinuses of the semilunar valves, 
initiating perfusion. This invasion occurs at the time of cardiac septation, following 
separation of the aorticopulmonary trunk, and involves apoptosis.128 The establishment of 
blood flow is needed for subsequent remodelling and maturation of the vessels. Coronary 
veins connect to the right atrium via the coronary sinus.124, 125 Other sources of coronary 
artery progenitors include the sinus venosus and the endocardium (Figure 1.1).36 Similar 
to heart development, a complete coronary network is established by E15. Congenital 
abnormalities of the coronary arteries can impact heart function and are associated with 





























Figure 1.1. Embryonic coronary artery development in the mouse. 
Coronary vessels arise from progenitors originating from three distinct sources, the 
proepicardial organ (PEO), sinus venosus and endocardium. Formation of these arteries 
involved epithelial-to-mesenchymal transition (EMT) followed by differentiation and 
growth. By E15 a fully formed vascular plexus supplies oxygen and nutrients to the heart. 
E: Embryonic Day, EMT: Epithelial-to-Mesenchymal Transition, EndMT: Endocardial-




1.3.1 Epithelial-to-Mesenchymal Transition  
EMT is a transdifferentiation process of epithelial cells into motile mesenchymal 
cells by way of transcriptional reprogramming.130 Cell polarity defines epithelial cells as 
they have luminal and basilar domains, connected to one another by adherence junctions, 
tight junctions, gap junctions and desmosomes. Delamination into a migratory cell type 
involves loss of this polarity, a dismantling of cell-to-cell connections and cytoskeletal 
rearrangement, all mediated via activating mesenchymal gene programs and repressing 
epithelial signatures. This switch in phenotype is carried out by local upregulations of EMT 
ligands and factors, as well as molecular signalling cascades initiated by receptor binding. In 
the cardiovascular system, transforming growth factor beta (TGF-β) and bFGF signalling 
induces the breakdown of the basement membrane, reorganizes actin filaments and allows 
for cell movement.36 In addition, TGF-β binding results in the upregulation of the 
transcription factors Snail and Slug, which further promote cell motility and repress 
epithelial genes, such as Cdh1 (E-cadherin).131 A hallmark of EMT induction is cleavage 
and endocytosis of E-cadherin, a transmembrane protein that forms cell junction in the 
epithelium.132 This is followed by the expression of N-cadherin, a mesenchymal protein, and 
together is known as the “cadherin switch.”130 Furthermore, cell motility is enabled by actin 
reorganization and polymerization in the direction of migration, along with a degradation of 
ECM.133 Following EMT and migration to the destination, the cells can re-differentiate into 
other cell types.  
1.3.2 Transcriptional Regulators of Coronary Artery Development  
Many transcription factors including Gata-4, Fog2 Wt1, VCAM-1 and α-4 integrin 
play critical roles in the development of coronary arteries.134, 135 The disruption of many 
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mediators of EMT have been implicated the pathogenesis of coronary artery anomalies. For 
instance, the master regulator of EMT in the embryonic heart, Wt1, is required for coronary 
artery development and is indispensable for epicardial EMT.136 Wt1 is a DNA binding 
protein, which directly regulates the expression of other mediators of EMT, such as Snail 
and Cdh1 (E-cadherin).137 Mutation of Wt1 in the epicardium is embryonic lethal between 
E16.5 and E18.5 due to cardiovascular defects.137 Additionally, Wt1 binds to the Raldh2 
promoter in epicardial cells, thereby controlling retinoic acid signaling, essential for EPDC 
formation.138 In fact, epicardium-specific mutation of the retinoic acid receptor reduced β-
catenin and FGF2 expression, resulting in abnormal arterial branching in the embryonic 
heart.138 In addition, genetic deletion of Gata-4 in mice impairs migration and EMT 
resulting in the absence of coronary arteries.125, 139, 140 Coronary artery defects are also noted 
in Tbx18 knockout (Tbx18-/-) mouse models, as Tbx18 is a transcription factor highly 
expressed in the PEO, controlling early artery development. Moreover, coronary 
arteriogenesis is also dependent on β-catenin signaling, as ablation of this factor in the 
epicardium impaired epicardial expansion, invasion and differentiation; while specific 
deletion in the PEO was embryonic lethal.141   
1.4 microRNA Regulation of Cardiovascular Development  
MicroRNAs (miRNAs) are a class of endogenous, short (20-26 nucleotide), non-
coding RNA molecules that post-transcriptionally regulate gene expression by degrading 
messenger RNA (mRNA) molecules or repressing their translation.142 A single miRNA 
molecule does not require perfect sequence complementarity to bind the 3’ untranslated 
region (UTR) of a target mRNA.142 This means that one microRNA can target and 
modulate the expression of many mRNAs, and a particular mRNA molecule can be 
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controlled by many different miRNAs. The human genome encodes over 2000 miRNAs 
and it’s predicted that one-third of all protein-coding genes are regulated by at least one 
miRNA.143 Specifically, the human heart expresses over 700 miRNAs, which, in turn, 
fine tune the expression of 30% of the heart’s protein coding genes.8 In developmental 
biology, miRNAs act as molecular coordinators of gene expression, switching on and off 
transcription factors, activators and repressors, in complex regulatory circuits.144 
Regulation through miRNA suppression of gene expression has been shown to be vital 
for heart development.145  
1.4.1 microRNA Biogenesis, Structure and Function  
miRNAs are transcribed in the nucleus by RNA Polymerase II or III.146 They can 
reside in coding and non-coding regions of the genome and can be the result of 
alternative splicing. Expression of miRNAs is controlled in a cell-type specific manner 
by transcription factors, thereby creating unique expression profiles for each organ. 
Transcription results in a double-stranded RNA hairpin molecule with a 5’ polyadenyl 
cap, known as a primary-miRNA (Figure 1.2).146 About 40% of human miRNAs are 
transcribed together as clusters containing upwards of 8 distinct miRNA sequences.147 
Micro-processing and cleavage of this primary-miRNA by the nuclear Drosha enzyme-
complex (an RNaseIII-type nuclease) and , DiGeorge syndrome critical region 8 protein 
(DGCR8) forms the ~70-nucleotide-long precursor-miRNA (pre-miRNA) molecule, 
which is transported to the cytosol via the Ran-GTP-dependent nuclear transport receptor 
Exportin5.148 In the cytosol, the ribonuclease Dicer and transactivator RNA-binding 
proteins (TRBP) cleave the precursor-miRNA hairpin loop resulting in a short, ~22 
nucleotide miRNA duplex of complementary strands.149 The thermodynamically less 
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stable RNA strand is loaded into the RNA-induced silencing complex (RISC) and 
functions as the guide strand to mediate miRNA-RISC interactions (Figure 1.2).142 150 
The RISC loading complex is composed of Dicer, TRBPs, protein activator of PKR and 
Argonaute-2 (Ago2), the latter of which is the RISC effector protein mediating mRNA 
destabilization, decay or translational inhibition (Figure 1.2).151 Specifically, the seed 
region of the mature miRNA, which usually spans from nucleotide 2 to 7 at the 5’ end of 
the miRNA, participates in complementary base pairing at the 3’ UTR of target mRNAs 
for mRNA repression.152 Consequently, miRNAs are highly conserved between species, 
therefore having the same mRNA targets. Bioinformatic algorithms can predict the 














microRNAs are transcribed in the nucleus as a long precursor transcript with a hairpin 
loop, known as the primary microRNA (pri-miR). Processing steps occur in the nucleus 
by the enzymes DROSHA and DGCR8 to produce a shorter precursor miRNA (pre-miR), 
which is exported into the cytosol by Exportin 5.  In the cytosol the precursor miRNA 
associated with the DICER, TRBP and Ago2 enzyme complex. The mature miRNA is 
loaded into the RNA-induced silencing complex (RISC) where it can execute its function 
and inhibit target mRNA expression via complementary binding to 3’ UTRs. This leads 
to target mRNA translational inhibition, cleavage or destabilization.  
  
Figure 1.2. microRNA biosynthesis and function. 
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1.4.2 microRNA in Cardiogenesis 
In normal cardiogenesis, miRNAs control the expression of many critical genes 
involved in proliferation and differentiation, and play roles in regulating the stages of 
heart development.153 The importance of miRNAs in heart development is illustrated in 
early cardiac progenitor-specific deletions of Dicer. Ablation of Dicer using Cre-
recombinase under the control of the endogenous Nkx2.5 promoter in mice, is embryonic 
lethal due to cardiac failure by E12.5.154 Deletion of Dicer in the CNC using the Wnt1-
Cre transgenic mouse resulted in profound craniofacial defects and major CHDs, 
including VSD and DORV, stemming from impaired migration and patterning of this 
lineage.155 Similarly, using the Gata5-Cre to conditionally knockout Dicer in the PEO and 
epicardium in mice led to complete mortality immediately after birth due to severe 
coronary vessel malformations stemming from impairments in EMT.156 In addition, 
vascular smooth muscle-specific Dicer knockout, with the SM22-Cre, resulted in 
mutant mice having hypoplastic coronary arteries and diminished cardiac contractility, 
with embryonic lethality around E16.5.157 These studies highlight the broad necessity of 
miRNAs for proper cardiac development as Dicer is required for their processing and 
function. Gain and loss-of-function experiments looking at specific miRNA families 
delineate the pivotal roles of particular miRNAs in cardiogenesis. In organ development, 
many miRNAs regulate the cell cycle and direct proliferation.158 For instance, 
overexpression of miR-195 under control of the -myosin heavy chain promoter in the 
embryonic heart results in VSD and ventricular hypoplasia in mice due to premature cell 
cycle arrest.159 The same CHDs were seen when miR-133a is overexpressed by the -
myosin heavy chain promoter, along with reduced cardiac function and left ventricular 
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dysfunction.160 Using the same promoter to overexpress miR-1-2 in mice, embryonic 
lethality occurs at E13.5 due to heart failure from ventricular hypoplasia, which is 
consistent with a significant decrease in proliferating cells and insufficient muscle 
mass.154 Interestingly, deletion of miR-1-2 also results in an abnormal cardiac phenotype 
and 50% embryonic lethality. miR-1-2-/- mice have decreased heart rate, prolonged 
ventricular depolarization and VSDs.161 These mice have greater heart-weight to body-
weight ratios and larger ventricular cardiomyocytes. Combined deletion of the miR-133a-
1-2 complex results in VSDs and is embryonic lethal in half of all double mutants. miR-
1-2 modulates expression of genes involved in cell cycle progression and karyokinesis, 
but also downregulates Hand2 by targeting its 3’UTR.161 Hand2 is a cardiogenic 
transcription factor, needed for cardiomyocyte expansion and proliferation.162 Thus, the 
close regulation of Hand2 expression by miR-1-2 is vital for normal heart development. 
Taken together, the gain and loss-of-function studies on miR-1-2 exemplify the critical 
role miRNAs play in fine-tuning gene expression in the embryonic heart. Notably, studies 
on human congenital heart disease have revealed that some CHDs are associated with 
altered miRNA expression. miRNA profiling of human fetal single ventricle 
malformation identified 48 differentially expressed miRNAs in the heart, many of which 
target genes involved in cardiac development.163 Moreover, in patients with Down 
Syndrome (Trisomy 21) who also presented with CHDs, 5 miRNAs (miR-99a, let-7c, 
miR-125b-2, miR-155 and miR-802) located on chromosome 21 were preferentially 
overexpressed in the heart.164 Finally, case studies on infants with non-syndromic TOF 
revealed 61 miRNAs significantly altered in expression in the myocardium compared to 
normal subjects.165 These animal models and clinical studies display the fundamental role 
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of miRNAs in fetal cardiovascular development, and the consequences of their 
dysregulation.  
1.4.3 microRNA-122 a novel player in CHD pathogenesis 
MiRNA-122 is a conserved, 22 nucleotide miRNA molecule that plays a critical 
role in liver development and homeostasis.166 MiRNA-122 is encoded on human and 
mouse chromosome 18 and generates a ~4.5 kilobase primary-miR, which is processed to 
a 66 nucleotide pre-miR-122. The gene expression of miR-122 is regulated by circadian 
rhythms; however, miR-122 has a >24-hour half-life which maintains its constant 
levels.167 The cytoplasmic poly(A) polymerase, GLD2, contributes to this stability by 
adding an adenosine tail to the mature transcript.168 It is highly expressed in the adult 
liver, where it serves as a key regulator of cholesterol and fatty-acid metabolism, as well 
as blood alkaline phosphatase levels.166, 169 In fact, just prior to birth, miR-122 copy 
numbers reach maximal levels (~50000 per cell) in the liver.170 Mir-122 is also an 
important host factor for hepatitis C virus (HCV) replication as it binds to the 5’ UTR of 
the viral genome, promoting HCV stability and accumulation, while protecting the RNA 
genome from degradation.171, 172 In addition, miRNA-122 is regarded as a potent tumor 
suppressor. Liver-specific knockout of miR-122 results in hepatobillary cysts leading to 
hepatocellular carcinoma (HCC).173 MiR-122 is repressed in primary tumors in HCC 
patients, and its decreased levels are associated with poor prognosis and acquisition of an 
invasive, metastatic phenotype.174 Interestingly, it has been shown in vitro that miRNA-
122 inhibits the angiogenic potential of endothelial cells. Transfection of miRNA-122 to 
human dermal microvascular endothelial cells reduced their proliferation, motility, and 
ability to form interconnected tubes.175 Correspondingly, it has been reported that 
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miRNA-122 is downregulated in many human cancers, which correlates with an increase 
in metastasis and EMT.174, 176-182 In addition, miR-122 inhibition of the Wnt signaling 
pathways was confirmed by a dual luciferase reporter assay, showing its targeting of -
catenin.183  
The molecular processes involved in cancer and angiogenesis are also critical 
components of cardiac development. Therefore, cardiac expression of miRNA-122 
during embryogenesis could have deleterious effects by suppressing proliferation and 
EMT. Recently, however, studies have shown the presence of miRNA-122 in the adult 
heart following injury. In fact, miRNA-122 is regarded as a novel biomarker for 
cardiomyopathies. Elevated plasma levels of miRNA-122 are present in patients 
following myocardial infarction (MI),184 and in patients with coronary artery disease,185 
with levels increasing linearly with the severity of atherosclerotic lesions.186 In fact, 
plasma levels of miR-122 are also acutely increased in patients following cardiac 
arrest.187 This elevation is noted in rat models of cardiac injury, as miRNA-122 is not 
only increased post-infarction in heart tissue, but also directly contributes to the apoptosis 
of cardiomyocytes.188 Thus, along with the established roles of miRNA-122 in the liver 
and as a tumor suppressor, emerging evidence supports its involvement in cardiac 
pathophysiology, as a biomarker and possible contributor, which provides support for 
investigating this molecule in maladaptive cardiac development. 
1.4.3.1 microRNA Silencing in vivo: antimiR-122 
In addition to having clinical value as a diagnostic marker, miRNA-122 is 
currently being tested as a therapeutic target in patients with chronic hepatitis C virus 
(HCV) infection.166, 189, 190 MiRNA-122 specifically binds to two distinct sites in the 5’ 
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non-coding region of the HCV genome and upregulates viral RNA levels, thereby 
facilitating viral replication.191, 192 Therefore, targeting miRNA-122 presents an avenue 
for anti-viral intervention. AntimiRNAs are chemically modified antisense 
oligonucleotides that are designed to bind endogenous miRNAs with high affinity and 
decrease their expression levels. Accordingly, to combat HCV infection, clinicians utilize 
a locked nucleic acid (LNA) modulation of antimiRNA-122 (Miravirsen, SPC3649), 
resistant to nuclease degradation in vivo.190, 193 Miravirsen has sequence complementarity 
to human mature miRNA-122 allowing perfect hybridization, thereby blocking its 
interaction with the viral RNA genome. Moreover, Miravirsen has sequence 
complementarity with primary and precursor miRNA transcripts, and inhibits miRNA-
122 biogenesis.189 Currently in clinical trials, Miravirsen administration to patients with 
chronic hepatitis C infections results in a dose-dependent and prolonged reduction in 
plasma HCV RNA, without affecting the levels of other miRNAs.190 
1.5 Congenital Heart Disease  
CHDs arise from perturbations in complex cellular and molecular processes 
underlying embryonic heart development. Thus, because of the intricate nature of cardiac 
development, a misstep in the orchestration could lead to abnormalities. Alterations in 
cardiogenic gene expression, cell migration or proliferation can have implications for 
heart structure, and can result in CHDs. Congenital malformations of the heart are the 
most common birth defect, accounting for 1-5% of live births.194, 195 Congenital heart 
disease is the leading cause of pediatric deaths in developed nations.196, 197 Some 
congenital defects can go unnoticed at birth; however, as the child matures and is 
involved in increasing amounts of physical activity, the congenital malformations can 
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manifest themselves. A spectrum of congenital heart defects exist that span from minor 
anomalies such as an atrial septal defect (ASD) to major malformations including 
transposition of the great arteries (TGA).198 Septal defects are holes in the ventricular or 
atrial septum, leading to a mixing of de-oxygenated and oxygenated blood. CHDs also 
affect sites distant to the actual myocardium such as the descending aorta, which can be 
narrowed resulting in coarctation. OFT defects such as persistent truncus arteriosus 
(PTA), and malformations in the valves of the heart contribute to the spectrum of defects 
of congenital heart disease and are a result of improper cardiogenesis. These defects 
compromise the function of the cardiovascular system as the ability of the heart to 
perfuse all tissues of the body with oxygenated blood is decreased. For instance, the 
inability of the endocardial cushions to complete the process of septation could result in a 
ventricular septal defect (VSD), which would allow for mixing of oxygenated and 
deoxygenated blood from the systemic and pulmonary circulations resulting in a 
decreased functional cardiac output. Congenital malformations can follow a pattern of 
incidence where multiple CHDs are present in the same heart. Tetralogy of Fallot (TOF) 
is an example of this phenomenon and is composed of a VSD, pulmonary stenosis, right 
ventricular hypertrophy and an overriding aorta.199, 200 Genetic and environmental factors 
are associated with CHDs. Mutations causing cardiac abnormalities can either be 
sporadic or familial.77 Teratogen exposure during gestation, such as polychlorinated 
biphenyls and pesticides, have been linked to CHDs, along with maternal alcohol 
consumption, smoking, anti-seizure medications and rubella infection.77 Surgical 
procedures to correct congenital malformations of the heart do not always have high 
efficacy.201 Individuals with CHDs commonly require multiple operations and drug 
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therapy, and are at an elevated risk for arrhythmias, bacterial endocarditis and heart 
failure, placing a large burden on the health care system.202 Patients often have extra-
cardiac co-morbidities, such as neurological deficits, which affect quality of life.203 The 
prevalence of neurodevelopmental disabilities in the population of patients with CHDs 
ranges from 10% to over 50% depending on the severity of the lesion and whether 
pediatric surgery was required.204 The spectrum of these abnormalities includes 
intellectual disability, autism spectrum disorder, and deficits in language, motor and 
social skills.205 In fact, attention deficit hyperactivity disorder is 3 to 4 times more 
prevalent in children with a CHD.206 Currently, an estimated 96,000 Canadian adults are 
living with a CHD,207 making this disease a major cause of mortality and morbidity for 
both adults and infants. Therefore, it is vital that research be conducted into how and why 
these malformations develop, and more significantly, what remedies during pregnancy 
can prevent their occurrence.  
1.5.1 Types of Congenital Heart Defects  
 The International Classification of Diseases (ICD-10) classifies 25 distinct types 
of anatomical or hemodynamic CHDs; however, due to varying nomenclature and the 
wide variety of cardiac lesions, some variation may exist.3 CHDs can be categorized 
based on severity of the morphological lesions and functional consequences. 
Conventionally, CHDs are grouped into three categories: mild, moderate and severe. The 
majority of CHD cases can be considered mild. The cardiac defects in these patients 
would be largely asymptomatic, often undergoing spontaneous resolution.208 Moderate 
CHDs are more complex and require expert care, but are less intensive than the severe 
cases. Severe CHDs include univentricular hearts, heterotaxy, conotruncal defects, and 
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atrioventricular canal defects, affecting one third of all patients with cardiac anomalies.209 
Expert cardiologic care and intervention are required for these patients in the first year of 
life. Accordingly, survival rate is dependent on the severity of the disease. This rate is 
estimated to be 98% for patients with a mild CHD, whereas only 56% for patients with a 
severe CHD.210 CHD-related hospitalizations in the US have steadily risen with a 
financial burden of $6.1 billion per annum.211 
1.5.1.1 Septal Defects  
 Septal defects are the most common cardiac malformations in humans.71 These 
manifest as hemodynamically significant shunts between the left and right chambers of the 
heart. ASDs involve a connection between the left and right atria, reducing heart function. 
These defects are considered mild lesions and are not cyanotic as the high pressure in the 
left atrium will cause oxygenated blood to partly shunt into the right atrium. There are three 
major types of ASDs: defects of the ostium primum, secondum or a common atrium, where 
the atrial septum is lacking completely.45 Ostium primum defects are less common but more 
severe, and stem from incomplete growth of the primary atrial septum at the level of the 
inferior margin due to partial development of the endocardial cushions.212 In comparison, 
ostium secondum defects arise from a failure in the proper formation of the primary or 
secondary atrial septum. The incidence of ASDs among patients with CHDs is 
approximately 11%, whereas the incidence of VSDs is upwards of 30%.45, 77 VSDs are the 
most common congenital anomaly in children and the second most prevalent abnormality in 
adults.213 Two types of VSDs exist, which differ in anatomic location and histologic 
variation, allow for shunting of blood between the left and right ventricle, and are 
functionally more severe than ASDs. A membranous VSD occurs more frequently, and is 
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usually a small shunt between the ventricles underneath the OFT, which is encircled by 
fibrous tissue. In contrast, muscular VSDs involve a shunt enclosed by a muscular border.45 
Accordingly, an open connection between all four chambers of the heart is considered an 
AVSD. The incidence of AVSD can be as high as 15% in patients with Down Syndrome.214 
1.5.1.2 Outflow Tract Defects  
 OFT defects manifest in the aorta and/or pulmonary artery and result in a 
reduction of the functional cardiac output. Similar to septal defects, these malformations 
also involve a mixing of the systemic and pulmonary circulatory systems. A persistent 
truncus arteriosus, also referred to as a common arterial trunk (CAT), occurs as a result of 
improper development of the aorticopulmonary septum, resulting in a shunt between both 
arteries. This defect is always accompanied by a subarterial VSD.45 Mutations in the 
Pax3 or Semaphorin3 gene in CNC progenitor cells can lead to CAT.215, 216 Next, as the 
name suggests, a DORV involves both arteries drawing blood from the right ventricle. In 
this case, the aorta is improperly connected to the right ventricle, thereby supplying the 
body with partially deoxygenated blood. Again, this defect occurs along with a VSD, 
compensating for the blood flow disruption.45 Finally, an overriding aorta represent an 
alignment malformation instead of septation defect, and is linked to abnormal cardiac 
looping. This defect is also accompanied by a VSD. Together, the incidence of OFT 
defects is between 20 to 30% of total CHDs in humans at birth.3 
1.5.1.3 Valvular Defects  
 Congenital valvular malformations can affect any of the four valves of the heart, 
and occurs in approximately 2% of the general population. These defects commonly have 
a genetic component as they tend to cluster in families.3 The aortic semilunar valve 
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separates the aorta from the left ventricle, whereas the pulmonary semilunar valve 
separates the pulmonary artery from the right ventricle. The mitral valve exists between 
the left atrium and the left ventricle, and the tricuspid valve is between the right atria and 
ventricle. Congenital valvular defects occur most frequently at the aortic valve. In fact, a 
bicuspid aortic valve, in which only 2 out of 3 valve leaflets develop, is present in 1-2% 
of the general population.217 Thickening of the aortic valve, also known as aortic valve 
sclerosis, is a common OFT obstruction and can be a consequence of abnormal valve 
remodeling in utero. The incidence of aortic valve sclerosis can be upwards of 25% in the 
aged population; however, calcification of the valve and rheumatic aortic valve disease, 
occurring later in life, can account for many cases.218 Therefore, this disease represents a 
significant health problem, contributing to approximately 20,000 deaths annually.3  
1.5.1.4 Hypoplastic Coronary Artery Disease  
 Congenital under-development of the coronary arteries can result in hypoplastic 
coronary artery disease. This rare congenital abnormality is characterized by a marked 
decrease in luminal diameter, length or number of the coronary arteries.219 This can occur 
in one or more of the major branches of the coronary artery tree, where no other 
compensatory collateral vessels exist. Hypoplastic coronary artery disease is usually 
asymptomatic at birth, but can manifest later in life under conditions of stress or physical 
exertion, possibly resulting in myocardial infarction or even sudden cardiac death.220 Due 
to the asymptomatic nature of this disease, the incidence is estimated to be 1% in the 
general population.221, 222 Post mortem analysis revealed hypoplastic coronary artery 
disease in 2.2% of cases with coronary artery anomalies.223 Coronary angiography is the 
current tool to diagnose these congenital anomalies.   
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1.5.2 Epidemiology and Environmental Risk Factors of Congenital 
Heart Disease  
In the general population, CHDs are the most common structural birth defect.3, 198, 224 
Congenital heart disease is the leading cause of pediatric deaths in developed nations.196 
It is estimated that 257,000 Canadians and about 2 million Americans are living with a 
CHD.207, 225 Approximately 40,000 infants are diagnosed with a CHD each year in the 
US, and a quarter of these patients will need invasive treatment in the first year of life.3 In 
the year 2000, the prevalence of CHDs in the province of Quebec was 14.75 per 1000 
males and 17.22 per 1000 females.198 This remained consistent with the rest of the 
country as 13.11 per 1000 children had a CHD in 2010.207 In terms of specific cardiac 
malformations, the Centre for Disease Control reports that complex CHDs, such as TOF 
and AVSD are as common as 1 in 2518 and 1 in 2122, respectively.226 Many 
epidemiologists have noted a steady increase in occurrence of CHDs over time. One 
study from metropolitan Atlanta states that from 1978 to 2005, malformations of the heart 
increased from 50.3 per 10,000 to 86.4 per 10,000.227 This increase in proportion is 
alarming and calls for increased research to be conducted in order to elucidate the 
mechanisms behind potential insults to the developing heart. The variation in prevalence 
rates can be attributed to age of the patient when the defect is detected. Severe CHDs are 
usually cyanotic and can be diagnosed in utero or just after birth. Mild defects may not be 
identified until later in life or adulthood, making population prevalence difficult to 
estimate.3 Nevertheless, prevalence rates are expected to increase over time due to 
improved screening techniques, such as fetal cardiac ultrasound by pulse oximetry.3  
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Both intrinsic and extrinsic risk factors are associated with the development of 
CHDs. Many of the intrinsic factors have been discussed in previous sections. These 
include mutations in key transcription factors, such as NKX2.5, that govern heart 
development, and chromosomal abnormalities, such as Trisomy 21.228, 229 Extrinsic 
factors are non-genetic, and represent environmental insults during pregnancy that 
compromise developmental pathways in the embryo. These risk factors can include 
maternal smoking, nicotine exposure, alcohol consumption, obesity, chlamydia or rubella 
infections, preeclampsia and high altitude.230-238 For instance, there was an exposure-
response relationship between overweight, moderately obese and severely obese pregnant 
women with CHD incidence in the offspring. In fact, offspring of severely obese women 
were at a 1.94 times greater risk of having TOF.233 Pregestational maternal diabetes is an 
established risk factor for offspring CHDs in both the clinic and experimental animal 
models, which will be described in the following sections.  
1.6 Pregestational Diabetes and Congenital Heart Defects  
Congenital malformations in the offspring of women with PGD include defects of 
the limb, neural tube and musculoskeletal systems. However, the predominant 
malformations are CHDs, which represent about 40% of the total malformations.9, 10 PGD is 
an established risk factor for congenital heart disease,239 and increases the risk of a CHD in 
the child by more than four-fold.194, 240-242 This is a major concern as it is estimated that 
451 million people are living with diabetes, and the incidence of this condition is 
increasing at a rate of 10 million people per year. It is projected that by the year 2040, 
approximately 693 million people will be affected.1 In terms of the developmental origins 
of congenital heart defects, this increase in diabetes world-wide is alarming as 
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approximately 3 to 9 females in every 1000 pregnancies surveyed in Europe and North 
America are diabetic prior to conception of their child.243 As this number increases with 
the increase in diabetes, more individuals will be born with congenital heart defects, 
inevitably placing a large burden on the healthcare system.  
We recently demonstrated that pregestational diabetes induced by streptozotocin 
(STZ) in mice results in CHDs and coronary artery malformations (CAMs) in the offspring, 
which simulates diabetes-induced congenital heart disease in humans.200, 244 In experimental 
animal models, the incidence of congenital malformations induced by pregestational 
diabetes has been successfully reduced by vitamin E, vitamin C, hydroxytoluene (BHT), 
superoxide dismutase-1 (SOD1) and N-acetylcysteine (NAC) treatment.244-249 In the clinic, 
new-borns of pregestational diabetic women have an altered heart rate variability, fetal 
acidaemia and fetal glycaemia.250 During development, a higher fetal heart rate has been 
reported by cardiotocographic analysis from the first to the third trimester in pregnancies 
complicated with pregestational diabetes.251, 252 Accordingly, offspring of these women also 
have an altered QRS complex.253 Although current prenatal care recommends tight glucose 
control before and during pregnancy, CHD incidence in the offspring of diabetic women 
remains unchanged, showing little improvement.240 Insulin or other anti-diabetic 
medication, such as metformin for Type 2 diabetes, are currently prescribed for women with 
diabetes during pregnancy. Although these drugs are not teratogenic, their long-term effect 
on the offspring’s health is not known. Compliance and maintenance are also major factors 
that can impact proper glycaemic control for diabetic women during pregnancy.254 In 
addition, pregnancy can exacerbate and complicate diabetes management, usually requiring 
higher dosing of medication. Finally, the prevalence of diabetes is rapidly rising among low-
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to-middle income populations, and access to proper prenatal care is often challenging.255 
Thus, research must be conducted to find alternate interventions that support current 
treatment practices, while being safe and accessible.  
1.6.1 Potential Mechanisms of Diabetic Embryopathy  
 Maternal diet, nutrition and body composition have both short-term and long-term 
consequences for the offspring.256 Uncontrolled maternal diabetes is not conducive to 
proper gestation. Specifically, the hyperglycemic environment to which the embryo is 
exposed is dangerous as increased serum glucose leads to oxidative stress in cells through 
numerous pathways. High levels of glucose will increase glycolysis in cells and will 
cause increased amounts of NADH and FADH2. These molecules act as electron sources 
for the mitochondrial electron transport chain, and higher levels of electrons flowing 
through this chain will lead to increased oxygen consumption and ATP formation.257 
Superoxide generation will accompany this energy production, resulting in a rise in ROS. 
Premature electron leak from the cytochrome chain occurs in pathological conditions, 
resulting in ROS. At several points during the oxidative phosphorylation process, 
electrons can react with oxygen, forming radicals.258 Mitochondrial ROS can stimulate 
the production of cytosolic ROS through several mechanisms. Hydrogen peroxide can 
lead to the activation of cellular Src kinase, which promotes NADPH oxidase activity, 
producing superoxide.259 These reactive molecules can damage DNA and proteins critical 
for organogenesis.260 The developing heart is sensitive to changes in glucose availability. 
Early cardiac progenitors mainly rely on glycolysis for energy production; however, as 
cardiomyocytes terminally differentiate they switch to mitochondrial oxidative 
metabolism pathways.261 In fact, the expression of glucose transporter 1 (GLUT1) is 
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upregulated in the embryonic heart in experimental models of maternal diabetes, 
facilitating the glucose overload.8 
 Consequently, recent murine studies are attempting to examine whether miRNA 
expression is altered in the embryonic heart under maternal pregestational diabetes. A 
global miRNA profiling study reported a differential expression pattern of 149 miRNAs 
in E12.5 hearts from diabetic dams compared to control.262 Of these, 3,960 miRNA-
mRNA complementary pairs were identified between 32 miRNAs and 2,111 mRNA 
transcripts; 284 of which are transcriptional regulators involved in cardiac hypertrophy, 
hypoplasia, and cardiomyocyte apoptosis.262 In addition, pregestational diabetes-induced 
changes in miRNA expression in maternal exosomes can be relayed to the developing 
fetal heart. RNA sequencing revealed 186 upregulated and 92 downregulated miRNAs in 
maternal exosomes isolated from STZ-induced diabetic dams, compared to control.263 In 
particular, levels of miRNA-122 are almost 3-fold higher in these diabetic exosomes.263 
Taken together, these changes in miRNA expression, especially the increase in miRNA-
122, during fetal heart development in a diabetic environment warrant further 
investigation as these findings could provide new insights into the pathogenesis of 
diabetes-induced CHDs. 
1.6.1.1 ROS  
 Molecules containing one or more unpaired elections in their valence orbital or 
unstable bonds are reactive. ROS can exist as neutral molecules, ions or radicals, such as 
hydrogen peroxide, the superoxide anion, or the hydroxyl radical, respectively.264 These 
species oxidize other molecules by removing electrons in order to make themselves 
stable. For instance, the superoxide anion can react with nitric oxide forming the highly 
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reactive peroxynitrite.258 Superoxide cannot readily cross plasma membranes, therefore 
having local, transient effects. This ion is spontaneously dismutated into hydrogen 
peroxide, which has long-lasting effects and is freely diffusible across membranes. This 
conversion can be catalyzed within cells by the enzyme superoxide dismutase.264 
Elevated concentrations of ROS can react with proteins, lipids, carbohydrates and nucleic 
acids causing non-specific damage and permanent functional changes. Along with 
mitochondrial ROS production, intracellular sources of ROS include peroxisomes, 
lysosomes, and the enzymes NADPH oxidase, xanthine oxidase and cytochrome p450.264 
A major contributor of ROS in endothelial cells is NADPH oxidases, which transfer 
electrons across membranes to an oxygen molecule.258 
1.7 Endothelial Nitric Oxide Synthase  
 Nitric oxide (NO) is a lipophilic, small gaseous molecule that has numerous roles 
in biological signaling processes, and, most notably, serves as a potent vasodilator.265 
Nitric oxide production within the cell is accomplished by the enzyme nitric oxide 
synthase (NOS), which catalyzes the conversion of L-arginine into nitric oxide through a 
NADPH-dependent reaction. Three isoforms of this enzyme, neuronal (nNOS, NOS1), 
cytokine-inducible (iNOS, NOS2), and endothelial (eNOS, NOS3) are distinctly 
expressed in mammalian cells and produce NO in a tissue-specific manner.266 nNOS is 
constitutively expressed in neurons of the central and peripheral nervous system, whereas 
iNOS is expressed in cells of the immune system and produces high levels of nitric oxide 
associated with inflammatory processes. eNOS is membrane bound and calcium-
sensitive, expressed in endothelial and myocardial cells, located on chromosome 7 in 
humans.267 They are homodimeric, haem-containing globular proteins, with a N-terminal 
43 
 
oxygenase domain and a C-terminal reductase domain, which are linked by a calmodulin 
binding sequence. The dimer produces NO in the coupled state, and requires 
Ca2+/calmodulin, flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and 
tetrahydrobiopterin (BH4) as cofactors.266 Calcium-activated calmodulin initiates the 
election transfer to produce nitric oxide, which, when produced, acts on soluble guanylyl 
cyclase to catalyze the formation of the second messenger, cyclic guanosine 
monophosphate (cGMP). Downstream targets of cGMP include protein kinases (PKGs), 
ion channels and cyclic nucleotide phosphodiesterases (PDEs).268 Activation or inhibition 
of protein function via S-nitrosylation is also a downstream effect of nitric oxide. 
Interestingly, eNOS can be itself S-nitrosylated, reducing its activity.269 Phosphorylation 
of eNOS at serine-1177 by Akt (protein kinase B) activates the enzyme, which itself is 
active when phosphorylated. Nitric oxide production via this PI3K/Akt/eNOS pathway 
represents a highly regulated biological process involved in endothelial cell permeability, 
vascular smooth muscle relaxation, calcium handling, immune regulation and 
neurotransmission.270 The vital role of eNOS-derived NO in cardiovascular health and 
development will be explored in following sections.  
1.7.1 Tetrahydrobiopterin  
The pteridine (6R) 5,6,7,8-tetrahydrobiopterin (BH4) is an antioxidant and 
cofactor for many metabolic enzymes, involved in the production of neurotransmitters 
and nitric oxide. As a cofactor, its heterocyclic ring structure functions to facilitate 
complex chemical reactions in a wide variety of biological processes.271 Aromatic amino 
acid hydroxylases utilize BH4 as a cofactor to produce monoamine neurotransmitters 
such as serotonin, melatonin, dopamine, norepinephrine and epinephrine. As stated 
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above, tetrahydrobiopterin is the principle co-factor for eNOS and can serve as an 
endogenous antioxidant as well. BH4 is essential for NOS-mediated nitric oxide 
synthesis, by all three isoforms, and serves both biochemical and structural functions.271 
It is required for eNOS homo-dimer stabilization and is an allosteric modulator of L-
arginine binding to the active site.272 BH4 participates in the biochemical formation of 
NO from O2 by donating an electron for the conversion of L-arginine to L-citrulline.
273 It 
“couples” the haem reduction to nitric oxide synthesis, and acts as a sequential one-
electron reductant and oxidant.266 However, BH4 is not consumed in this process as it 
recaptures its electron from the iron-containing heme group, facilitating NO release.274 
BH4 biosynthesis within the cell is carried out via a three-step enzymatic process with the 
conversion of the nucleotide GTP into 7,8-dihydroneopterin triphosphate as the rate-
limiting first step. The enzyme that catalyzes this conversion is GTP cyclohydrase 1 
(GTPCH-1). It is encoded by the gene GHC1 on chromosome 14 in humans. The next 
steps are catalyzed by 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase.271 
GTPCH-1 expression and activity are tightly regulated at transcriptional, translational 
and post-translational levels. For example, a negative feedback loop exists whereby BH4 
allosterically downregulates activity of GTPCH-1 when it is bound, in a dose-dependent 
manner, to the feedback regulatory protein, GFRP. Conversely, the interaction of GFRP 
with L-phenylalanine can reverse this effect, and increase GTPCH-1 activity and BH4 
production.275 Along with this de novo biosynthesis pathway, BH4 can also be recycled 
within the cell through a salvage pathway. The enzyme dihydrofolate reductase (DHFR) 
regenerates BH4 by reducing dihydrobiopterin (BH2), a byproduct of oxidation. DHFR is 
ubiquitously expressed and needed by eukaryotes and prokaryotes for normal cellular 
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metabolism. Apart from being involved in BH4 recycling, it also catalyzes the reduction 
of folate to tetrahydrofolate, which is required for many biological processes, such as 
amino acid biosynthesis.276 Therefore, the cellular bioavailability of BH4 is balanced 
between its de novo synthesis, oxidation to BH2 and regeneration. Due to the critical role 
of nitric oxide in the cardiovascular system, BH4 administration has been tested for its 
clinical viability at improving endothelial function in many studies. Intravascular infusion 
of BH4 to chain smokers improved their endothelium-dependent vasodilation.277 
Similarly, in patients with hypercholesterolaemia, BH4 infusion improved coronary 
microvascular circulation.278 In accordance, BH4 intra-arterial administration prevented 
ischemia reperfusion injury in the human forearm. 279 
1.7.1.1 Sapropterin Dihydrochloride 
 Sapropterin dihydrochloride is an FDA-approved synthetic formulation of BH4, 
prescribed for the treatment of phenylketonuria.280 Orally active and stable, this drug is 
marketed as Kuvan® and has been manufactured by Biomarin Pharmaceuticals since 
2007.281 Patients with PKU are unable to metabolize the amino acid phenylalanine, 
present in many food products, due to a mutation in the metabolizer phenylalanine 
hydroxylase (PAH).282 This enzyme uses BH4 as a cofactor to oxidize phenylalanine to 
tyrosine. When mutated its activity is reduced leading to hyperphenylalaninemia, the 
toxic accumulation of phenylalanine in the blood. Complete phenylalanine restriction is 
recommended for patients with PKU; however, long-term compliance can be difficult, 
especially in youth and pregnant women. Treatment with sapropterin can activate the 
residual PAH enzyme, allowing for the metabolism of phenylalanine, thereby decreasing 
its levels in the blood. PKU patients administered sapropterin have increased 
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phenylalanine tolerance, thereby allowing a relaxation in dietary restrictions.282 This drug 
has an acceptable safety profile and is prescribed as 100 mg tablets at a starting dose of 
10 mg/kg/day.281 
1.7.2 BH4 Cycling and eNOS Coupling; a Positive Feedback Loop  
BH4 production, either through de novo synthesis or regeneration, promotes 
eNOS function, generating nitric oxide (Figure 1.3).283 In fact, diminished levels of BH4 
or depletion of L-arginine can uncouple the eNOS dimer, rendering it incapable of 
producing nitric oxide, instead generating oxygen derived free radicals.284 Similarly, in 
states of oxidative stress, this process is insulted at many levels, sustaining the oxidative 
environment and leading to cellular dysfunction. The production of ROS is often 
amplified because of a positive-feedback loop; ROS generates more ROS. As mentioned 
above, GTPCH-1 is an enzyme involved in antioxidant biosynthesis. Specifically, it 
catalyzes the formation of BH4, an essential co-factor for eNOS.285 Recently, a study has 
indicated that ROS causes the release of zinc from GTPCH-1, rendering it less functional 
(Figure 1.3).286  Consequently, the intracellular levels of BH4 decline and eNOS is left 
without a cofactor, triggering its uncoupling. When eNOS is uncoupled, it cannot form 
nitric oxide, which has its own developmental implications, and instead generates ROS in 
the form of superoxide. This superoxide anion participates in a rapid reaction with low 
levels of NO in the cell and forms the peroxynitrite anion (ONOO-) (Figure 1.3).287 This 
species is normally in equilibrium with peroxynitrous acid (ONOOH), which can decay 
and form ONOOH•, another reactive radical. Proteins are especially vulnerable to 
modification by the peroxynitrite system, as it incurs covalent changes to the amino acid 
residues cysteine, methionine, tryptophan, and tyrosine.288 ONOO- specifically 
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inactivates GTPCH-1, decreasing de novo BH4 synthesis, and the additional oxidative 
stress furthers the oxidation of BH4 into BH2.286 BH2 is unable to couple eNOS, and 
competes with BH4 for eNOS binding, exacerbating the superoxide production. Mice 
lacking GTPCH-1 in the endothelium display significantly decreased BH4 levels, eNOS 
uncoupling and increased ROS production, resulting in loss of vasodilation.  
Another enzyme inactivated by O2
- and ONOO- is dihydrofolate reductase 
(DHFR), responsible for the recycling of BH2 back to BH4.273, 289 Experiments done in E. 
coli demonstrate peroxynitrite-induced alterations to the catalytic site of DHFR, resulting 
in functional compromise.276 Therefore, both the salvage and endogenous synthesis 
pathways are crippled due to ROS, furthering the oxidative environment (Figure 1.3). In 
states of oxidative stress, BH4 levels decline, and eNOS function is impaired. 
Specifically, oxygen activation is functionally uncoupled to L-arginine oxygenation, 
resulting in decreased NO production.290 Instead, activated O2, in the form of superoxide, 
is released from the enzyme, perpetuating the oxidative environment of the cell. The 
relationship between eNOS function and diabetes has been well established. Endothelial 
dysfunction is a common consequence of diabetes and is mediated by oxidative stress-
induced eNOS uncoupling.291-293 Previous studies indicate that dissolution of the eNOS 
dimer also occurs in aging vessels and in cardiovascular disease states, such as 
hypertension, ischemia-reperfusion injury and heart failure.294-296 Treatment with BH4 
has been shown to recouple eNOS and improve vascular endothelial function in 












Figure 1.3. eNOS uncoupling and inactivation in states of oxidative stress. 
The functional eNOS dimer, producing nitric oxide, is seen on the left. eNOS 
dysfunction, on the right, occurs in states of oxidative stress, where BH4 is oxidized, the 
dimer is uncoupled and eNOS is inactive. In this state, nitric oxide is no longer produced 
and instead superoxide radical is generated. The salvage and de novo BH4 biosynthesis 
pathways are actively producing BH4 in normal conditions, but are impaired by oxidative 





1.7.3 The role of eNOS in Cardiovascular Development  
 eNOS is vital for heart development. Expression of the synthase starts at E9.5 in 
the endothelium and cardiomyocyte precursors of the heart tube, and peaks at E13.5, after 
which it begins to decline, but remains detectable at birth and into postnatal 
development.270 The lung, liver, gastrointestinal tract, reproductive organs and brain all 
express NOS3 during their organogenesis.298 In vitro incubation of NOS inhibitors to 
embryonic stem cell-derived cardiomyocytes inhibited their maturation.298 Interestingly, 
mouse embryonic stem cells exogenously treated with a NO donor or transfected with 
NOS promoted their differentiation into cardiomyocytes, inducing the expression of 
cardiac specific genes.299 Induced pluripotent stem cells and E14.5 ventricular tissue both 
deficient in NOS3 show consistent transcriptome profiles, and particularly an up-
regulation of glucose metabolism genes.300 Gata4, a transcription factor needed for 
cardiomyocyte specification and heart development, can modulate and increase the 
expression of eNOS by binding to its promoter region.301 The importance of eNOS in 
heart development has been showcased through the spectrum of cardiovascular anomalies 
seen in eNOS-/- mice. Embryonic deletion of nNOS or iNOS display normal cardiac 
phenotypes, however eNOS null mice have a high rate of CHDs, with a 75% incidence of 
septal malformations in the offspring. These mice have increased postnatal mortality, 
impaired heart function, and significant elevations in embryonic apoptosis in the heart.119 
In addition, these mice have severe valvular malformations, including bicuspid aortic 
valves (30 – 40% incidence), underdeveloped mitral and tricuspid valves, which have 
significant regurgitation during systole (analyzed using pulse-wave Doppler), along with 
aortic valve sclerosis and calcification.302-304 During embryonic development, eNOS null 
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mice has less Snail+ mesenchymal cells in the endocardial cushions, suggesting impaired 
EndMT. This was coupled with significantly lower mRNA levels of genes involved in 
valve formation, such as Tgf- and Bmp2.303 Accordingly, patients with bicuspid aortic 
valve disease had lower eNOS protein expression in aortic endothelial cells compared 
with tricuspid aortic valves patient specimens.305 eNOS-derived NO regulates cell growth 
and protects early cardiac progenitors against apoptosis.119 This is accomplished through 
S-nitrosylation and inactivation of caspase-3.306 Shear stress-induced NO production and 
up-regulation of superoxide dismutase also prevented endothelial cell death via inhibiting 
caspase-3 activity.307 eNOS is also required for cardiomyocyte proliferation, as well as 
VEGF expression to form the capillary network supplying the muscle.108 In fact, eNOS 
intimately controls coronary artery development in mice, as loss of this enzyme results in 
coronary artery hypoplasia and spontaneous postnatal myocardial infarction.110 Key 
transcription factors that control EMT and vasculogenesis are downregulated in this 
model, including Gata4, Wt1, Vegf, bFGF and EPO, all of which are rescued by eNOS 
overexpression, restoring normal vasculature.110 The congenital coronary artery 
anomalies and CHDs seen in eNOS knockout mice in utero and at birth impair heart 
function in adult mice. Adult eNOS-/- mice display heart failure, characterized by a 
molecular switch from - to -myosin heavy chain expression as well as an increase in 
atrial naturetic peptide levels.308 Inhibition of eNOS function using L-NAME induces 
comparable levels of fibrosis to eNOS null mice, following transverse aortic 
constriction.309 eNOS restoration in the heart of eNOS-deficient mice attenuates LV 
hypertrophy, cardiac dysfunction and protected against adverse myocardial remodeling 
after aortic banding.310 Mechanistically, eNOS-derived NO signaling reduces cardiac 
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calcium currents, decreasing the sympathetic β-adrenergic response and arrhythmia 
incidence, protecting the heart. The same is true in the embryonic heart, as NO regulation 
of L-type calcium channels also promotes mouse embryonic stem cell differentiation into 
cardiomyocytes.311 Thus, the indispensable role of eNOS in the development of the heart 
and coronary vascular means that any alterations to the NO balance could prove 
deleterious.  
1.8 Rationale and Hypothesis  
CHDs are the most common birth defect and the leading cause of death in the first 
year of infant life. Environmental, non-genetic factors are associated with the majority of 
CHDs seen in the clinic, while inherited genetic mutations only account for 15% of 
reported cases.195 Pregestational diabetes is an important risk factor of CHDs, 
heightening the risk by 3 – 5 times.240 While good glycemic control in diabetic mothers 
lowers the risk, the incident of CHDs in their children is still higher than in the general 
population.241 The rapid increase of young adults with diabetes and pre-diabetes is 
alarming, and warrants further research to broaden our understanding of the pathogenesis 
of congenital cardiovascular malformations and their prevention. Due to of the critical 
roles of eNOS and miRNAs in heart development, this thesis aims to study the effects 
of sapropterin and antimiR-122 on CHDs and coronary artery malformations in a 
mouse model of pregestational diabetes.  
We hypothesized that:  
(1) BH4 treatment during the full gestational term of pregnant female mice with 
pregestational diabetes will decrease the incidence of CHDs and CAMs in 
52 
 
fetal hearts, through changes in gene expression, cell migration and 
proliferation, ROS handling and eNOS coupling, and 
(2) microRNA-122 is involved in pregestational diabetes-induced CHDs and 
CAMs, and antimiR-122 treatment will prevent these congenital cardiac 
abnormalities.  
1.8.1 Aim 1: Sapropterin on Diabetes-Induced CHDs  
The first aim of this study was to determine if BH4 treatment during the full 
gestational term of female mice with pregestational diabetes could decrease the incidence 
of CHDs in fetal hearts by mitigating altered gene expression, cell proliferation, SHF 
development, ROS levels, and eNOS coupling. Previous animal studies, as well human 
clinical data, have suggested a strong association between diabetic pregnancy and CHD 
incidence. In addition, eNOS has been demonstrated to play a vital role in embryonic 
heart development.270 The activity of this enzyme is compromised in diabetes, leading to 
endothelial dysfunction. Specifically, the eNOS dimer can be uncoupled, increasing the 
already high levels of oxidative stress brought on by hyperglycemia.312 Sapropterin 
dihydrochloride (Kuvan®) is an orally active synthetic form of BH4 and an FDA 
approved drug for the treatment of phenylketonuria.281 We hypothesized that maternal 
diabetes-induced oxidative stress would lead to eNOS uncoupling in the developing 
myocardium, resulting in increased ROS, altered cardiogenic gene expression, 
decreased proliferation and development of SHF structures, and subsequent CHDs 
and damped cardiac function. We further hypothesized that exogenous sapropterin 
treatment would re-instate oxidative balance and recouple eNOS in the embryonic 
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heart, promote cell proliferation of cardiac progenitors and decrease the incidence 
of CHDs.  
Objectives: 
1. Characterize the spectrum of CHDs induced by pregestational maternal diabetes, 
and test if sapropterin therapy can rescue the disease phenotype.  
2. Utilize lineage tracing to determine the impact of maternal diabetes on the 
development of the SHF.   
3. Determine if the eNOS dimer is uncoupled and if there is elevated ROS in the 
embryonic myocardium from diabetic dams, and assess if sapropterin treatment 
can recouple eNOS and reduce ROS.  
1.8.2 Aim 2: Sapropterin on Diabetes-Induced CAMs  
 Congenital coronary artery malformations (CAMs) affect about 1% of the general 
population.221-223 Hypoplastic coronary artery disease (HCAD) is a congenital 
abnormality characterized by marked decrease in luminal diameter and length of 
coronary vasculature.313 HCAD usually is asymptomatic at birth, and can go unnoticed 
until the individual is older and/or subjected to increased physical exertion. Without 
intervention, this could lead to myocardial infarction and even sudden cardiac death.220 
As this disease is asymptomatic at birth and possibly for much of adulthood, it is pressing 
that preventative precautions be taken during gestational coronary artery development. 
The development of the coronary vasculature occurs in tandem with heart development, 
but is distinct in its cellular origin and molecular drivers. It involves coordinated EMT 
and differentiation, with eNOS again playing a major role. In fact, eNOS-/- mice display 
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hypoplastic coronary arteries and post-natal myocardial infarction.110 Additionally, 
experiments in mice have indicated that hyperglycemia during pregnancy can induce 
coronary artery anomalies.200 Therefore, we hypothesized that pregestational diabetes 
would result in CAMs, akin to hypoplastic coronary artery disease, which would be 
a result of impaired EMT during embryonic development. Further, we hypothesized 
that sapropterin treatment would promote epicardial EMT and reduce the 
incidence of CAMs in offspring of pregestational diabetes.    
 Objectives: 
1. Analyze CAMs induced by pregestational diabetes, and determine if sapropterin 
treatment can reduce their incidence.  
2. Determine if epicardial EMT is impaired by diabetic pregnancy, and if sapropterin 
can regulate the process under high glucose conditions.  
3. Elucidate the impact of hyperglycemia during gestation on eNOS phosphorylation 
and oxidative stress in the fetal heart.  
1.8.3 Aim 3: Role of microRNA-122 in Heart Development  
 MicroRNAs play an important role in cardiogenesis, often acting as temporal 
switches, turning on and off gene programs that govern developmental stages of the 
heart. miRs are short, non-coding RNA molecules that post-transcriptionally regulate 
gene expression by repressing mRNA.145 These small RNA molecules can freely cross 
the placenta and enter fetal circulation. Patients with diabetes have a dysregulation in 
miRNA expression.314 Diabetic pregnancy may illicit changes in the miRNA profile, in 
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either the mother or the fetus, contributing to the pathogenesis of CHDs. Our preliminary 
data confirms the finding of a differential miRNA transcriptome profile in embryonic 
hearts from diabetic dams. In our laboratory, using global microarray analysis, we found 
that miR-122 is upregulated 14-fold in E10.5 hearts from diabetic dams compared to 
control. miR-122 is required for liver homeostasis and acts as tumor suppressor, by 
inhibiting the expression of genes involved in proliferation and epithelial to mesenchymal 
transition (EMT); two processes critical to cardiogenesis. Therefore, we hypothesized 
that miR-122 would be upregulated in fetal hearts from diabetic dams and would 
impair key developmental processes, such as cell proliferation, migration and 
apoptosis, in the heart. We further hypothesized that antimiR-122 treatment to 
diabetic dams would reduce the incidence of CHDs in the offspring.  
 Objectives: 
1. Validate the expression of miR-122 in embryonic hearts from diabetic dams, and 
determine if the expression of miR-122 targets is altered.  
2. Determine the effects of miR-122 on cell proliferation, apoptosis and EMT in the 
embryonic heart. 
3. Determine if in vivo administration of antimiR-122 could reduce the incidence of 
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2 Chapter 2 
2.1 Chapter Summary 
 Tetrahydrobiopterin (BH4) is a co-factor of endothelial nitric oxide synthase 
(eNOS), which is critical to embryonic heart development. We aimed to study the effects 
of sapropterin (Kuvan®), an orally active synthetic form of BH4 on eNOS uncoupling 
and congenital heart defects (CHDs) induced by pregestational diabetes in mice. Adult 
female mice were induced to pregestational diabetes by streptozotocin and bred with 
normal males to produce offspring. Pregnant mice were treated with sapropterin or 
vehicle during gestation. CHDs were identified by histological analysis. Cell 
proliferation, eNOS dimerization and reactive oxygen species (ROS) production were 
assessed in the fetal heart. Pregestational diabetes results in a spectrum of CHDs in their 
offspring. Oral treatment with sapropterin in the diabetic dams significantly decreased the 
incidence of CHDs from 59% to 27% and major abnormalities, such as atrioventricular 
septal defect and double outlet right ventricle were absent in the sapropterin treated 
group. Lineage tracing revealed that pregestational diabetes resulted in decreased 
commitment of second heart field progenitors to the outflow tract, endocardial cushions, 
and ventricular myocardium of the fetal heart. Notably, decreased cell proliferation and 
cardiac transcription factor expression induced by maternal diabetes were normalized 
with sapropterin treatment. Furthermore, sapropterin administration in the diabetic dams 
increased eNOS dimerization and lowered ROS levels in the fetal heart. Sapropterin 
treatment in the diabetic mothers improves eNOS coupling, increases cell proliferation 
and prevents the development of CHDs in the offspring. Thus, sapropterin may have 




Congenital heart defects (CHDs) are the most common structural birth defect, 
occurring in 1-5% of live births, making them the leading cause of death in the first year 
of infant life.1, 2 The prevalence of CHDs has been rapidly increasing,3 and it is estimated 
that approximately 2.4 million Americans, including 1 million children, are living with a 
congenital malformation of the heart.2 CHDs are formed when complex cellular and 
molecular processes underlying embryonic heart development are disturbed. The heart is 
developed from three pools of progenitor cells: the first heart field (FHF), the second 
heart field (SHF) and cardiac neural crest (CNC).4 The FHF progenitors initially form the 
primary heart tube. SHF cells are then added to the heart tube to form the right ventricle, 
give rise to myocardial and endothelial cells of the outflow tract and semilunar valves, as 
well as the vascular smooth muscle cells at the base of the aorta and pulmonary trunk. 
The CNC cells contribute to septation of the outflow tract and remodeling of semilunar 
valves, while the left ventricle is mainly formed from FHF progenitors. The SHF is 
particularly significant to CHDs as many common cardiac abnormalities including atrial 
and ventricular septal defects, cardiac valve malformation, double outlet right ventricle 
and truncus arteriosus, are caused by defects in SHF progenitors.4  
Pregestational diabetes (type 1 or 2) in the mother increases the risk of a CHD in 
the child by more than four-fold.5, 6 While good glycemic control in diabetic mothers 
lowers the risk, the incident of CHDs in their children is still higher than the general 
population.7, 8 The prevalence of pregestational diabetes has nearly doubled from 0.58% 
to 1.06% from 1996 to 2014 in Northern California,9 and has reached 4.3% in Saudi 
Arabia.10 As the prevalence of pregestational diabetes further increases in women during 
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their reproductive age, more individuals will be born with CHDs, inevitably placing a 
large burden on the healthcare system.11, 12 
Uncontrolled maternal diabetes is not conducive to proper gestation. 
Hyperglycemia leads to cellular oxidative stress through numerous pathways,13 which 
include increased electron transport chain flow resulting in mitochondrial dysfunction, 
non-enzymatic protein glycosylation and glucose auto-oxidation all contributing to 
reactive oxygen species (ROS) generation.14, 15 Increased oxidative stress can lead to the 
inactivation of many molecules and proteins necessary for proper heart development. 
Endothelial nitric oxide synthase (eNOS) is intimately regulated by redox balance within 
the cell and is vital for cardiogenesis.16 eNOS expression in the embryonic heart regulates 
cell growth and protects early cardiac progenitors against apoptosis.17 The importance of 
eNOS in heart development has been demonstrated in eNOS-/- mice by a spectrum of 
cardiovascular anomalies such as ventricular septal defects (VSDs), valvular 
malformations and hypoplastic coronary arteries.17-19  
Tetrahydrobiopterin (BH4) has antioxidant properties and is a critical co-factor for eNOS 
function.20 It is required for eNOS dimer stabilization and is an allosteric modulator of 
arginine binding to the active site.21 In states of oxidative stress, BH4 levels decline, and 
eNOS is uncoupled, resulting in decreased NO synthesis and increased superoxide 
production, perpetuating the oxidative environment of the cell.22 The production of ROS 
is amplified by this feedback loop, further inducing eNOS uncoupling. Treatment with 
BH4 has been shown to recouple eNOS and improve vascular endothelial function in 
diabetes.23, 24 However, the potential of BH4 to reduce the severity and incidence of 
CHDs is not known. Sapropterin dihydrochloride (Kuvan®) is an orally-active, synthetic 
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form of BH4 and an FDA approved drug for the treatment of phenylketonuria.25 The 
present study was aimed to examine the effects of sapropterin in mice with pregestational 
diabetes. We hypothesized that sapropterin treatment during gestation re-couples eNOS, 
improves cell proliferation in SHF derived cells, and reduces CHD incidence in the 
offspring of mice with pregestational diabetes. 
2.3 Methods 
2.3.1 Animals 
 All procedures were performed in accordance with the Canadian Council on 
Animal Care guidelines and approved by the Animal Care Committee at Western 
University. C57BL/6 wild type and Rosa26mTmG mice were purchased from Jackson 
Laboratory (Bar Harbor, Maine). Mef2ccre/+ embryos were obtained from Mutant Mouse 
Regional Resource Center (Chapel Hill, NC) and rederived. All animals were housed in a 
12-hour light/dark cycle and given ad libitum access to standard chow and water. A 
breeding program was established to generate embryonic, fetal and post-natal mice.  
2.3.2 Induction of Diabetes and Sapropterin Treatment  
 A study flow chart in Figure 2.1 illustrates timelines of saline or streptozotocin 
(STZ) injection, breeding, sapropterin or insulin treatment and assessments of fetal hearts 
in 5 groups of mice. Female C57BL/6 mice, 8 to 10 weeks old were made diabetic 
through five consecutive daily injections of STZ (50 mg/kg body weight, IP, Sigma) 
freshly dissolved in sterile saline. Mice were randomly assigned to STZ (n=37) or saline 
treatment (n=19) groups. One week following the last STZ injection, non-fasting blood 
glucose levels were measured with a tail snip procedure using a glucose meter (One 
Touch Ultra2, LifeScan, Burnaby, BC). Mice were categorized as diabetic if blood 
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glucose measurements exceeded 11 mmol/L, and were subsequently bred to 10 to 12 
week old C57BL/6 male mice. In the morning when a vaginal plug was observed 
indicating embryonic day 0.5 (E0.5), the female diabetic mouse was placed in a separate 
cage with littermates. A cohort of diabetic and control female mice were treated with 
sapropterin dihydrochloride (Kuvan®, BioMarin Pharmaceutical Inc.) at a dose of 10 
mg/kg body weight per day during gestation. Sapropterin was dissolved in water and 
mixed with a small amount peanut butter in a weigh boat, ensuring it was fully consumed 
by the mouse. At the time of feeding, mice were separated and individually housed in 
cages for about 15 min until the sapropterin or vehicle containing peanut butter mixture 
was fully consumed under an investigator’s watch. All mice were fed in the morning, 
once per day. Non-fasting blood glucose levels were monitored throughout pregnancy. 
To prevent hyperglycemia, a long acting form of insulin (Lantus®, Sanofi Aventis) was 






Figure 2.1. Experimental design to examine the effects of sapropterin (BH4) on 
congenital heart defects induced by pregestational diabetes.  
A study flow chart illustrates timelines of saline or STZ injection, breeding, sapropterin 
or insulin treatment and assessments of fetal hearts in 5 groups of mice. IP indicates 
intraperitoneal injection; PO, oral administration; STZ, streptozotocin. BG, blood 
glucose; E, embryonic day; eNOS, endothelial NO synthase; OFT, outflow tract; ROS, 
reactive oxygen species. 
 
2.3.3 Histological and Immunohistochemical Analysis 
 Fetal samples were harvested at E10.5, E12.5 and E18.5 for histological and 
immunohistochemical analysis. To diagnose CHDs in E18.5 hearts, fetuses were 
decapitated and the isolated thorax was fixed overnight in 4% paraformaldehyde, 
dehydrated in ethanol and paraffin embedded. Samples were sectioned in 5 μm slices and 
hematoxylin/eosin (H&E) or toluidine blue stained to visualize morphology. Images were 
taken and analyzed using a light microscope (Observer D1, Zeiss, Germany). Embryonic 
samples at E10.5 and E12.5 were fixed in 4% paraformaldehyde for 1 and 2 hours, 
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respectively, and processed as described above. Immunostaining to analyze cell 
proliferation at E10.5 using anti-phosphohistone H3 (pHH3) antibody (1:1000, Abcam), 
and sex determination at E18.5 using anti-sex-determining region Y protein antibody 
(1:200, Santa Cruz) were performed after antigen retrieval in citrate buffer (10 mmol/L, 
pH 6). This was followed by incubation with biotinylated goat anti-mouse IgG (1:300, 
Vector Laboratories) secondary antibody. The signal was amplified by the ABC reagent 
(Vector Laboratories) allowing for visualization through 3-3’di-aminobenzidine 
tetrahydrochloride (DAB, Sigma) with hematoxylin as a counterstain. Blinded pHH3+ 
cell counts within the outflow tract (OFT) were taken from at least 3 heart sections per 
heart and normalized to OFT length.  
2.3.4 Lineage Tracing the Second Heart Field  
 Fate mapping of SHF progenitors was performed using the SHF specific 
Mef2ccre/+ transgenic mouse and the global double fluorescent Cre reporter line 
Rosa26mTmG that has LoxP sites on either side of a tomato-red fluorescence membrane 
protein (mT) cassette, which is proceeded by a green fluorescence protein (GFP, mG) 
cassette. In the Mef2cCre/+ transgenic line with C57BL/6 background, elements of the 
Mef2c promoter drives Cre recombinase expression in all SHF derived cells. When 
crossed with the Rosa26mTmG mice this results in a GFP signal that is detected in all SHF 
derived cells.26, 27 In all other tissues, the absence of the Cre results in mT expression and 
red fluorescence. Diabetes was induced in homozygous Rosa26mTmG females (8 to 10 
weeks old) by STZ as described above. Hyperglycemic Rosa26mTmG female mice were 
crossed with Mef2ccre/+;Rosa26mTmG males to generate E9.5 and E12.5 
Mef2ccre/+;Rosa26mTmG embryos, which were fixed, embedded and sectioned in the same 
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manner as above. Immunostaining for membrane bound GFP was conducted using an 
anti-GFP (1:500, Abcam) primary antibody, followed by biotinylated goat anti-rabbit IgG 
(1:300, Vector Laboratories) secondary antibody using DAB for visualization. The SHF 
derived cells, which are GFP+, were blindly quantified and compared between control 
and diabetic groups.  
2.3.5 Analysis of Superoxide Levels 
 Hearts collected from E12.5 fetuses from all four groups were cryo-sectioned 
(CM1950, Leica, Germany) into 8 m thick slices and placed onto slides. A subset of 
cryo-sectioned embryonic hearts from untreated and sapropterin-treated diabetic dams 
were incubated with either 300 M L-NAME (Sigma), a nitric oxide synthase inhibitor, 
or 100 units/mL superoxide dismutase (SOD, Sigma), recombinant antioxidant enzyme 
for 30 minutes. Samples were then probed with 2 M dihydroethidium (DHE) 
(Invitrogen Life Technologies, Burlington, Canada) for 30 minutes in a dark humidity 
chamber at 37 C. After cover glass was mounted, DHE fluorescence signals were 
visualized using a fluorescence microscope (Observer D1, Zeiss, Germany). Five – 8 
images from each sample were captured at fixed exposure times for all groups and the 
fluorescence intensity per myocardial area was blindly quantified using AxioVision 
software.  
2.3.6 Measurement of Cardiac Function 
 Pregnant dams were anesthetized and M-mode echocardiography images of E18.5 
embryonic hearts were recorded using the Vevo 2100 ultrasound imaging system with a 
MS 700 transducer (VisualSonics, Toronto, Canada) as previously described.18, 19 Briefly, 
an incision was made to the abdominal wall of the pregnant dam to expose the uterine 
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sacs containing the E18.5 fetuses. The transducer was aligned to the uterine sac to obtain 
a short-axis view of the fetal heart. The end diastolic left ventricular internal diameter and 
end systolic left ventricular internal diameter were measured from the short-axis M-mode 
images to calculate LV ejection fraction and fractional shortening. 
2.3.7 Western Blotting for eNOS Dimers and Monomers 
 Ventricular myocardial tissues from E12.5 hearts were dissected in PBS and used 
for measurement of eNOS dimerization. In order to not disrupt the dimer, proteins were 
isolated from three pooled hearts from each group via sonication using a non-reducing 
lysis buffer, on ice.28 Protein lysates without boiling were run on an 8% SDS-PAGE at 4 
C followed by transferring to a nitrocellulose membrane and immunoblotted with anti-
eNOS polyclonal antibody (1:3000, Santa Cruz). This technique resulted in two distinct 
bands at 260 and 130 kDa, representing the eNOS dimer and monomer, respectively.28 
Proteins isolated from cultured coronary artery microvascular endothelial cells was boiled 
and separated with the sample, acting as an eNOS monomer size control. 
2.3.8 Real-Time RT-PCR 
 Total RNA was isolated from E12.5 hearts using TRIzol reagent (Invitrogen). 200 
nanograms of RNA were synthesized into cDNA with Moloney murine leukemia virus 
reverse transcriptase and random primers. Real-time PCR was conducted on cDNA using 
Evagreen qPCR MasterMix (Applied Biological Systems, Vancouver, BC). Primers were 
designed for Gata4, Gata5, Nkx2.5, Tbx5, Notch1, GCH1, DHFR using the Primer3 
software v 4.1.0. The primer sequences are listed in Table 2.1. Eppendorf Realplex 
(Eppendorf, Hamburg) was used to amplify samples for 35 cycles. Values were 
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normalized to 28S ribosomal RNA, and mRNA levels were extrapolated through a 
comparative CT method.
19  
Table 2.1. Specific primer sequences used in real-time PCR analysis. 
Gene Accession no.  Product Size Primer Sequence 
Gata4 NM_008092.3  134 
F: GCCTGCGATGTCTGAGTGAC 
R: CACTATGGGCACAGCAGCTC  
Gata5 NM_008093.2  167 
F: ACCCCACAACCTACCCAGCA 
R: GCCCTCACCAGGGAACTCCT  
Nkx2.5 NM_008700.2  162 
F: GACAGCGGCAGGACCAGACT 
R: CGTTGTAGCCATAGGCATTG  
Tbx5 NM_011537.3  103 
F: AGGAGCACAGTGAGGCACAA 
R: GGGCCAGAGACACCATTCTC  
Notch1 NM_008714.3  142 
F: CAGCTTGCACAACCAGACAGA  
R: TAACGGAGTACGGCCCATGT 
Gch1 NM_008102.3 117 
F: TCAAGAGCGCCTCACCAAAC 
R: TTCTGCACGCCTCGCATTAC 
Dhfr NM_010049.3 153 
F: GAATCAACCAGGCCACCTCA 
R: TTGATGCCTTTTTCCTCCTG 
28S NR_003279.1  178 
F: GGGCCACTTTTGGTAAGCAG 
R: TTGATTCGGCAGGTGAGTTG  
F: forward primer; R: reverse primer 
2.3.9 Determination of Biopterin Levels 
 Tissue and plasma biopterin levels were determined using ultra-performance 
liquid chromatography (UPLC) coupled to mass spectrometry. Briefly, dams were 
anesthetized with an intraperitoneal injection of ketamine and xylazine cocktail at E12.5. 
Whole embryos were harvested followed by blood collections from the dams for (UPLC) 
analysis. About 1 mL of blood was collected via cardiac puncture using a 23-gauge 
heparinized needle inserted into the beating left ventricle of the dam.  Plasma samples 
were then diluted 1:4 with 150 µl of acetonitrile containing internal standard (100 µM 
aminopimilic acid and 2.5 µM chlorpromazine) before injection into the UPLC 
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instrument. Total BH4 and BH2 levels were assessed using a Waters Acuity I Class 
UPLC system coupled to a XEVO G2-S quadrupole time-of-flight mass spectrometer 
(Waters Corporation: Milford, Massachusetts) as previously described.29   
2.3.10 Statistical Analysis 
 Data are presented as the mean ± SEM. Statistical analysis was performed using 
GraphPad Prism (Version 5, GraphPad Software, La Jolla, CA, USA). For comparisons 
between two groups, unpaired Student’s t-test was used. Multiple group comparisons 
between diabetic and control dams with and without sapropterin treatment, and their 
interactions were conducted using two-way analysis of variance (ANOVA) followed by 
the Bonferroni post-hoc test. Two-way repeated measures ANOVA followed by 
Bonferroni post-hoc test was used to analyze blood glucose differences over time 
between control and diabetic dams with or without sapropterin treatment. The incidence 










2.4.1 Effects of sapropterin on blood glucose, fertility, litter size 
and biopterin levels in pregestational diabetes 
 This study was conducted in the same pregestational diabetes model we recently 
employed.30, 31 One week following the final administration of STZ, female mice with 
random blood glucose levels >11 mmol/L were bred with normal adult males. During 
gestation, blood glucose levels in the diabetic dams were progressively increased from 
E0.5-18.5 compared to both sapropterin treated and untreated control mice (Fig. 2.2A). 
Treatment with insulin but not sapropterin in the diabetic mice restored blood glucose to 
normal levels. Diabetic dams had a significant lower fertility rate (38%) compared to 
controls (82%, P<0.05), which was improved to 64% by sapropterin treatment (Fig. 
2.2B).  
 Diabetic dams had a significantly smaller litter size (P<0.01), which was 
improved by sapropterin treatment (Fig. 2.2C). Indeed, absorbed or dead fetuses were 
more commonly seen in utero in diabetic dams. Fetal body weight was significantly 
lower from diabetic dams than controls (P<0.001), and was restored to normal weight 
with sapropterin (P<0.001, Fig. 2.2D). To assess biopterin levels following oral 
sapropterin administration, maternal blood and embryos were collected at E12.5. Our 
data show that sapropterin treatment significantly increased plasma BH2 levels in the 
diabetic mothers (P<0.01, Fig. 2.2E). BH2 levels in E12.5 embryos from sapropterin-
treated dams were elevated by 91.3% (P=0.0537, Fig. 2.2F), and BH4 levels in E12.5 





Figure 2.2. Blood glucose levels of pregnant mice, percent successful plugs, litter 
size, fetal body weight and biopterin levels. 
(A) Non-fasting blood glucose levels from before mating (basal) to E18.5 during 
pregnancy in STZ-treated and control female mice with and without sapropterin (BH4) 
administration (n = 4-8 mice per group). (B) The percent of successful pregnancy. The 
numbers in the brackets indicate the number of successful pregnancy at the day of fetus 
harvest to total plugs. (C) The offspring litter size measured at the day of fetus harvest (n 
= 5-11 litters per group). (D) Fetal body weight at E18.5 (n = 5-8 fetuses per group). (E-
G) Levels of BH2 in maternal plasma, and fetal BH2 and BH4 levels at E12.5 with or 
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without BH4 treatment in the diabetic dams (n = 3-9 mice per group). Two-way repeated 
measures ANOVA (A) or two-way ANOVA (C-D) followed by Bonferroni post-hoc test 
was used. B was analyzed by Fisher’s exact test. E-G were analyzed by unpaired 
Student’s t test. *P<0.05, ***P<0.001 vs. corresponding controls, and ††P<0.001 vs. 
untreated diabetes. Data are means ± SEM in A, C-G. 
2.4.2 Sapropterin prevents CHDs induced by pregestational 
diabetes 
 CHDs were observed in 59.4% of offspring from diabetic dams (Table 2.2 and 
Fig. 2.3). Normal control heart sections are shown in Fig. 2.3A-C. Septal defects 
constituted a large proportion of the anomalies with 47.4% atrial septal defects (ASD, 
Fig. 2.3D) and 37.8% ventricular septal defects (VSD, Fig. 2.3E). The diagnosis of ASD 
was based on a complete or partial absence of the septum secondum and/or primum in 
multiple serial heart sections. Hypoplastic left heart was seen in 21.1% of offspring from 
diabetic dams. In particular, 2 of these hearts displayed the characteristics of hypoplastic 
left heart syndrome, with an underdeveloped left ventricle, a small ascending aorta, ASD 
and abnormal mitral valve. Whereas, 6 hearts had an isolated hypoplastic left ventricle. 
One fetus had an atrioventricular septal defect (AVSD). Outflow tract (OFT) defects 
were also common in offspring from diabetic mothers. A double outlet right ventricle 
(DORV) was present in one of the offspring (Fig. 2.3F) and truncus arteriosus was seen 
in another fetus (Fig. 2.3G). Maternal diabetes also resulted in cardiac valve defects with 
37.8% thickened aortic valves (Fig. 2.3H) and 29.7% thickened pulmonary valves (Fig. 
2.3I). Finally, 24.3% of hearts from diabetic mothers displayed a narrowing aorta (Fig. 
2.3H vs. B). Treatment with sapropterin to diabetic dams during pregnancy significantly 
decreased the overall incidence of CHDs to 26.5% (Table 2.2). Specifically, offspring 
from sapropterin-treated diabetic mothers show a significantly lower incidence of ASD 
and thickened aortic valves, and did not display any VSD, AVSD, truncus arteriosus, 
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DORV or hypoplastic left heart (Table 2.2, Fig. 2.3J-O). Cardiac anomalies were seen in 
all litters from diabetic dams, and every dam in the sapropterin treatment group had at 
least one offspring with a CHD. No CHDs were seen in diabetic dams who received a 
daily dose of insulin to maintain normal blood glucose levels, indicating that CHDs seen 
in the diabetic offspring were induced through hyperglycemia (Table 2.2, Fig. 2.3P-R). 
The incidence of CHDs was significantly higher in males than females (65% vs. 47%, 
P<0.05). Furthermore, sapropterin treatment was more effective in reducing the incidence 
of CHDs to 16% in females compared to 35% in males (P<0.05, Fig. 2.3S). Cardiac 
function of E18.5 fetuses was assessed through echocardiography. LV fractional 
shortening and ejection fraction were significantly decreased in offspring of diabetic 
dams, and were recovered by sapropterin treatment (P<0.001, Fig. 2.3T and U). In 
addition, anterior wall thickness of the fetal heart during systole and diastole was reduced 
in offspring of diabetic dams, which was restored following sapropterin treatment 
(P<0.01, Fig. 2.3V and W). Pregestational diabetes also induced neural tube defects 
(NTD) in our model. A case of exencephaly in the offspring of mother with 




Table 2.2. The rate of congenital heart defects in the offspring of diabetic and 















Data was analyzed using Fisher’s exact test. *P <0.05, **P <0.001 vs. untreated control, 
†P <0.05, ††P <0.001 vs. STZ. ASD: atrial septal defect, VSD: ventricular septal defect, 
AVSD: atrioventricular septal defect, DORV: double outlet right ventricle. N indicates 
total number of fetuses, dams are litter numbers. 
 
  
 Control STZ BH4 STZ+BH4 STZ+Insulin 
 N dams N dams N dams N dams N dams 
 14 3 38 9 23 4 34 5 20 3 
 n % n % n % n % n % 
Normal 14 100 16 40.6** 23 100 25 73.5†† 20 100 
Abnormal 0 0 22 59.4** 0 0 9 26.5†† 0 0 
ASD 0 0 18 47.4** 0 0 9 26.5 0 0 
VSD 0 0 14 37.8* 0 0 0 0.0†† 0 0 
Truncus 
Arteriosus 
0 0 1 2.7 0 0 0 0.0 0 0 
AVSD 0 0 2 5.4 0 0 0 0.0 0 0 




0 0 14 37.8* 0 0 0 0.0†† 0 0 
Aortic Valve 
Stenosis 
0 0 11 29.7* 0 0 1 2.9†† 0 0 
RV 
Hypertrophy 
0 0 9 24.3 0 0 0 0.0†† 0 0 
Hypoplastic 
Left Heart 
0 0 8 21.1 0 0 0 0.0†† 0 0 
Narrowing 
of the Aorta 
























Figure 2.3. Effects of sapropterin (BH4) on congenital heart defects induced by 
pregestational diabetes. 
Representative histological sections of E18.5 hearts from offspring of diabetic mothers 
with and without BH4 treatment. (A-C) show hearts sections from controls. 
Pregestational diabetes resulted in atrial septal defect (D), ventricular septal defect (E), 
double outlet right ventricle (F), truncus arteriosus (G), thickened aortic (H) and 
pulmonary (I) valves. BH4 treatment in diabetic dams shows normal heart morphology 
(J-O). Diabetic dams on insulin therapy to control blood glucose levels show normal fetal 
heart morphology (P-R). Scale bars are 200 μm. (S) Incidence of CHDs as percent of 
offspring separated by sex at E18.5 from diabetic dams with or without BH4 treatment. 
*P<0.05 vs. STZ group of corresponding sex; †P<0.05 vs. corresponding males. (T-W) 
LV fractional shortening and ejection fraction, anterior wall thickness during systole 
(LVAWTs) and diastole (LVAWTd) assessed by echocardiography in E18.5 offspring (n 
= 5-7 fetuses per group). *P<0.05, ***P<0.001 vs. corresponding controls, and 
††P<0.001 vs. untreated diabetes. (X) An exencephaly was seen in the offspring of 
mother with pregestational diabetes. A normal control fetus is shown on the right panel. 
Fetuses are harvested at E13.5. S-W were analyzed by two-way ANOVA followed by 
Bonferroni post-hoc test. Data are means ± SEM in T-W. Ao indicates aorta; LA, left 




2.4.3 Sapropterin prevents myocardial and valvular abnormalities 
induced by pregestational diabetes 
 The free walls of the right and left ventricle at E18.5 were measured at the mid-
ventricular region (Fig. 2.4A).  The RV and LV myocardium was thinner in the offspring 
of diabetic mothers compared to those of control offspring, which was prevented by 
sapropterin treatment (P<0.001, Fig. 2.4B and C). Additionally, since valve leaflets were 
thickened (Fig. 2.3H and I), we assessed glycosaminoglycans, a component of 
extracellular matrix in the cardiac valves using toluidine blue staining. Our data show that 
glycosaminoglycans occupied a greater space in the leaflets of aortic and pulmonary 
valves (light purple color) from E18.5 fetal hearts of diabetic mothers compared to 
controls (Fig. 2.5A and B). Treatment with sapropterin decreased these extracellular 
polysaccharides in both aortic and pulmonary valves (P<0.01, Fig. 2.5D and E). There 
was no significant difference in glycosaminoglycan content in the mitral valve, however 
the distal tip of mitral valve was thicker in the offspring of diabetic dams (P<0.01, Fig. 
2.5F). Notably, the area of aortic orifice and diameter of pulmonary artery were 
significantly smaller in hearts from diabetic mothers compared to controls (P<0.01, Fig. 



















































(A) Representative images of myocardial wall thickness in control and pregestational 
diabetes with and without BH4 treatment. Arrows indicate compact myocardium 
boundary from which measurements were obtained. (B-C) Quantification of right and left 
ventricular myocardial thickness, respectively. n = 6 per group from 3 – 6 litters, ***P 
<0.01 vs. untreated control, †P<0.01 vs. untreated diabetes. Data are means ± SEM in B-
C and analyzed using two-way ANOVA followed by Bonferroni post-hoc test. Scale bars 




Figure 2.4. Effects of sapropterin (BH4) on fetal heart wall thickness of pregestational 






(A-C) Representative images of toluidine blue staining of glycosaminoglycans (GAG) in 
aortic, pulmonary, and mitral valves in E18.5 hearts. (D) The ratio of GAG+ area to total 
valve leaflet area. (E) Pulmonary valve leaflet thickness. (F) Mitral valve leaflet 
thickness. (G) Total aortic orifice area. (H) Pulmonary artery luminal diameter at the base 
of the orifice. LCC, left coronary cusp; NCC, noncoronary cusp; RCC, right coronary 
cusp; RC, right cusp; LC, left cusp; S, septal; L, lateral. Scale bars are 50, 20 and 20 μm 
in A, B and C, respectively.  *P<0.05, **P<0.01 vs. controls. †P<0.01, ††P< 0.01 vs. 
untreated diabetes. n = 4-7 hearts per group from 3 – 4 litters. Data are means ± SEM in 
B-C and analyzed using two-way ANOVA followed by Bonferroni post-hoc test. 
 
 
2.4.4 Effects of sapropterin on outflow tract length and cell 
proliferation in the fetal heart 
 Since offspring of diabetic mothers show OFT defects, we aimed to investigate 
changes in cell proliferation at a critical stage in OFT formation. At E10.5 sagittal 
sections of whole embryos reveal a shortened OFT in hearts from diabetic mothers 
compared to control (P<0.001, Fig. 2.6A), which was restored with sapropterin treatment 
(P<0.05, Fig. 2.6E). To further analyze this change, phosphorylated histone H3, a marker 
for the mitotic phase of cell division, was used to compare the levels of proliferating cells 
in the OFT at E10.5 using the same hearts (Fig. 2.6B-D). Embryos from mice with 
pregestational diabetes had a significantly lower number of proliferating cells in the OFT 
(P<0.01, Fig. 2.6F-G). Sapropterin treatment was able to prevent impaired cell 
proliferation in the OFT in hearts from diabetic dams (P<0.001, Fig. 2.6F-G).  
  
Figure 2.5. Effects of sapropterin (BH4) on aortic, pulmonary and mitral valve 




Figure 2.6. Effects of sapropterin (BH4) on outflow tract development and cell proliferation 
in E10.5 hearts of pregestational diabetes. 
109 
 
(A) Length of the OFT was measured via sagittal sections according to the line. (B-D) 
Immunostaining for phosphorylated histone H3 marking proliferating cells in the OFT 
(B-C) and ventricular myocardium (D). Panel C is the magnification of boxed area in 
panel B. (E) Quantification of OFT length. (F) Quantification of pHH3+ cells in the OFT. 
(G) Quantification of pHH3+ cells in the ventricle. n = 3-6 hearts per group from 2 – 4 
litters, **P<0.01 vs. untreated control, †P<0.05 vs. untreated control, ††P<0.01 vs. 
untreated diabetes. Data are means ± SEM in E-G and analyzed using two-way ANOVA 
followed by Bonferroni post-hoc test.  Scale bars are 50 μm and 20 μm, respectively. 
OFT indicates outflow tract; pHH3, phosphorylated histone H3. 
 
2.4.5 Fate-mapping of SHF derived cells in the fetal heart of 
diabetic mothers 
 In order to better understand the spectrum of malformations induced by maternal 
diabetes seen at birth, embryonic lineage tracing of the SHF was carried out. Fate 
mapping using Mef2c-Cre and the global double fluorescent Cre reporter line 
Rosa26mTmG identified all SHF derived cells as GFP+. At E9.5, the number of GFP+ SHF 
cells and total number of cells in the heart were significantly less than control (P<0.01, 
Fig. 2.7A, D and E). Furthermore, significantly less GFP+ SHF cells were infiltrated into 
the endocardial cushion at E12.5 in diabetic embryos compared to control (P=0.0476, 
Fig. 2.7B and F). Additionally, E12.5 hearts from diabetic mothers had thinner 
ventricular walls with significantly less myocardial cell layers than controls (P<0.01, Fig. 





Figure 2.7. Effects of pregestational diabetes on SHF progenitor contribution to 
E9.5 and E12.5 hearts. 
Fate mapping using the mT/mG reporter showing GFP+ cells expressing Cre recombinase 
under the control of the anterior heart field specific Mef2c transcription factor. 
Representative sections of OFT of E9.5 (A) and E12.5 (B) hearts from control and 
diabetic mothers. (C) Representative sections showing the cell layers of the RV 
myocardium from E12.5 hearts. Quantification of SHF GFP+ cells (D) and total number 
of cells (E) in the OFT cushions at E9.5. Quantification of SHF GFP+ cells in the OFT 
cushions (F) and number of cell layers in the RV myocardium (G) at E12.5. N = 3 per 
group from 2 litters in D and E. N = 5 per group in F and G from 2 – 4 litters. *P<0.05, 
**P<0.01, ***P<0.001 vs. control. Data are means ± SEM in D-G and analyzed using 
unpaired Student’s t test. Scale bars are 50 μm. GFP indicates green fluorescent protein; 





2.4.6 Sapropterin prevents maternal diabetes-induced 
downregulation of regulators of heart development   
 Pregestational diabetes induces changes in gene expression in the developing 
heart.32 To determine if key transcriptional regulators of heart development were altered 
under maternal diabetes and with sapropterin treatment, qPCR analysis was performed 
from E12.5 hearts. Our data show that the mRNA levels of Gata4, Tbx5, Nkx2.5, Gata5, 
Bmp10 and Notch1 were significantly lower compared to controls (P<0.05, Fig. 2.8A-F). 
Treatment with sapropterin significantly improved mRNA levels of these transcription 
factors (P<0.001, Fig. 2.8A-F). Additionally, gene expression of BH4 biosynthesis 
enzymes including GTP cyclohydrolase 1 (Gch1) and dihydrofolate reductase (Dhfr) was 
significantly decreased in embryonic hearts from diabetic mothers (P<0.05, Fig. 2.8G and 
H). Of note, sapropterin treatment completely recovered the expression of Dhfr (P<0.001, 





Figure 2.8. Effects of sapropterin (BH4) on molecular regulators of heart 




Real-time RT-PCR of cardiac transcription factors and regulators in E12.5 hearts of 
offspring from control and diabetic mothers. (A-F) The expression of Gata4, Tbx5, 
Nkx2.5, Gata5, Bmp10 and Notch1 were significantly decreased under maternal diabetes 
and restored with BH4 treatment. (G-H) The expression of Gch1 and Dhfr was 
significantly decreased with maternal diabetes. BH4 treatment rescues expression of 
DHFR. n = 4 – 7 hearts per group. *P<0.05, **P<0.01 vs. untreated control, and †P<0.05, 
††P<0.01 vs. untreated diabetes. Data are means ± SEM and analyzed using two-way 
ANOVA followed by Bonferroni post-hoc test. 
 
2.4.7 Sapropterin decreases oxidative stress and improves eNOS 
dimerization in fetal hearts of pregestational diabetes 
 To examine the effects of sapropterin on ROS in the developing heart, DHE probe 
was used to label the oxygen radical. Quantification of red fluorescence intensity 
indicates that superoxide generation was significantly elevated in embryonic hearts from 
mice with pregestational diabetes compared to control (P<0.05, Fig. 2.9A and 2.B). 
Sapropterin treatment significantly reduced myocardial ROS levels to basal conditions 
(P<0.05 Fig. 2.9B). Pre-treatment with L-NAME, a NOS inhibitor, and SOD, an 
antioxidant enzyme, significantly decreased DHE fluorescence in embryonic hearts from 
diabetic dams indicating eNOS uncoupling and superoxide generation, respectively 
(P<0.05 Fig. 2.9B). Finally, eNOS uncoupling has been implicated as a mechanism for 
endothelial dysfunction in diabetes.23 To assess the effects of sapropterin on eNOS 
coupling, eNOS dimerization was analyzed using Western blotting in non-reducing 
conditions, which yields two bands at 260 and 130 kDa, representing the intact dimer and 
monomer of eNOS, respectively. Figure 2.9C shows a representative blot of the dimer 
and monomer of eNOS. In control conditions, there was a higher level of eNOS dimers 
than monomers, indicating a functional eNOS enzyme. However, embryonic hearts from 
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diabetic dams show a significant decrease of dimer/monomer ratios compared to controls 
(P<0.05, Fig. 2.9D), which was restored by sapropterin treatment (P<0.01, Fig. 2.9D). 
 
Figure 2.9. Effects of sapropterin (BH4) on superoxide production and eNOS 
dimer/monomer protein levels in E12.5 hearts. 
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(A) Representative images of DHE staining in the ventricular myocardium of E12.5 
hearts from control and diabetic dams with and without BH4 administration. A subset of 
heart sections from diabetic dams were pre-treated with L-NAME (300 M) or SOD (100 
units/mL) for 30 minutes prior to DHE probing. (B) Quantification of DHE fluorescence 
signals. (C) Representative Western blotting showing eNOS dimer and monomer bands 
of E12.5 hearts from control and diabetic dams with and without BH4 treatment. 
Denatured endothelial cell lysate validates the size of the eNOS monomer band. (D) 
Densitometric analysis of eNOS dimer/monomer ratios.  n = 5 – 6 hearts per group from 
2 – 4 litters. *P<0.05 vs. untreated control, ††P<0.01 vs. untreated diabetes, #P<0.05 vs. 
untreated diabetes. Data are means SEM in B and D, and analyzed using two-way 
ANOVA followed by Bonferroni post-hoc test. DHE indicates dihydroethidium; EC, 
endothelial cell; L-NAME, Nω-Nitro-L-arginine methyl ester; SOD, superoxide 
dismutase.   
 
2.5 Discussion 
 The present study utilized a clinically relevant model of CHDs induced by 
pregestational diabetes we recently established.30, 31 Consistent with our previous studies, 
a spectrum of CHDs were observed in the offspring of diabetic mothers. The CHDs range 
from ASD, VSD and valve thickening, to major malformations including AVSD, DORV, 
truncus arteriosus and hypoplastic left heart, as clinically categorized by Hoffman et al.33 
Sapropterin treatment was able to prevent all major defects and significantly reduce the 
overall level of defects induced by pregestational diabetes. Other changes in the fetal 
heart such as thinner ventricular myocardium, thickened valves, stenosis of the aorta and 
pulmonary artery, impaired cardiac function along with decreased cell proliferation and 
gene expression induced by maternal diabetes, were normalized with sapropterin 
treatment. Furthermore, sapropterin administration in the diabetic dams increased eNOS 
dimerization and decreased ROS levels in the fetal heart. Our study suggests that 
sapropterin improves eNOS coupling and prevents CHDs in pregestational diabetes in 




Figure 2.10. Schematic summary of sapropterin on diabetes-induced CHDs . 
eNOS uncoupling and CHDs induced by pregestational diabetes and the inhibitory effects 
by sapropterin treatment. Abnormalities of both second heart field (SHF) and non-SHF 
derived structures are prevented by sapropterin treatment. LV indicates left ventricle; 
OFT, outflow tract; ROS, reactive oxygen species; RV, right ventricle. 
 
In this model, STZ was used to induce hyperglycemia in female mice at least 7 
days before they were bred with normal healthy males. Since STZ has a short plasma 
half-life of 10 minutes in rodents,34 it is unlikely that STZ would cause any teratogenic 
effects in the fetus. To confirm that hyperglycemia is the cause of CHD in this model, a 
group of mice were treated with insulin to lower glucose levels in diabetic dams. Our data 
show that insulin treatment abrogated CHDs in pregestational diabetes, which is 
consistent with clinical studies that good glycemic control in women with pregestational 
diabetes lowers the incidence of CHDs.7 It should be noted that the incidence of CHDs 
found in the diabetic groups with or without sapropterin treatment at E18.5 may be an 
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underestimate as fetuses may have been absorbed in utero at around E12.5. To study the 
effects of sapropterin on maternal diabetes, blood glucose levels were assessed during 
pregnancy. Our data show that sapropterin treatment in the diabetic dams had no effect 
on the hyperglycemic state of the animal, suggesting that the beneficial effects of 
sapropterin on fertility (or percent successful pregnancy), litter size, and heart 
development under pregestational diabetes are independent of blood glucose levels. In 
humans, sex-related differences in the prevalence of CHDs have been reported. In a 
recent large cohort study with 9,727 cases of CHDs, the male to female ratio was 55% to 
45%, indicating a significant predisposition of CHDs in the male sex.35 In agreement with 
clinical studies, our data show a male dominance of CHDs in the offspring of diabetic 
mothers. Notably, sapropterin treatment appears to be more effective in preventing CHDs 
in females than in males.  
We have recently shown that defects in SHF signaling results in thin myocardium, 
septal defects and OFT defects.26, 36 The defective SHF progenitor contribution may 
explain the majority of heart malformations in the OFT, cardiac septum and cardiac 
valves induced by pregestational diabetes. Since sapropterin treatment significantly 
prevented these CHDs in the offspring of diabetic dams, it is likely that impairment in 
SHF progenitors will be diminished by maternal sapropterin treatment, which still needs 
to be confirmed in future studies. Considering the presence of hypoplastic left heart and 
OFT septation defect (truncus arteriosus), it is possible that pregestational diabetes also 
impairs FHF and CNC cells in our model. Notably, these defects were all prevented in 
diabetic dams treated with sapropterin. These findings are consistent with previous 
studies showing that oxidative stress during diabetic pregnancy disrupts CNC migration 
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and causes OFT defects in rodents,37, 38 which are prevented by treatment with vitamin E, 
an antioxidant.39 Our results suggest that sapropterin treatment improves the function of 
both SHF and non-SHF (FHF and CNC) progenitors in pregestational diabetes (Fig. 
2.10). 
 Cell proliferation is critical to cardiac morphogenesis and the growth of the fetal 
heart.40 Decreased cell proliferation results in shortening of OFT length, thin myocardium 
and CHDs.36, 41 In the present study, E10.5 hearts show less cell proliferation and a 
shorter OFT in embryos from diabetic dams. Furthermore, E18.5 hearts from diabetic 
dams are notably smaller and their ventricular walls are significantly thinner than control 
hearts. These abnormalities were all prevented by sapropterin treatment. Previous studies 
have shown that BH4 increases DNA synthesis and cell proliferation in erythroid cells.42 
Additionally, BH4 mediates the proliferative effects of epidermal growth factor and nerve 
growth factor in PC12 cells.43 We have previously shown that eNOS promotes 
cardiomyocyte proliferation.17, 44 Since BH4 increases eNOS coupling as shown by 
higher dimer/monomer ratios in our study, it is possible that a normalized eNOS 
signaling may contribute to the improved cell proliferation by sapropterin treatment. 
Increases in cell apoptosis may also contribute to CHDs. However, we have previously 
shown that the incidence of cell apoptosis in fetal hearts of diabetic offspring is low 
(about 1%) and was not affected by anti-oxidant treatment, suggesting an insignificant 
role of apoptosis in our model.31 We therefore did not assess cell apoptosis in the present 
study. 
Cardiac transcription factors including Gata4, Gata5, Nkx2.5 and Tbx5 are critical 
to normal heart development, and genetic mutations of these transcription factors result in 
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CHDs in humans.45 Interestingly, both eNOS and ROS can alter the expression of these 
transcription factors.16, 31 For example, deficiency in eNOS decreases the expression of 
cardiac transcription factors including Gata4 during embryonic heart development.19 
Additionally, the expression of cardiac transcription factors was downregulated in the 
fetal heart of offspring of diabetic mothers, which was restored by treatment with an 
antioxidant, N-acetylcysteine.31 In agreement with our previous studies, we showed a 
downregulation of Gata4, Gata5, Nkx2.5 and Tbx5 in fetal hearts of offspring from 
diabetic mothers in the present study. Decreased expression was also seen in Bmp10, 
essential in cardiac growth and chamber maturation.46 Importantly, sapropterin 
administration to diabetic dams restored the expression profile of these factors to normal 
levels. We also assessed the expression of Gch1 and Dhfr, which are enzymes 
responsible for de novo BH4 biosynthesis and recycling of BH2 back to BH4, 
respectively. Both GCH1 and DHFR are sensitive to oxidative stress and NO signaling.21, 
47 Of note, NO has been shown to stabilize DHFR protein from ubiquitination and 
degradation by S-nitrosylation.48 During pregestational diabetes, GCH1 and DHFR 
transcript levels in the fetal heart were downregulated, which was normalized by 
sapropterin treatment. Our findings indicate a possible gene regulatory mechanism 
governing DHFR expression. Recent studies show a strong interaction between eNOS 
and Notch1 promoting semilunar valve and outflow tract development.49 Here we show 
that Notch1 mRNA is decreased in embryonic hearts from diabetic dams, which is 
rescued with sapropterin treatment. Our results indicate a perturbed NO-Notch1 signaling 
pathway in the fetal hearts of diabetic dams. Together, these effects are consistent with 
the ability of sapropterin treatment to recouple eNOS and restore ROS balance in the 
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embryonic heart of diabetic dams. It should be noted that nNOS and iNOS are 
dispensable for heart development since nNOS-/- and iNOS-/- mice do not exhibit any 
developmental abnormalities of the heart.16   
A major non-cardiac malformation induced by pregestational diabetes is NTD 
such as anencephaly, exencephaly and spina bifida.50 It has been reported that 25-40% 
offspring of diabetic dams have NTDs when the fetuses are examined at E10.5.51, 52 To 
analyze cardiac malformation, we examined the fetuses at E18.5 and may have missed 
most of the NTDs, which are likely absorbed beyond E10.5. This may be the reason that 
we only observed one exencephaly in the present study and a low incidence of NTDs 
(4.8%) in our previous study.31 Additionally, BH4 biosynthesis is important to neural 
tube development. Inhibition of GCH1 activity, a rate limiting enzyme in the biosynthesis 
of BH4, interrupts neural tube closure, which can be prevented by BH4 treatment in chick 
embryos.53 Furthermore, GCH1 haplotypes are significantly associated with a higher risk 
of NTD in infants.54 It is possible that sapropterin treatment may prevent NTD induced 
by pregestational diabetes, a hypothesis that needs to be tested in future studies. 
Surprisingly, the GCH1 knockout mice die at E13.5 due to bradycardia without any 
structural anomalies.55 Apart from being a cofactor of eNOS, BH4 is also a substrate for 
aromatic amino acid hydroxylases.56 BH4 treatment at postnatal day 14 elevated 
dopamine levels in the brain and fully restored the loss of tyrosine hydroxylase protein 
caused by the BH4 deficiency in infant mice,57 indicating an important role of BH4 in 
dopaminergic function of the brain. The effects of pregestational diabetes and sapropterin 
treatment on tyrosine hydroxylase expression and dopamine levels in the fetal brain are 
beyond the scope of the present investigation.  
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In summary, the present study demonstrates that treatment with sapropterin 
(Kuvan®), an orally active synthetic form of BH4 during gestation improves eNOS 
coupling, reduces ROS and increases cell proliferation in the embryonic heart of 
offspring of diabetic mothers. Notably, sapropterin treatment prevents the development of 
major CHDs induced by pregestational diabetes. Sapropterin is an FDA approved drug to 
treat phenylketonuria (PKU), a genetic disorder due to mutations of phenylalanine 
hydroxylase (PAH) gene leading to low levels of phenylalanine hydroxylase.25 Our study 
suggests that sapropterin may also have therapeutic potential in preventing CHDs in 
offspring of women with pregestational diabetes. 
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3 Chapter 3 
3.1 Chapter Summary 
 Endothelial nitric oxide synthase (eNOS) and oxidative stress are critical to 
embryonic coronary artery development. Maternal diabetes increases oxidative stress and 
reduces eNOS activity in the fetal heart. Sapropterin (Kuvan®) is an orally active, 
synthetic form of tetrahydrobiopterin (BH4) and a co-factor for eNOS with antioxidant 
properties. The aim of the present study was to examine the effects of sapropterin on 
embryonic coronary artery development during pregestational diabetes in mice. Diabetes 
was induced by streptozotocin to adult female C57BL/6 mice. Sapropterin (10 
mg/kg/day) was orally administered to pregnant mice from E0.5 to E18.5. Fetal hearts 
were collected at E18.5 for coronary artery morphological analysis. Sapropterin treatment 
to diabetic dams reduced the incidence of coronary artery malformation in offspring from 
50.0% to 20.6%. Decreases in coronary artery luminal diameter, volume and abundance 
in hearts from diabetic mothers, were prevented by sapropterin treatment. Maternal 
diabetes reduced epicardial epithelial-to-mesenchymal transition (EMT) and expression 
of transcription and growth factors critical to coronary artery development including 
hypoxia-inducible factor 1a (Hif1a), Snail1, Slug, -catenin, retinaldehyde 
dehydrogenase 2 (Aldh1a2) and basic fibroblast growth factor (bFGF) in E12.5 hearts. 
Additionally, eNOS phosphorylation was lower while oxidative stress was higher in 
E12.5 hearts from maternal diabetes. Notably, these abnormalities were all restored to 
normal levels after sapropterin treatment. In conclusion, sapropterin treatment increases 
eNOS activity, reduces oxidative stress and prevents coronary artery malformation in 
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offspring of pregestational diabetes. Sapropterin may have therapeutic potential in the 
prevention of coronary artery malformation in pregestational diabetes.   
3.2 Introduction 
Diabetes is a global health concern. In 2013, approximately 21.4 million 
pregnancies worldwide were affected by diabetes, of which 16% were pregestational 
diabetes.1 Women with pregestational diabetes are at an increased risk of having a child 
with a congenital heart defect (CHD).2 Hypoplastic coronary artery disease (HCAD) is a 
congenital abnormality characterized by a marked decrease in luminal diameter and 
length of one or more major branches of coronary arteries.3-6 HCAD can be 
asymptomatic at birth but are often associated with myocardial infarction and sudden 
cardiac death under physical exertion later in life.7, 8 In the clinic, newborns are screened 
for many forms of CHDs, however, coronary artery branches are not reliably imaged 
using non-invasive tools perinatally.9 HCAD is a rare form of congenital coronary artery 
malformations (CAMs) including anomalous origins of the left and right coronary 
arteries, single coronary artery, and coronary artery fistula, which collectively affect ~1% 
of the general population.10, 11 While the clinical etiology of congenital coronary artery 
anomalies is undefined, we have recently shown that pregestational diabetes results in 
CAMs in the fetal heart of offspring in mice.12  
The heart is the first functional organ to form during embryogenesis, and 
vascularization in the primitive heart initiates at E9.5 in the proepicardial organ.13, 14 Cells 
from this primitive structure migrate to cover the surface of myocardium, forming an 
epicardium, which is fully formed by E12.5. These cells then undergo coordinated 
epithelial-to-mesenchymal transition (EMT) and become epicardial-derived cells 
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(EPDCs).14 EPDCs migrate to the subepicardial space and differentiate into vascular 
smooth muscle cells, endothelial cells and adventitial fibroblasts, all which are needed to 
form coronary vessels.14 The endocardium and sinus venosus also contribute to this 
coronary plexus, and a complete coronary network is established by E15.15, 16 A misstep 
in any of these processes including alterations in gene expression, cell proliferation and 
epicardial EMT may result in coronary artery malformations.  
Hyperglycemia-induced reactive oxygen species (ROS) is not conducive to heart 
and coronary artery development as it oxidizes cardiogenic and angiogenic molecules. 
Endothelial nitric oxide synthase (eNOS) is critical to embryonic heart development as 
nitric oxide (NO) regulates transcription factor expression, progenitor cell growth and 
EMT.17 In fact, eNOS-/- mice display hypoplastic coronary arteries and postnatal 
myocardial infarction.18 Tetrahydrobiopterin (BH4) is a co-factor for eNOS, and an 
antioxidant. It stabilizes the enzyme dimer and allows arginine binding.19 Under 
oxidative stress, BH4 levels decline and eNOS is uncoupled and unable to form NO, 
instead generates superoxide.20 BH4 improve eNOS coupling and vascular endothelial 
function in diabetes.21 However, the ability of BH4 to regulate coronary artery 
development in the fetal heart is not known. The FDA-approved drug, sapropterin 
dihydrochloride (Kuvan®), is a stable, orally active, synthetic form of BH4. In the 
present study, we aim to determine the effects of sapropterin on coronary artery 
development under pregestational diabetes in mice. Our hypothesis was that sapropterin 







 C57BL/6 wild-type mice were purchased from Jackson Laboratory (Bar Harbour, 
Maine), and a breeding program was implemented to generate postnatal and fetal mice. 
All animals used in this study were handled according to the National Institute of Health 
Guide for the Care and Use of Laboratory Animals (8th edition, 2011). All procedures 
were approved by the Animal Care Committee at Western University, following the 
Canadian Council on Animal Care guidelines.  
3.3.2 Induction of Diabetes and Sapropterin Treatment 
 Diabetes was induced to six to eight-week old female C57BL/6 mice by 
streptozotocin (STZ, 50 mg/kg body weight, I.P.) injections for five consecutive days, as 
previously described.22, 23 STZ was dissolved in a sterile saline solution at the time of 
administration, with sterile saline as vehicle controls. Non-fasting blood glucose levels 
were measured one week following the last injection using a glucose meter (One Touch 
Ultra2, LifeScan Canada, Burnaby, BC). Mice with blood glucose levels above 11.0 
mmol/L were considered to be diabetic and subsequently bred with adult wild-type male 
mice. A vaginal plug indicated embryonic day 0.5 (E0.5) and the pregnant female mice 
were placed in a cage with littermates. A subset of the diabetic dams received a 10 mg/kg 
per body weight oral dose of sapropterin dihydrochloride (Kuvan®, BioMarin 
Pharmaceutical Inc., Novato, CA, USA) each day of gestation. Sapropterin 
dihydrochloride was dissolved in water and combined with a small amount of peanut 




3.3.3 Histological and Immunohistochemical Analysis 
 To analyze coronary artery development and resulting vasculature, embryos were 
harvested at E12.5 and E18.5 for morphological and immunohistochemical analyses. 
Briefly, the thoraces of embryos were isolated and fixed in 4% paraformaldehyde 
overnight. The samples were dehydrated, paraffin embedded and subsequently serial 
sectioned into 5-m sections. Prior to immunostaining, antigen retrieval was conducted in 
citric acid buffer (0.01 mol/L, pH 6.0) for 12 minutes at 94C using a microwave (BP-
111; Microwave Research & Applications, Inc., Carol Stream, IL).  The following 
primary antibodies were applied and incubated overnight; anti--smooth muscle actin 
(1:3,000, mus monoclonal, Sigma-Aldrich A2547, Lot 032M4822), biotinylated lectin-1 
(1:250, Bandeiraea Simplicifolia, Sigma-Aldrich L2380, Lot 054M4086V), anti-sex-
determining region Y protein antibody (1:200, mus monoclonal, Santa Cruz SC-398567, 
Lot J1316), anti-Wt1 (1:300, rb polyclonal, Santa Cruz SC-192, Lot F0513), anti-E-
cadherin (1:200, goat polyclonal, Santa Cruz SC-31020, Lot D2413), and anti-
phosphohistone H3 (pHH3) (1:500, rb polyclonal, Abcam ab5176, Lot GR72823-1), 
followed by either biotinylated goat anti-rabbit IgG (1:500) or biotinylated donkey anti-
goat IgG (1:500), for one hour. Signals were amplified through the ABC reagent (Vector 
Laboratories), which enabled visualization by 3-3’ diaminobenzidine tetrahydrochloride 
(DAB, Sigma). Counterstaining was performed with Mayer’s Hematoxylin (Thermo 
Scientific, Waltham, MA), and images were captured with a light microscope (Observer 
D1, Zeiss). To analyze coronary artery volume and branching, the AMIRA software (FEI 
Visualization Sciences Group) was used to create three-dimensional reconstructions of -
smooth muscle actin stained sections 25-m apart. A ratio of coronary artery to 
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myocardial volume was obtained using the AMIRA software. Counts of coronary 
arteries, capillaries, and coronary progenitor cells were taken from a minimum of three 
heart sections and normalized to the myocardium.  
3.3.4 Analysis of 4-hydroxynonenal Levels 
 To analyze lipid peroxidation as an indication of oxidative stress in embryonic 
hearts, E12.5 ventricles from all four groups were harvested and embedded in FSC22 
frozen section media (Leica). Samples were cryosectioned (CM1950, Leica) into 8 m 
thick sections, and immunostained with 4-hydroxynonemal (4-HNE) antibody (1:300, 
goat polyclonal, ABM Y072093, Lot AP1217). This was followed by CY3-conjugated 
anti-goat IgG secondary antibody (1:1000; Jackson Immunoresearch). Signals were 
detected using fluorescence microscopy (Observer D1, Zeiss, Oberkochen, Germany). 
Using a fixed exposure time, a minimum of 4 images were captured per heart, and 
fluorescence intensity per area of myocardium were measured using AxioVision 
Software (Zeiss, Oberkochen, Germany).  
3.3.5 Assessment of Epicardial EMT using ex vivo Heart Explant 
Culture 
To assess epicardial EMT, ventricles of E12.5 embryonic hearts from non-diabetic dams 
were harvested and cultured on a collagen gel matrix for 96 hours. To prepare the 
collagen matrix, 1 mg/mL type I rat tail collagen (BD Bioscience) was added to 2x M199 
media (M5017; Sigma) containing 5 mM D-glucose or 30mM D-glucose in a 24-well 
plate. The casted collagen wells were hydrated with 500 L 1x M199 media plus 10% 
FBS and insulin-transferrin-selenium, with or without 0.1 mM BH4 (Sigma), and 5 mM 
or 30 mM D-glucose. E12.5 ventricles were isolated in sterile saline, placed centrally in a 
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well containing the set collagen matrix and media, and incubated at 37°C for 4 days. 
Images were captured with a phase contrast microscope (Zeiss, Oberkochen, Germany), 
and spindle-shaped cell outgrowth distance was quantified.  
3.3.6 Western Blotting for eNOS and Akt Phosphorylation 
 Ventricular myocardial tissue from E14.5 hearts, isolated in PBS, was used to 
analyze eNOS and Akt activity. Briefly, 30 g of protein from isolated ventricular tissue 
was separated via 10% SDS-PAGE and transferred to a nitrocellulose membrane. Blots 
were probed with antibodies against p-NOS3 (Ser1177; 1:1000, rb polyclonal, Cell 
Signaling 9571S, Lot 7), NOS3 (1:1000, rb polyclonal, Santa Cruz SC-654, Lot G2414), 
p-Akt (Ser473; 1:5000, rb polyclonal, Cell Signaling 9271, Lot 19), Akt (1:5000, rb 
polyclonal, Cell Signaling 9272, Lot 22), and -actinin (1:5000, mus monoclonal, Sigma-
Aldrich A7811, Lot 029K4844). Washed blots were probed with horseradish peroxidase–
conjugated secondary antibodies (1:2500; Bio-Rad). The signal was detected using 
enhanced chemiluminescence and quantified by densitometry.  
3.3.7 Real-time RT-PCR Analysis 
 Total RNA was extracted from E12.5 hearts using TRIzol reagent (Invitrogen). 
200 nanograms of RNA was reverse transcribed using the Maloney murine leukemia 
virus reverse transcriptase and random primers. Evergreen qPCR MasterMix (Applied 
Biological Systems, Vancouver, BC) was used to conduct Real-time PCR on cDNA. 
Primers were designed for HIF-1, Aldh1a2, -catenin, bFGF, Slug, Snail1, and Tbx18 
using the Primer3 software v 4.1.0 (Table 3.1). Samples were amplified for 35 cycles 
using the Eppendorf Realplex (Hamburg, Germany). mRNA levels were extrapolated 
using a comparative CT method by normalizing to 28S-Ribosomal RNA.  
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Table 3.1. Specific primer sequences for real-time PCR analysis. 
Gene Accession no. Product Size Primer Sequence 
Hif1- NM_001313919 237 F: CAGCCTCACCAGACAGAGCA 
R: GTGCACAGTCACCTGGTTGC 
Snail1 NM_011427.3  133 F: CACACGCTGCCTTGTGTCT 
R: GGTCAGCAAAAGCACGGTT 
Slug NM_011415.2  161 F: CAACGCCTCCAAGAAGCCCA 
R: GAGCTGCCGACGATGTCCAT 
Aldh1a2 NM_009022.4  219 F: GGCAGCAATCGCTTCTCACA 
R: CAGCACTGGCCTTGGTTGAA 
-catenin NM_001165902.1  178 F: CTTGGCTGAACCATCACAGAT 
R: AGCTTCCTTTTTGGAAAGCTG 
bFgf NM_008006.2 174 F: CAAGGGAGTGTGTGCCAACC 
R: TGCCCAGTTCGTTTCAGTGC 
Tbx18 NM_023814.4 199 F: GAGCAGCAACCCGTCTGTGA  
R: GGGACTGTGCAATCGGAAGG 
28S NR_003279.1  178 F: GGGCCACTTTTGGTAAGCAG 
R: TTGATTCGGCAGGTGAGTTG  
F: forward primer; R: reverse primer 
 
 
3.3.8 Statistical Analysis 
 Data are shown as mean  SEM. A two-way analysis of variance (ANOVA) was 
used for multiple group comparisons between diabetic and control dams with and without 
sapropterin treatment, and their interactions, followed by the Bonferroni post-hoc test 
(Version 5, GraphPad Software, La Jolla, CA, USA). The incidence of coronary artery 





3.4.1 Sapropterin prevents coronary artery malformations in 
offspring of diabetic mice without altering blood glucose 
levels 
 The present study was conducted using the same model of pregestational diabetes 
previously employed.12, 22, 23 A week following STZ administration, diabetes was 
confirmed by measuring non-fasting blood glucose levels. Female mice with >11 mmol/L 
blood glucose were considered diabetic and bred with normal males. The glycemic state 
of the diabetic dam steadily increased from 15.9 ± 4.9 mmol/L at E0.5 to 25.1 ± 4.4 
mmol/L by E18.5 (Table 3.2). The diabetic dams fed with sapropterin during gestation 
displayed a similar increase in hyperglycemia, gradually reaching 26.9 ± 5.2 mmol/L at 
the end of pregnancy. Of note, treatment with sapropterin did not affect blood glucose 
levels in either the control or diabetic groups. A daily dose of insulin was administered to 
a cohort of diabetic dams throughout gestation, which normalized their elevated blood 
glucose levels (Table 3.2).  
 Half of all fetuses from untreated diabetic dams examined at E18.5 displayed 
CAM. This ratio was significantly reduced to 20.6% with sapropterin treatment (Table 
3.2). Furthermore, 36.8% of fetal hearts presented with both CHD and CAM. Sapropterin 
effectively prevented the dual defect occurrence, as no hearts from the offspring of 
sapropterin-treated diabetic dams had both CHD and CAM. No CAMs or CHDs were 
found in either of the control groups or the insulin treatment groups, indicating that any 
vascular abnormalities seen were induced by diabetes and not a teratogenic effect of STZ. 
Finally, CAM incidence or the effectiveness of sapropterin treatment did not show any 
bias towards the male or female sex (Table 3.2).  
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Table 3.2. Effects of sapropterin (BH4) on nonfasting maternal blood glucose levels 
and incidence of CAMs in E18.5 hearts during pregestational diabetes. 
 





Litters (n)  3 9 4 5 3 
Blood glucose at E0.5 (mmol/L) 7.5 ± 1.8 15.9 ± 4.9* 8.0 ± 0.6 16.8 ± 4.2†  6.2 ± 0.8 
Blood glucose at E18.5 (mmol/L) 7.5 ± 0.6 25.1 ± 4.4** 9.1 ± 1.0 26.9 ± 5.2†† 7.6 ± 0.7 
CAM/total fetuses (n)  0/14 19/38* 0/23 7/34† 0/20 
Males: CAM/total fetuses (n) 0/14 9/38* 0/23 3/34 0/20 
Females: CAM/total fetuses (n) 0/14 10/38* 0/23 4/34 0/20 
CAMs (%)  0.0 50.0 0.0 20.6 0.0 
 
3.4.2 Sapropterin prevents diabetes-induced fetal hypoplastic 
coronary arteries and restores capillary density 
 Hearts with hypoplastic coronary arteries have marked decreases in vessel number 
and luminal diameter.12 Immunostaining with -smooth muscle actin and biotinylated 
lectin-1 was used to identify hypoplastic coronary arteries and capillaries, respectively in 
E18.5 hearts. The left coronary artery originating from the aortic orifice in fetuses from 
diabetic dams was significantly smaller in luminal diameter than control (P<0.01, Fig. 
3.1A and E). Similarly, the diameter of the right ventricular coronary artery in offspring 
from diabetic dams was also smaller than control (P<0.001, Fig. 3.1B and F). Sapropterin 
treatment prevented this diabetes-induced reduction in luminal diameter of the left and 
right coronary arteries (P<0.05, Fig. 3.1A, B, E and F). Sapropterin treatment also 
rescued a maternal diabetes-induced decrease in coronary artery abundance within the 
ventricular myocardium (P<0.01, Fig 3.1C and G). Interestingly, strong -smooth muscle 
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actin staining was noted in hearts from diabetic dams throughout the myocardium at 
E18.5, suggesting a delayed maturation of cardiomyocytes. Finally, immunostaining of 
lectin-1 marking endothelial cells revealed a reduced capillary density in the ventricular 
myocardium of E18.5 hearts from diabetic dams comparted to controls, which was 
restored to normal with sapropterin treatment (P<0.05, Fig. 3.1D and H). Coronary 
arteries were reconstructed in 3-dimensions to illustrate branching and extrapolate 
volume measurements. Figure 2A shows a notable decrease of coronary artery 
arborisation in E18.5 hearts from diabetic dams. The typical branching patterns were 
restored in offspring from diabetic mothers treated with sapropterin, resulting in 























Representative histological sections of E18.5 hearts from offspring of control and 
diabetic dams with and without BH4 treatment. -smooth muscle actin staining of 
vascular smooth muscle cells specifying the left (A) and right (B) coronary artery, with 
arrows indicating diameter of the artery lumen measurements. (C) -smooth muscle actin 
Figure 3.1. Effects of sapropterin (BH4) on coronary artery malformations induced 
by pregestational diabetes. 
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staining for total number of coronary arteries throughout the ventricular and septal 
myocardium. (D) Biotinylated lectin-1 immunostaining marking endothelial cells 
forming myocardial capillaries in the right ventricle. (E-H) Analysis of left (E) and right 
(F) coronary artery diameter, coronary artery abundance (G) and capillary density (H). n 
= 7 – 9 per group, *P<0.05, **P<0.01 and ***P<0.001 vs. untreated control, †P<0.05 
and ††P<0.01 vs. untreated diabetes. Scale bars represent 50, 20, 200 and 20 μm in A, B, 




(A) Frontal views of 3D reconstructions of the coronary arteries with superimposed 
myocardium. (B) Total coronary artery volume normalized to myocardial volume. n = 4 
hearts per group. **P<0.01 vs. untreated control, ††P<0.01 vs. untreated diabetes. 
 
Figure 3.2. Effects of sapropterin (BH4) on coronary artery volume at E18.5. 
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3.4.3 Sapropterin regulates coronary artery progenitor proliferation 
and EMT  
 To determine if diabetes-induced perturbations in coronary artery formation could 
give rise to the hypoplastic phenotype seen at E18.5, and whether sapropterin affected 
coronary artery precursors, epicardial proliferation and EMT were examined at E12.5. 
The epicardium is the source of coronary artery progenitors, which migrate from this 
epithelial layer via EMT into the myocardium.24 Immunostaining for phosphorylated 
histone H3 (pHH3), marking cells undergoing division, revealed less proliferation, 
reduced cell density, a loosely attached epicardium in hearts from diabetic dams 
compared to controls (P<0.01, Fig. 3.3A and D). Sapropterin treatment restored the 
number of pHH3+ cells to almost control levels and rescued epicardial detachment (Fig. 
3.3A). Concurrent with these changes in proliferation, a significantly greater number of 
E-cadherin+ epicardial cells were found in embryonic hearts from diabetic dams, which 
was abrogated by sapropterin treatment (P<0.01, Fig. 3.3B and E). To determine the 
number of cells actively going through the process of EMT, immunostaining for the 
transcription factor Wt1 was conducted and showed significantly fewer positive cells in 
the epicardium and subepicardium in E12.5 hearts from diabetic dams compared to 
controls (P<0.05, Fig. 3.3D). These abnormalities were also prevented by sapropterin 





Figure 3.3. Effects of sapropterin (BH4) on epicardial cell proliferation and markers 
of EMT in E12.5 hearts. 
(A) Representative images of immunostaining for phosphorylated histone H3 marking 
proliferating cells (red arrows), (B) E-cadherin (brown staining) representing cell-to-cell 
adhesion, and (C) Wt1+ cells (brown staining) indicating EMT. Quantification of pHH3+ 
cells (D), E-cadherin+ cells (E) in the epicardium, and Wt1+ cells in the epicardium (F) 
and subepicardium (G). n = 3 – 6 hearts per group, *P<0.05, **P<0.01 vs. untreated 




3.4.4 Tetrahydrobiopterin normalizes high glucose-impaired 
epicardial EMT ex vivo 
 To further investigate the ability of sapropterin to restore epicardial EMT and 
thereby prevent diabetes-induced CAMs, effects of BH4 on EPDC migration was studied 
ex vivo under high glucose conditions. The ventricular myocardium of E12.5 hearts from 
control dams was isolated and cultured on collagen gel in both high glucose (30 mmol/L) 
and normal glucose (5 mmol/L) conditions for 4 days (Fig. 3.4A). The outgrowth radius 
of spindle shaped cells from the explanted heart tissue was measured. The data shows 
that high glucose impaired EPDC migration through the collagen matrix with 
significantly shorter outgrowth distance compared to normal glucose (P<0.01, Fig. 3.4A). 
The addition of 0.1 mmol/L BH4 restored the distance travelled by the spindle-shaped 
EPDCs to normal levels (P<0.05, Fig. 3.4A and B).  
 
Figure 3.4. Effects of BH4 on epicardial EMT ex vivo. 
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(A) Representative images of epicardial cell outgrowth and EMT from E12.5 heart 
explants grown on a collagen matrix in normal (5 mM) and high (30 mM) glucose 
conditions with and without BH4 (0.1 mM). Dashed line indicated the border of the 
migrated cells. (B) Measurements of the average distance traveled by epicardial cells. (C)  
Quantification of spindle shaped cells (epicardial-derived cells, EPDCs) that have 
undergone EMT. *P<0.05, **P<0.01. n = 3-5 explants per group from five litters. 
 
3.4.5 Sapropterin restores expression of coronary vessel 
development and growth genes 
 Pregestational diabetes has been shown to alter gene expression in the developing 
heart.12, 22, 25 To determine if the expression of key transcriptional regulators and 
signaling molecules responsible for epicardial EMT, angiogenesis, differentiation and 
growth were affected by maternal diabetes and sapropterin treatment, qPCR analysis was 
performed on E12.5 hearts. The mRNA levels of Hif-1, Snail1, Slug, Aldh1a2, -
catenin, bFGF, and Tbx18 were significantly lower in hearts from diabetic dams 
compared to controls (P<0.05, Fig. 3.5A-G). Treatment with sapropterin significantly 
improved the expression levels of Hif-1, Snail1, Aldh1a2, -catenin and bFGF (P<0.05, 







Figure 3.5. Effects of sapropterin (BH4) on gene expression of transcription and 
growth factors critical to coronary artery development in E12.5 hearts of offspring 
from diabetic and control dams. 
mRNA levels were analyzed by qPCR. (A-G) The expression of Hif-1, Snail1, Slug, 
Aldh1a2, -catenin, bFGF, and Tbx18 were significantly decreased under maternal 
diabetes. All (A, B, D-F) were restored to control levels by BH4 treatment except Slug 
and Tbx18 (C and G). (H) eNOS expression was not significantly changed. n = 4 – 7 
hearts per group. *P<0.05, **P<0.01 vs. untreated control, and †P<0.05, ††P<0.01 vs. 
untreated diabetes. 
 
3.4.6 Sapropterin inhibits oxidative stress and restores activity of 
the Akt/eNOS pathway 
 To assess levels of oxidative stress in the developing myocardium, 
immunofluorescent staining of 4-hydroxynonenal (4-HNE), a product of lipid 
peroxidation, was conducted on E12.5 hearts. Quantification of red fluorescence intensity 
indicated higher levels of myocardial 4-HNE in offspring from diabetic dams compared 
to controls (P<0.05, Fig. 3.6A and B). Sapropterin administration to diabetic dams 
significantly reduced lipid peroxidation (P<0.05, Fig. 3.6B). Next, we assessed the 
effects of pregestational diabetes on Akt and eNOS activity in E14.5 hearts. Western 
blotting was used to analyze the phosphorylated and total amounts of Akt and eNOS (Fig. 
3.6C). Fetal hearts from diabetic dams had significantly lower levels of p-Akt and p-
eNOS compared to controls, without any major changes in total protein levels (P<0.001, 
Fig. 3.6C-E). Phosphorylation of both enzymes was recovered to control levels with 





Figure 3.6. Effects of sapropterin (BH4) on oxidative stress and Akt/eNOS 
phosphorylation in fetal hearts. 
(A) Representative immunoflourescence images of 4-hydroxynonenal staining for lipid 
peroxidation in the ventricular myocardium at E12.5. (B) Quantification of 4-HNE red 
immunofluorescence signal. (C) Representative Western blots for phosphorylated and 
total levels of Akt and eNOS with -actinin as a loading control in E14.5 hearts. (D and 
E) Densitometric analysis of phosphorylated to total protein levels of Akt (D) and eNOS 






 The current study displays the efficacy of the FDA-approved drug sapropterin 
dihydrochloride (Kuvan®) in preventing congenital malformations of coronary arteries 
induced by a clinically relevant model of pregestational diabetes (Figure 3.7). In 
accordance with our previous studies,12 CAMs were observed in the offspring of diabetic 
female mice. These CAMs manifest as hypoplastic coronary arteries, with marked 
decreases in luminal diameter and abundance, which translates to an overall reduction in 
the volume of coronary vasculature. We show that daily sapropterin administration to 
diabetic dams prevents hypoplastic coronary arteries, restores myocardial coronary 
arborisation and increases capillary density. Additionally, sapropterin decreases oxidative 
stress, improves Akt/eNOS activity and epicardial EMT, leading to normal coronary 
artery development. 
 
Figure 3.7. Schematic summary of sapropterin on diabetes-induced CAMs. 
Oral sapropterin (Kuvan®) treatment inhibits oxidative stress, improves Akt/eNOS 




Recently, we have shown the effectiveness of sapropterin in preventing CHDs in 
the offspring of diabetic mice.23 Sapropterin treatment throughout gestation to diabetic 
dams decreased the incidence of CHDs in their offspring from 59.4% to 26.5%, despite 
dams having a comparable hyperglycemic status.23 No major CHDs were reported in the 
treatment group, and insulin administration completely prevented the presence of 
malformations.23 Correspondingly, our previous work show that N-acetylcysteine (NAC) 
treatment in the same model of pregestational diabetes, significantly reduced the 
incidence of CHDs and CAMs from 58.1% to 16.3% and from 46.6% to 6.0%, 
respectively.12, 22 In fact, only 3% of fetal hearts from diabetic dams treated with NAC 
showed dual congenital heart and coronary artery anomalies.12 In the present study, 
sapropterin treatment completely prevented the presence of both a CHD and CAM within 
the same heart, and significantly reduced CAM incidence from 50.0% to 20.6%. Whether 
sapropterin and NAC have an additive or synergistic effect in preventing CHDs and 
CAMs remains to be determined in future studies.  
STZ is commonly used in animal models of diabetes to induce congenital 
malformations.12, 22, 23, 25 Following STZ administration in our study, the glycemic levels 
of female mice steadily rose throughout pregnancy. Daily insulin treatment, the clinical 
gold-standard for controlling hyperglycemia in diabetes,26 to a cohort of these diabetic 
mice normalized blood glucose levels. Interestingly, no CAMs were seen with insulin 
treatment, indicating that STZ does not have teratogenic effects on coronary artery 
development, and the defects seen in non-insulin treated STZ cohort are due to 
hyperglycemia. Unlike insulin, sapropterin did not affect blood glucose levels of the 
diabetic dam, suggesting that its beneficial effects are independent of maternal glucose 
150 
 
levels. Clinically, a male predominance of coronary artery anomalies has been reported.27, 
28. In the present study, the incidence of pregestational diabetes-induced CAMs did not 
show a sex bias and sapropterin treatment was equally effective in both females and 
males. Of note, in dams with blood glucose exceeding 30 mmol/L, fetuses harvested at 
E18.5 were 69% females, suggesting that more males with CAMs may have succumbed 
to maternal diabetes, which may explain a lack of sex difference in the incidence of 
CAMs in our study.   
The epicardium is a major source of coronary arteries during embryonic heart 
development. Between E11.5 and E12.5 many cells in the epicardium undergo EMT and 
delaminate, forming EPDCs.14, 29 These EPDCs migrate into the myocardium and 
differentiate into vascular smooth muscle cells, endothelial cells and perivascular 
fibroblasts, and form coronary arteries.13 Wt1 is the master regulator of epicardial EMT, 
and transcriptionally controls the expression of many mediators of EMT such as Snail1, 
Aldh1a2 and E-cadherin.30, 31 In mice deficient of Wt1, epicardial cells fail to undergo 
EMT, resulting in null coronary artery formation.32 In the present study, consistent with 
our previous work,12 pregestational diabetes decreased epicardial and subepicardial 
expression of Wt1, and inhibited epicardial cell proliferation and EMT in the developing 
heart. We also showed lower mRNA levels of many drivers of EMT including, Snail1, 
Slug, and Aldh1a2, and increased expression of E-cadherin. Notably these changes were 
restored to control levels with sapropterin treatment. Interestingly, BH4 has been shown 
to increase cell proliferation in retinal microvascular endothelial cells, mesangial (smooth 
muscle) cells of the kidney, and human vascular endothelial cells (HUVECs), and 
promote cell migration and tubulogenesis.33-35 Consistent with these studies, we showed a 
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pro-angiogenic effect of sapropterin in the fetal heart of diabetic pregnancies in the 
present study.  
Akt and eNOS are critical for proper heart development. In fact, Akt1/3 double 
knockout mice exhibit CHDs and early neonatal lethality.36 We have previously shown 
that eNOS-deficient mice display major cardiac defects including ASD, VSD and 
hypoplastic coronary arteries.18, 37, 38 Diabetes impairs eNOS function. For example, 
eNOS Ser1177 phosphorylation is decreased in the heart of diabetic patients 39 and eNOS 
is uncoupled in E12.5 hearts from diabetic dams.23 In the present study, maternal diabetes 
induces a significant reduction in Akt and eNOS phosphorylation in E14.5 hearts, which 
was restored by sapropterin treatment. eNOS-derived NO is a key signaling molecule 
involved in proliferation, differentiation, EMT and ROS handling.17 High levels of 4-
hydroxynonenal, a marker of lipid peroxidation, reduces eNOS phosphorylation in bovine 
aortic endothelial cells by decreasing cellular BH4 bioavailability.40 In our study, 
sapropterin treatment in diabetic dams significantly reduced ROS and 4-hydroxynonenal 
levels in fetal hearts. These findings suggest that sapropterin prevents hyperglycemia-
induced oxidative stress and maintains redox balance and eNOS function in the 
developing heart. 
 A notable observation from immunohistochemical analysis is α-SMA positive 
staining in cardiomyocytes in addition to coronary arteries in E18.5 hearts of offspring 
from diabetic mothers. During early cardiogenesis, immature cardiomyocytes express α-
SMA and as cardiac development progresses, α-SMA is eventually replaced by cardiac 
actin isoforms.41, 42 The persistent α-SMA expression in cardiomyocytes and smaller 
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heart size at E18.5 in offspring of pregestational diabetes suggest that maternal diabetes 
delays fetal heart maturation, which is also prevented by sapropterin treatment.  
 The present study is limited to simulate type 1 diabetes. In pregnant women, the 
prevalence of pregestational type 2 diabetes is rapidly increasing in recent years.43 The 
effects of type 2 diabetes on CAMs remain to be investigated in future studies. 
Additionally, coronary arteries are formed from at least 3 sources of progenitors, the 
epicardium, endothelial cells of sinus venosus and the endocardium.14-16 The present 
study examined the changes of epicardial progenitors, which is considered a major 
contributor to coronary arteries.14 Whether the other two sources of coronary progenitors 
are affected by pregestational diabetes and/or sapropterin requires further investigation. 
 In conclusion, oral treatment with the FDA-approved drug sapropterin 
dihydrochloride (Kuvan®), a stable, synthetic form of BH4, prevents the development of 
CAMs induced by maternal diabetes in mice. Sapropterin increases Akt and eNOS 
phosphorylation, decreases oxidative stress in the developing heart, and promotes cell 
proliferation, EMT and growth of coronary artery progenitors. Sapropterin did not 
negatively affect litter size, fetal weight or heart development in our studies,23 suggesting 
an excellent safety profile in normal mouse pregnancies. Currently sapropterin is 
prescribed as a phenylalanine hydroxylase activator for patients with phenylketonuria 
(PKU), a genetic disorder. The potential of sapropterin as a treatment to prevent CHDs 
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4 Chapter 4 
4.1 Chapter Summary 
Pregestational maternal diabetes increases the risk for congenital heart defects 
(CHDs) in infants by over four times. Diabetes may alter maternal/fetal microRNA 
(miRNA) profiles leading to the pathogenesis of CHDs. An elevation of miR-122 has 
recently been reported in patients with impaired glucose tolerance, insulin resistance and 
obesity. miR-122 is highly abundant in the liver and acts as tumor suppressor. The aim of 
the present study was to determine if miR-122 is elevated in embryonic hearts from 
diabetic female mice, and to examine the effects of antimiR-122 on pathogenesis of 
CHDs during pregestational diabetes. Diabetes was induced by streptozotocin (50 mg/kg, 
IP x5) to adult female C57BL/6 mice. Diabetic females were treated with a locked 
nucleic acid (LNA) antimiR-122 or scramble LNA control (10 mg/kg, SC x2), and their 
offspring’s hearts were examined at E18.5 for morphology and function. RT-qPCR 
analysis showed that miR-122 was upregulated in E12.5 hearts of offspring from diabetic 
dams. In cultured E12.5 hearts, treatment with miR-122 or high glucose inhibited cell 
proliferation and epicardial EMT, and increased apoptosis. These effects of miR-122 and 
high glucose were abrogated by antimiR-122 transfection. Downregulation of genes 
critical to cell cycle progression, angiogenesis, and heart development, such as Cyclin 
D1, Snail1, Gata4 and Hand2 under high glucose conditions, was also prevented by 
anitmiR-122 transfection. Furthermore, in vivo antimiR-122 treatment to diabetic dams 
decreased the incidence of CHDs and improved cardiac function of fetuses compared to 
scramble LNA controls. The current study reveals for the first time a critical role of miR-
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122 in CHD pathogenesis, and may have therapeutic implications in preventing CHDs 
during pregestational diabetes.  
4.2 Introduction 
Congenital heart defects (CHDs) are the most prevalent birth defect, accounting 
for 1 to 5% of live births, and represent the leading, non-infectious cause of pediatric 
mortality and morbidity worldwide.1-4 These defects result from perturbations in complex 
molecular and cellular processes underlying normal embryonic heart development, 
compromising cardiac structure and function at birth. Adverse genetic and environmental 
factors impair cardiogenesis and increase the likelihood of CHDs. Pregestational 
maternal diabetes increases the incidence of CHDs in children by more than four-fold.5-8 
Importantly, the incidence of both type 1 (insulin-dependent) and type 2 (insulin 
resistant) diabetes (T1D and T2D) is rapidly increasing in women of childbearing age and 
youth aged 10 -19 years.9-11 In fact, between 2000 and 2010, there was a 37% rise in 
pregnancies affected by pregestational diabetes in the U.S.12 Despite glycemic control, 
congenital malformations occur at higher rates from pregnancies with pregestational 
diabetes.13 With the rising number of women with pregestational diabetes, more children 
are predicted to be born with CHDs, conferring a greater burden on the healthcare system 
as this pediatric population enters into adulthood.14   
The heart is the first functional organ to arise during mammalian embryogenesis, 
and involves the combination of three pools of progenitor cells in a spatiotemporal 
specific manner, reliant upon regulated cell proliferation, apoptosis and epithelial-to-
mesenchymal transition (EMT).15 First and second heart field-derived (FHF and SHF) 
multipotent cardiac progenitors undergo proliferation followed by differentiation into 
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cardiomyocytes, which further clonally expand resulting in chamber ballooning and 
formation of the left and right ventricles.16,17 The canonical Wnt/-catenin signaling 
pathway directs proliferation of the SHF allowing for cardiac looping and outflow tract 
(OFT) development.18 Conversely, a basal level of apoptosis is necessary for proper heart 
development, as it induces changes in both the endocardial cushions and myocardial 
microenvironment, signaling differentiation and development of cardiac valves, OFT, 
coronary vasculature and conduction system.19 Additionally, EMT is required for 
coronary artery formation, causing a delamination and migration of epicardial cells into 
the myocardium, whereby they differentiate into smooth muscle cells, fibroblasts and 
endothelial cells, forming the vasculature. This trans-differentiation process is mediated 
by upregulations of EMT factors, such as Wt1 and Snail1/2, which promote cell 
motility.20,21 Thus, an insult to any of these coordinated cellular processes could result in 
a misstep in heart development and lead to a CHD.  
miRNAs are short, single-stranded RNA molecules that post-transcriptionally 
modulate gene expression by targeting mRNA transcripts at the 3’ UTR and repressing 
their expression.22 These endogenous, non-coding nucleic acids are key players in the 
pathogenesis of diabetes and its cardiovascular comorbidities, and are recently being 
recognized for their diagnostic potential, serving as biomarkers for disease progression, 
and therapeutic targets.23 miRNAs are expressed in the embryonic heart and their levels 
of expression are critical to heart development. For example, targeted deletion of miR-1-2 
causes ventricular septal defects and 50% mortality at late gestation while overexpression 
of miR-1 in the embryonic heart under the control of -myosin heavy chain results in 
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lethality at E13.5.24 Maternal diabetes changes maternal and fetal miRNA profiles which 
may contribute to the pathogenesis of CHDs.25-27  
miR-122 is a conserved, 22 nucleotide molecule that plays a critical role in liver 
development and homeostasis. It regulates lipid and cholesterol metabolism, and serves 
as a tumor suppressor, protecting against hepatocellular carcinoma (HCC) by inhibiting 
proliferation and angiogenesis.28-30 In patients with impaired glucose tolerance, insulin 
resistance, obesity, metabolic syndrome or T2D, elevated levels of circulating miRNA-
122 (miR-122) have been reported.31-35 Upregulation of plasma miR-122 was 
demonstrated in T2D rodent models on a high-fat, high-sucrose diet.32,36 However, the 
role of miR-122 in pathogenesis of CHDs during pregestational maternal diabetes is 
unknown. RNA sequencing of maternal exosomes from STZ-induced diabetic and 
control dams noted significant alterations in plasma miRNAs, with a 3-fold increase in 
miR-122.27 Using a global miRNA microarray we found a 14-fold upregulation in miR-
122 in E10.5 hearts from diabetic dams compared to control. The present study aimed to 
assess miR-122 expression in embryonic hearts from maternal diabetes, and delineate its 
role in CHD pathogenesis during pregestational diabetes using anti-miR-122 treatment in 
mice. We hypothesized that miR-122 will be upregulated in embryonic hearts from mice 
with pregestational diabetes, which will decrease cell proliferation and epicardial EMT, 
and increase apoptosis in the developing heart, contributing to the pathogenesis of CHDs. 
In addition, anti-miR-122 treatment will reduce the incidence of CHDs induced by 





 All procedures on mice in this study were performed in accordance with the 
Canadian Council on Animal Care guidelines and approved by the Animal Care 
Committee at Western University. C57BL/6 wild-type mice were purchased from 
Jackson Laboratory (Bar Harbor, Maine), and a breeding program was implemented to 
harvest fetal mice. Animals were housed in a 12-hour light/dark cycle and given ad 
libitum access to normal chow and water. All animals used in this study were handled 
according to the National Institute of Health Guide for the Care and Use of Laboratory 
Animals (8th edition, 2011). 
4.3.2 Induction of Diabetes and AntimiR-122 Treatment 
 The in vivo and ex vivo experimental approach in Figure 4.1 illustrating timelines 
for saline or streptozotocin injection, breeding, anti-miR-122 or scramble LNA 
administration, organ culture conditions, and assessment of fetal hearts in 6 randomly 
assigned groups of mice. Female C57BL/6 mice, 8 to 10 weeks old were made diabetic 
through five consecutive, daily injections of streptozotocin (STZ, 50 mg/kg body weight, 
IP, Sigma), as we previously described.37 STZ was dissolved in sterile saline (0.9% 
NaCl) at time of administration; sterile saline served as vehicle control. One week 
following the last STZ injection, non-fasting blood glucose levels were measured with a 
tail snip procedure using a glucose meter (One Touch Ultra2, LifeScan Canada, Burnaby, 
BC). Mice were categorized as diabetic if blood glucose measurements exceeded 11 
mmol/L, and were subsequently injected with locked nucleic acid (LNA) oligos for anti-
miR-122 or scramble control at a dose of 10 mg/kg, dissolved in sterile saline, 
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subcutaneously. A LNA oligo is a modified nucleic acid with a phosphothiate backbone 
and methylene bridge connecting the 2’ oxygen and 4’ carbon, enhancing stability and 
uptake in vivo (Exiqon, Qiagen). Mice were then bred with 10 to 12-week-old C57BL/6 
male mice, and E0.5 was confirmed with presence of a vaginal plug after which pregnant 
dams were places in a cage with littermates. At E7.5, the dams received another 10 mg/kg 
dose of anti-miR-122 or scramble LNA control, subcutaneously. This dose was 
determined based on the manufacturer’s in vivo guidelines (Exiqon, Qiagen). Food and 
water intake, as well as non-fasting blood glucose levels were monitored throughout 
pregnancy. Fetal samples were collected at E18.5 for morphological and gene expression 
analysis, following in utero echocardiography. E12.5 embryonic hearts were isolated 
from a cohort of LNA-untreated control and STZ-induced diabetic dams for gene 
expression analysis. E10.5 and E12.5 hearts were collected under sterile conditions for 




Figure 4.1. Ex vivo and in vivo approaches to examine the effects of miR-122 on 
heart development, and antimiR-122 on pregestational diabetes-induced CHDs. 
Flow charts illustrate timelines of saline or streptozocin injection, breeding, embryonic 
heart harvest and culture, anti-miR-122 administration and assessment of fetal hearts for 
gene expression at E12.5, and cardiac morphology and function at E18.5. To determine 
miR-122 levels in the embryonic heart, E12.5 hearts from control and STZ-induced 
diabetic dams were collected for RNA isolation and gene expression analysis. In order to 
determine the effects of miR-122 on heart development, E10.5 and E12.5 hearts from 
control dams were cultured ex vivo for 4 days in normal or high glucose media, with 
miR-122 or antimiR-122 transfection for 24 hours. Two in vivo doses of anti-miR-122 or 
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scramble LNA to control and diabetic dams were administered according to this timeline 
to determine their effects on the fetal heart. 
 
4.3.3 Histological Analysis 
 Fetal cardiac and liver samples were collected at E18.5 for histological analysis 
from control and diabetic dams treated with anti-miR-122 or scramble LNA. 
Morphological analysis of cardiac structures in order to diagnose CHDs was performed at 
E18.5 by first decapitating the fetuses and isolating the thorax in PBS. After removing 
skin and fascia, samples were fixed in 4% paraformaldehyde overnight at 4 C, after 
which samples were dehydrated in ethanol and embedded in paraffin. The hearts were 
serial sectioned into 5 m slices using a Leica RM2255 microtome, and mounted onto 
positively charged albumin/glycerin-coated slides. Following dewaxing of the slides, they 
were stained with hematoxylin/eosin (Thermo Scientific, Waltham, MA) to visualize 
morphology under a light microscope (Observer D1; Zeiss, Germany). Fetal liver 
samples were processed, sectioned and stained in the same manner.  
4.3.4 Embryonic Heart Explant Culture 
 Figure 1 depicts the ex vivo organ culture system used to assess the effects of 
miR-122 and its antagonist, anti-miR-122, on gene expression, proliferation, apoptosis 
and EMT in heart development. E10.5 hearts from control, untreated dams were isolated 
in sterile saline and placed individually in wells of a 24-well plate with 500 L of M199 
cardiomyocyte media (with 10% FBS and 1% penicillin/streptomycin) containing either 5 
or 30 mM D-glucose per well. JetPrime transfection reagent and buffer system (Polypus 
Transfection, Illkirch, France) was used to transfect miR-122 to a cohort of explants in 
normal (5 mM) D-glucose media, or anti-miR-122 to a subset of explants in high (30 
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mM) D-glucose media for 24 hours, according to the manufacturer’s protocol. After 4 
days of culture at 37°C in 5% CO2, the media was removed and the hearts were either 
cryosectioned or used for gene expression analysis.  
4.3.5 Ex vivo Assessment of Epicardial EMT 
 To investigate the effects of miR-122 on epicardial EMT during cardiogenesis, 
E12.5 hearts from control, non-diabetic dams were harvested in sterile conditions, 
dissected into small pieces in sterile saline, and placed on a collagen matrix. The collagen 
matrix was prepared using 1 mg/mL type I rat tail collagen (BD Bioscience) diluted with 
2x M199 cardiomyocyte media (M5017; Sigma) containing either 5 or 30 mM D-glucose 
in a 24-well plate. The casted wells were then hydrated with 500 L 1x M199 media plus 
10% FBS, 1% penicillin/streptomycin and insulin-transferrin-selenium, with either, 5 or 
30 mM D-glucose, matching the collagen layer. The pieces of E12.5 ventricles were 
placed centrally in the well on top of the matrix, and the JetPrime transfection reagent 
and buffer system (Polypus Transfection, Illkirch, France) was used to deliver miR-122 
to a cohort of explants in the 5 mM D-glucose condition, or anti-miR-122 to a subset of 
explants in the 30 mM D-glucose group. The transfection was removed after 24 hours, 
and explants were again incubated at 37°C in 5% CO2 for 72 hours. After culture, images 
were captured by phase contrast microscopy (Observer D1; Zeiss, Germany), and 
spindle-shaped EPDCs, which are epicardial cells that have undergone EMT, were 
quantified and normalized to the area of the explant.  
4.3.6 Immunofluorescence   
 To determine the effects of miR-122 on proliferation and apoptosis during cardiac 
development, E10.5 heart explants from all 4 groups were aspirated and embedded in 
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FSC22 frozen section media (Leica) following 4 days of culture. Samples were 
cryosectioned into 8 m thick sections using the CM1950 cryostat (Leica), and mounted 
on glass slides. Immunostaining for proliferation and apoptosis markers was performed 
using anti–phosphohistone H3 antibody (1:1000; Abcam) and anti-cleaved caspase 3 
antibody (1:1000; Cell Signaling), respectively. After 2 hours of primary antibody 
incubation, CY3-conjugated anti-goat IgG fluorescent secondary antibody (1:1000; 
Jackson Immunoresearch) was aliquoted onto the slides for 1 hour, followed by Hoechst 
33342 (Invitrogen). Fluorescence microscopy (Observer D1, Zeiss, Oberkochen, 
Germany) was used to detect signals and capture images from which positive cells were 
counted and normalized to myocardial area using the AxioVision Software (Zeiss). 
4.3.7 Real-time RT-PCR analysis 
 Total RNA from individual E12.5 hearts, E10.5 heart explants and E18.5 livers 
was isolated using miRNeasy Mini Kit (Qiagen, Burlington, Ontario, Canada). Stem-loop 
pulsed reverse transcription was performed by using Moloney Murine Leukemia Virus 
(MMLV) reverse transcriptase to synthesize cDNA from 800 nanograms of total RNA 
with specific primers for miR-122, snord-47, as previously described.38 RT using random 
primer was also conducted. Primers were specifically designed using the Primer3 
software v 4.1.0 (Table 4.1) for miR-122, snord-47, 28S, GLD2, Gata4, Hand2, EPO, 
Cyclin D1, Wnt1, Snail1, and Slug. Real-time PCR analysis was performed using 
EvaGreen qPCR MasterMix (Applied Biological Material, Vancouver, British Columbia, 
Canada). Sample amplification was set for 35 cycles via the usage of Eppendorf Realplex 
(Eppendorf, Hamburg, Germany). Transcript levels were normalized with snord-47 
miRNA or 28S, and extrapolated through the approach of comparative CT method.39 
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Primer Sequence (5’ → 3’) 










28S NR_003279.1 178 
Forward: GGGCCACTTTTGGTAAGCAG 
Reverse: TTGATTCGGCAGGTGAGTTG 








Gata4 NM_008092.4 137 
Forward: CACTATGGGCACAGCAGCTC 
Reverse: GCCTGCGATGTCTGAGTGAC 
Hand2 NM_010402.4.1 159 
Forward: GCTACATCGCCTACCTCATGGAT 
Reverse: TCTTGTCGTTGCTGCTCACTGT 
Cyclin D1 NM_007631.2 155 
Forward: CTGACACCAATCTCCTCAACG 
Reverse: CTCACAGACCTCCAGCATCCA 
Snail1 NM_011427.3 133 
Forward: CACACGCTGCCTTGTGTCT 
Reverse: GGTCAGCAAAAGCACGGT 
Slug NM_011415.2 161 
Forward: CAACGCCTCCAAGAAGCCA 
Reverse: GAGCTGCCGACGATGTCAT 
Wt1 NM_144783.2 214 
Forward: GATGTGCGGCGTGTATCTGG 
Reverse: GCTGGTCTGAGCGAGAAAACCT 
Wnt1 NM_021279 241 
Forward: CTGGAACTGCCCCACTGCT 
Reverse: GCCAAAGAGGCGACCAAAAT 
EPO NM_007942.2 165 
Forward: GGAATTGATGTCGCCTCCAG 
Reverse: GCAGCAGCATGTCACCTGTC 
RT: Reverse Transcription  
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4.3.8 Fetal Echocardiography  
 To assess the effects of anti-miR-122 treatment on cardiac function, in utero fetal 
echocardiography using the Vevo 2100 ultrasound imaging system was conducted. Dams 
were anesthetized and an incision was made to the abdomen to expose the uterine sacs 
containing the E18.5 fetuses. A MS 700 transducer (VisualSonics, Toronto, ON, Canada) 
was positioned to obtain a short-axis view of the fetal heart, and M-mode 
echocardiography images of fetal hearts were recorded with, as previously described.39,40 
LV ejection fraction and fractional shortening were calculated by measuring the end-
diastolic LV internal diameter and end-systolic LV internal diameter from the short-axis 
M-mode images.  
4.3.9 Statistical Analysis 
 Statistical analysis was performed using GraphPad Prism, Version 5 (GraphPad 
Software, La Jolla, CA) and data are presented as mean  SEM. An unpaired Student t 
test was used for comparisons between 2 groups. For multiple group comparisons 
between normal and high glucose conditions with miR-122 or anti-miR-122 treatment, a 
one-way ANOVA, followed by the Tukey’s post hoc test was conducted. CHD incidence 






4.4.1 miR-122 is upregulated in the fetal heart of pregestational 
diabetes 
 Since miR-122 is highly expressed in the liver, we first assessed miR-122 levels 
in the adult liver. RT-qPCR analysis shows that miR-122 was abundantly expressed in 
the liver compared to the LV myocardium of the adult mice (P<0.001, Figure 4.2A). 
Subsequent analysis revealed that significantly higher levels of miR-122 were present in 
E12.5 hearts from diabetic dams compared to control (P<0.05, Figure 4.2B). To verify 
that miR-122 is expressed in the fetal heart, the levels of primary-miR-122, a longer 
precursor transcript, existing only in the nucleus was analyzed. Pri-miR-122 was 
significantly increased in E12.5 hearts from diabetic dams compared to control (P<0.05, 
Figure 4.2C). Once in the cytoplasm, mature miRNA transcripts are processed by 
cytoplasmic poly(A) polymerases, which confer stability to the RNA molecules. miR-122 
is stabilized by GLD2,41 and we found it to be significantly elevated in E12.5 hearts from 
diabetic dams compared to control (P<0.001, Figure 4.2D). Taken together, these results 
show, for the first time, that a significantly higher level of miR-122 is expressed in hearts 





Figure 4.2. Expression analysis of miR-122, Pri-miR-122 and GLD2. 
(A) Real-time qPCR of miR-122 in the liver and left ventricle of adult mice. Gene 
expression analysis of E12.5 hearts from control or diabetic dams for miR-122 (B), pri-
miR-122 (C) and GLD2 (D). (E) miR-122 expression analysis from E10.5 explanted 
hearts following four days of culture in normal (5 mM) or high (30 mM) D-glucose 
conditions transfected with either miR-122 or anti-miR-122. n = 3 to 6 hearts per group. 
Data are mean ± SEM. *P<0.05, ** P<0.01 and ***P<0.001 vs. respective controls. 
 
4.4.2 Gene targets of miR-122 in the embryonic heart 
 To identify 3’ UTR mRNA targets of genes critical to embryonic heart 
development that are affected by miR-122, the miRbase and TargetScan online databases 
were used. Over 200 genes were predicted to be the targets of miR-122, however direct 
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targets that have an active role in embryonic heart development include, Gata4, Hand2, 
EPO, Cyclin D1, Wnt1, Snail1, and Slug (Figure 4.3B-H), which are critical to cell cycle 
progression, angiogenesis and cardiogenesis. An ex vivo embryonic heart culture was 
used to further assess the effects of miR-122 and antimiR-122 on the expression of these 
genes in E10.5 hearts under normal or high glucose conditions. Transfection of miR-122 
significantly elevated its levels in the cultured hearts, compared to control, whereas miR-
122 was not detectable in antimiR-122 transfected hearts (P<0.001, Figure 4.2D). Hearts 
exposed to high glucose media showed a slight elevation in miR-122 levels, however this 
change was not statistically significant. Hyperglycemia is known to alter gene expression 
in the embryonic heart.37,42,43 In agreement with this notion, mRNA levels of Gata4, 
Hand2, Cyclin D1, Wnt1 and EPO were significantly reduced in the high glucose (30 
mM) compared to the normal glucose (5 mM) conditions (P<0.05, Figure 4.3A-D, G). 
Strikingly, in normal glucose conditions miR-122 transfection significantly lowered the 
expression of these genes in the cultured hearts compared to control (P<0.05, Figure 
4.3A-C, E-F). Treatment with antimiR-122 in the high glucose conditions was effective 
in restoring expression back to normal levels for all 6 genes (P<0.05, Figure 4.3A -F). In 
addition, antimiR-122 treatment significantly elevated Gata4, Hand2, Cyclin D1, and 
Snail1 levels back to normal when compared to miR-122 administration (P<0.05, Figure 
4.3A-C, E). Taken together, these results demonstrate that miR-122 and high glucose 
independently inhibit the expression of genes required for heart development, and the 









mRNA isolated from E10.5 hearts and analyzed by RT-qPCR. Values are normalized to 
reference gene 28S. (A) Gata4, (B) Hand2, (C) Cyclin D1, (D) Wnt1, (E) Snail1, (F) 
Slug, (G) EPO. miR-122 to 3’ UTR sequence complementarity prediction was performed 
using online databases (miRbase, TargetScan). n=4-5 per group from three litters. Data 
are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. 
 
4.4.3 Role of miR-122 in Cell Proliferation and Apoptosis in the 
Embryonic Heart 
 MiR-122 is a tumor suppressor and many studies have shown its ability to inhibit 
cell proliferation and increase apoptosis.44-46 These two processes are integral to 
embryonic heart development.47,48 E10.5 explanted hearts were cultured for four days in 
normal or high glucose conditions. A subset of hearts cultured in normal glucose were 
transfected with miR-122, and a cohort of hearts grown in high glucose were transfected 
with antimiR-122. Cell proliferation was analyzed using immunostaining for 
phosphorylated histone H3 (pHH3). Results show that high glucose or miR-122 
transfection significantly lowered pHH3+ cells in E10.5 hearts compared to normal 
glucose control (P<0.001, Figure 4A and C). Transfection with antimiR-122 under high 
glucose conditions restored cell proliferation to normal control levels (P<0.05, Figure 
4.4A and C). Conversely, cell apoptosis as assessed by immunostaining of cleaved 
caspase 3 revealed a significant higher level of cell death under high glucose conditions 
as well as miR-122 transfection (P<0.05, Figure 4.4B and D). Notably, antimiR-122 
transfection in explants grown under high glucose conditions significantly lowered the 







Figure 4.4. Effects of miR-122 and high glucose on cell proliferation and apoptosis 
in the embryonic heart. 
Representative images of immunohistological staining of pHH3 (A) and cleaved caspase 
3 (B). E10.5 hearts isolated from normal dams were used for ex vivo heart explant 
cultures. Explants cultured in 5 mM D-glucose were transfected with miR-122; whereas 
those exposed to 30 mM D-glucose received antimiR-122 for 24 hours. Heart sections 
were incubated with rhodamine phalloidin and DAPI to stain for pHH3+ or cleaved 
caspase 3+ cells and nuclei, respectively. Quantification of pHH3+ (C) and cleaved 
caspase 3+ cells (D). n = 5-6 hearts per group. Data are mean ± SEM. *P<0.05, 
**P<0.01, ***P<0.001; Scale bar is 20 μm. 
 
4.4.4 Role of miR-122 in epicardial EMT 
 In addition to inhibiting cell proliferation, miR-122 has been shown to impede 
EMT in tumorgenesis.45,49,50 High glucose has been previously shown to impair epicardial 
EMT ex vivo.42 To study the role of miR-122 on epicardial EMT in the developing heart, 
an ex vivo EMT assay was performed by culturing E12.5 hearts on a collagen matrix for 4 
days. The number of spindle like cells, which are epicardial-derived cells (EPDCs) that 
underwent EMT and migrated into the collagen matrix was counted and their migration 
distance was measured (Figure 4.5A). The data indicates that, after 4 days of culture, the 
number of EPDCs was significantly lowered by miR-122 transfection and by high 
glucose compared to normal glucose control (P<0.01, Figure 4.5C). However, treatment 
with antimiR-122 to the high glucose cultures restored the number of EPDCs back to 
control levels (P<0.001, Figure 4.5C). During EMT, mesenchymal cells migrate away 
from the explant to form the outgrowth area. The outgrowth distance, which is the 
distance from the edge of the explant to the edge of the outgrowth area, was quantified 
(Figure 4.5A-B). The data demonstrates that outgrowth distance was significantly 
reduced in the presence of miR-122 and under high glucose conditions compared to the 
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normal glucose control (P<0.001, Figure 4.5B). Finally, antimiR-122 transfection under 
high glucose conditions restored the outgrowth distance to normal glucose levels 
(P<0.001, Figure 5B). 
 






(A) Representative images of E12.5 heart explant cultures grown on collagen matrix. 
Dashed lines outline the edge of the EPDC outgrowth area. (B) Quantification of the 
number of spindle shaped EPDCs normalized to the total explant area. (C) Quantification 
of outgrowth distance from the cultured heart explants. Values are measured from the 
edge of the explant to the edge of EPDC outgrowth area. n =5 - 8 explants per group from 
four litters. Data are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. Scale bar is 50 μm.  
 
4.4.5 Effects of antimiR-122 on blood glucose, litter size, cardiac 
function and fetal liver 
 To study the role of miR-122 in heart development in vivo, a stable, a locked 
nucleic acid (LNA) version of antimiR-122 was formulated. STZ-induced diabetic female 
mice received two subcutaneous 10 mg/kg doses of either antimiR-122 or scramble LNA 
control, one prior to pregnancy and one during pregnancy. Figure 4.6A shows the blood 
glucose profile of female mice before pregnancy to fetal harvest with progressive 
increases throughout gestation, which were not affected by antimiR-122 or scramble 
LNA control. While CHDs were present in an equal number of male and female offspring 
from diabetic dams administered scramble LNA, anti-miR-122 treatment was more 
effective in preventing CHDs in males compared to females (P<0.05, Figure 4.6B). No 
significant changes in offspring litter size was noted between the two groups (Figure 
4.6C). Next, cardiac function of E18.5 fetuses was measured using M-Mode 
echocardiography. Left ventricle ejection fraction (Figure 4.6D) and fractional shortening 
(Figure 4.6E) were significantly higher in offspring of diabetic dams treated with 
antimiR-122 compared to scramble LNA (P<0.001). Finally, fetal livers were analyzed at 
E18.5 to determine whether the antimiR-122 treatment had any adverse consequences on 
normal development in vivo. As antimiR-122 treatment is expected to decrease the 
abundance of miR-122, the levels of miR-122 in the fetal liver were analyzed.51 Indeed, 
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qPCR results indicate that antimiR-122 treatment significantly reduced miR-122 levels in 
the fetal liver in offspring of control and diabetic dams compared to scramble LNA 
administration (P<0.01, Figure 4.6F). This result indicates that antimiR-122 treatment 
decreases miR-122 levels in mice. To determine whether antimiR-122 treatment had any 
effect on the fetal liver, hepatic histology was examined. No significant differences were 
seen in the average number of nuclei per liver section, or the ratio of sinusoid area to total 











(A) Blood glucose profile of diabetic dams administered with antimiR-122 (n=4) or 
scramble LNA control (n=5-6). (B) Sex differences in CHDs incidence in the offspring of 
diabetic dams administered with antimiR-122 or scramble LNA. (C) The offspring litter 
size measured at the day of fetus harvest (n=6-7 per group). (D) Ejection fraction and (E) 
fractional shortening measured through fetal echocardiography (n=4 per group). (F) 
E18.5 fetal liver miR-122 levels in offspring of control and diabetic dams treated with 
scramble LNA or anti-miR-122 (n=4 per group). (G) Effects of antimiR-122 on fetal liver 
morphology at E18.5. Representative histological sections of E18.5 liver samples from 
dams administered with scramble LNA or antimir-122. Scale bar is 100 μm. (H) Average 
number of nuclei per fetal liver section and (I) ratio of sinusoid area to total fetal hepatic 
area (n=4 per group). Data are mean ± SEM except B. *P<0.05, **P<0.01, ***P<0.001 
vs. respective controls. 
 
4.4.6 Anti-miR-122 administration reduces the incidence of 
diabetes-induced CHDs  
 CHDs were observed in 55.6% of offspring from diabetic dams treated with 
scramble LNA. This ratio was significantly reduced to 23.0% with antimiR-122 treatment 
(Table 4.2). Congenital malformations of the heart were present in all litters from 
scramble LNA-treated diabetic dams, and every dam in the antimiR-122 treatment group 
had at least one offspring with a CHD.  Septal defects were commonly found in both 
groups. Atrial septal defects (ASD, Figure 4.7A) were observed in similar proportions. 
Diabetic dams treated with scramble LNA had 22.2% of offspring with a ventricular 
septal defect (VSD, Figure 4.7B), which was reduced to 4.2% with antimiR-122 
treatment (Figure 4.7E). Two fetal hearts with double outlet right ventricles (DORV) 
were present in the scramble LNA group (Figure 4.7C), whereas normal aortic 
connections were maintained with antimiR-122 treatment (Figure 4.7F). Other severe 
CHDs of the outflow tract, such as truncus arteriosus and a vascular ring constricting the 
esophagus and trachea were only present in fetuses from diabetic dams treated with 
scramble LNA. Valvular defects were also prevalent in offspring of diabetic dams given 
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scramble LNA. Thicker pulmonary (13.9%, Figure 4.7G) and aortic (19.4%, Figure 4.7H) 
valves were more common in hearts from scramble-treated diabetic dams compared to 
antimiR-122-treated diabetic dams (2.6% and 7.4%, Figure 4.7J-K, respectively). Finally, 
non-compaction of the ventricular myocardium was more prevalent in the right ventricle 
of offspring from scramble-treated diabetic dams (8.3%, Figure 4.7I). No such defect was 
seen in offspring of diabetic dams administered with antimiR-122 (Figure 4.7L).   
Table 4.2. The rate of congenital heart defects in the offspring of diabetic dams 
treated with anti-miR-122 or scramble LNA. 
 STZ +  







 N dams N dams N dams N dams 
 36 7 39 5 24 2 17 2 
 n % n % n % n % 
Normal 16 44.4** 30 76.9†† 24 100.0 17 100.0 
Abnormal 20 55.6** 9 23.0††  0 0.0 0 0.0 
ASD 7 19.4* 6 18.5 0 0.0 0 0.0 
VSD 8 22.2* 2 4.2† 0 0.0 0 0.0 
AVSD 2 5.6 0 0.0 0 0.0 0 0.0 
DORV 2 5.6 0 0.0 0 0.0 0 0.0 
TGA 1 2.8 0 0.0 0 0.0 0 0.0 
Truncus 
Arteriosus  
1 2.8 0 0.0 0 0.0 0 0.0 
OA 1 2.8 0 0.0 0 0.0 0 0.0 
Vascular Ring 1 2.8 0 0.0 0 0.0 0 0.0 
PA Stenosis 1 2.8 0 0.0 0 0.0 0 0.0 
Thick PV 5 13.9 1 2.6 0 0.0 0 0.0 
Thick AV 7 19.4* 4 7.4 0 0.0 0 0.0 
NCVM 3 8.3 0 0.0 0 0.0 0 0.0 
 
Morphological analysis was performed on E18.5 hearts. Data was analyzed using the 
Chi-square test. *P<0.05, **P<0.001 vs. scramble control, †P<0.05, ††P<0.001 vs. 
scramble diabetes. ASD: atrial septal defect, VSD: ventricular septal defect, AVSD: 
atrioventricular septal defect, DORV: double outlet right ventricle, PA: pulmonary artery, 
OA: overriding aorta, PV: pulmonary valve, AV: aortic valve, NCVM: Non-compaction 






Figure 4.7. Effects of antimiR-122 on congenital heart defects induced by 
pregestational diabetes. 
Representative histological sections of E18.5 hearts from offspring of diabetic mothers 
either administered with antimiR-122 or scramble LNA during gestation. Scramble LNA 
administered to diabetic dams resulted in offspring with atrial septal defect (A), 
ventricular septal defect (B), double outlet right ventricle (C), thickened pulmonary (G) 
and aortic (H) valves, and noncompaction of the myocardium (I). AntimiR-122 treatment 
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reduced or fully prevented the incidence of these defects: intact atrial septum (D), intact 
ventricular septum (E), normal aortic connections (F), normal pulmonary (J) and aortic 
valves (K), and normal compact myocardium (L). Scale bars are 200 μm. 
 
4.5 Discussion 
 Pregestational diabetes is an established risk factor for CHDs, and increases the 
risk in infants by 3 to 5 times.5,7 The molecular mechanisms behind the pathogenesis of 
diabetes-induced cardiac malformations require further understanding, and effective 
preventative measures need to be elucidated. Here, we employ an ex vivo and in vivo 
approach to delineate the effects of miR-122 upregulation in embryonic heart 
development, and test the efficacy of antimiR-122 treatment in a clinically relevant 
model of diabetes-induced CHDs in mice. The results of this study demonstrate that 
pregestational diabetes results in a high incidence of offspring CHDs and impaired 
cardiac function, which are rescued by maternal antimiR-122 treatment. This study also 
shows an upregulation of miR-122 in embryonic hearts from diabetic dams, and 
experimentally verified its target genes critical to heart development. miR-122 decreases 
the proliferative capacity of the developing heart, increases apoptosis, and inhibits 




Figure 4.8. Schematic summary showing the effect of miR-122 on embryonic heart 
development. 
Our findings suggest that pregestational diabetes induces cardiac expression of miR-122 
in the early heart tube, which negatively affects heart development. miR-122 alters the 
expression of key genes involved in cell proliferation, apoptosis and epicardial EMT, 
processes crucial to proper cardiogenesis. AntimiR-122 administration to diabetic dams 
during gestation reduces the incidence of congenital heart defects in their offspring. 
 
 We recently demonstrated, using the same model of pregestational diabetes, the 
efficacy of the drug sapropterin dihydrochloride (Kuvan) at reducing the incidence of 
CHDs from 59.4 to 26.5% in E18.5 fetal mice.37 Accordingly, our previous work testing 
N-acetylcysteine treatment in this model prevented these cardiac malformations in a 
comparable fashion from 58.1 to 16.3%.43 In a similar manner, maternal exercise also 
abrogated the effects of diabetes on the fetal heart by reducing the rate of CHDs from 
56.8 to 25.0%.52 These studies, as well as others, all focus on mitigating the damaging 
consequences of hyperglycemia-induced oxidative stress on the embryonic heart.53-55 
187 
 
However, in the present study we show that antimiR-122 treatment to diabetic dams 
significantly reduces offspring CHD incidence from 55.6 to 23.0%, specifically 
decreasing the VSD rate from 22.2 to 4.2%, via a potential epigenetic mechanism. By 
controlling aberrant miR-122 upregulation during diabetic pregnancy, the incidence of 
offspring cardiac malformations is reduced, and normal cardiac function is restored. 
Since antimiR-122 or antioxidant treatment alone does not completely prevent diabetes-
induced CHDs, further studies are required to investigate whether the combination of 
antimiR-122 and N-acetylcysteine has a synergistic effect in preventing these 
malformations.  
  miRNAs play an indispensable role in cardiogenesis, acting as molecular 
switches, turning on and off gene programs controlling different stages of heart 
development.56 In fact, cardiac progenitor-specific deletion of Dicer, a cytosolic RNase 
essential for miRNA maturation, results in major CHDs, such as VSD and DORV, and 
can be embryonic lethal depending on progenitor lineage.57-59 Here we show a 3-fold 
increase in both miR-122 and pri-miR-122 in E12.5 hearts from diabetic dams. During 
embryonic development, miR-122 expression is normally limited to the developing liver, 
where it maintains hepatic transcriptome signatures, and has been shown to direct 
differentiation of mouse embryonic stem cells into hepatocytes.60,61 miR-122 is also 
regarded as a tumor suppressor, and miR-122 null mice spontaneously develop 
hepatocellular carcinoma.30  In the present study, we noted high miR-122 abundance in 
the fetal liver. Our novel finding is that miR-122 expression was elevated in embryonic 
hearts from diabetic dams. Expression of primary and precursor miR-122 transcripts 
follows circadian rhythm regulation, with expression fluctuating diurnally.62 However,  
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the mature miRNA is sustained at constant levels in the cytosol due to the cytoplasmic 
poly(A) polymerase, GLD2, which confers stability and prolongs the half-life of miR-122 
by adding a 3’ adenosine cap.41 In the present study, mRNA levels of GLD2 were 
significantly elevated in embryonic hearts from diabetic dams, suggesting miR-122 
stabilization is a possible cause of its higher levels in our model. To identify miR-122 
target genes critical to embryonic heart development, E10.5 and E12.5 heart explant 
culture was employed. Downregulations of Gata4 and Hand2 were seen with miR-122 
transfection. Gata4 is involved in SHF progenitor proliferation and differentiation, 
necessary for atrioventricular septation and OFT formation.63 Similarly, deletion of 
Hand2 in the cardiac neural crest results in VSD and DORVs, and in the SHF, Hand2 
protects the pharyngeal mesoderm against apoptosis.64,65 Accordingly, in the present 
study, miR-122 transfection to E10.5 hearts induced high levels of apoptosis. This data 
agrees with previous findings that transduction of miR-122 promoted cell apoptosis in 
H9C2 cultured cardiomyocytes, and that its knockdown enhanced cell survival.44 The 
increase in apoptosis could be due to miR-122 targeting the X-linked inhibitor of 
apoptosis (XIAP), relieving the inhibition of caspase-mediated programmed cell death 
pathways.66 miR-122-induced apoptosis was similar to levels seen in the high glucose 
conditions, which is consistent with our previous in vivo findings of increased cell death 
in the endocardial cushion of E12.5 hearts from diabetic dams.43 Targeting of the 
cardiogenic factors, Gata4 and Hand2, as well as induction of apoptosis by miR-122 may 
contribute to the diabetes-induced outflow tract defects, such as TGA, truncus arteriosus 
and DORV in E18.5 fetuses.  
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 Regulated cell proliferation is vital for cardiac morphogenesis and growth of the 
fetal heart. Proliferation deficiencies can result in thin, non-compact myocardium, 
shortening of the outflow tract and its incomplete septation, leading to the spectrum of 
CHDs.67,68 In the present study, miR-122 targeted and inhibited the expression of Cyclin 
D1, thereby halting cell cycle progression, which may translate into a reduced number of 
pHH3-postive cells in these heart explants. AntimiR-122 in high glucose conditions 
restored both Cyclin D1 levels and cell proliferation to normal. In addition to inhibiting 
cell cycle progression, miR-122 targets the growth factor receptors, TGFR2, IFG1R and 
FGFR1 in the liver.69,70 Ligands for these receptors, TGF-, FGF-10 and IGF-2, originate 
from the epicardium and promote proliferation and expansion of the adjacent 
myocardium.71-73 Furthermore, in the present study, E12.5 heart explants grown on 
collagen exhibited stunted outgrowth and epicardial EMT with miR-122 transfection. 
Their migratory capacity and outgrowth mirrored the hearts in high glucose conditions, 
which is in agreement with our previous findings.42 In fact, in a similar model of diabetes 
we have demonstrated an in vivo increase in E-cadherin expression, decreased Wt1-
postive cells in the epicardium, as well as a downregulation of transcriptional drivers of 
epicardial EMT.42 Here, we demonstrate that miR-122 targets and significantly reduces 
the transcript abundance of Snail, Slug and EPO by 2-fold. This is consistent with its role 
as a tumor suppressor, inhibiting EMT.74 Recently, studies have explored the association 
of miR-122 with TGF-1/Smad signaling or the Wnt/-catenin signaling pathway in the 
development of liver fibrosis or cancer, particularly focusing on EMT and 
tumorigenesis.45,75 They indicate that miR-122 reverses the ‘cadherin switch’ necessary 
for EMT, by increasing E-cadherin expression and decreasing N-cadherin levels via its 
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inhibition of Smad4.75 Likewise, addition of miR-122 mimic to HCCs significantly 
diminished Wnt1 and -catenin protein expression, decreasing tumor size.45 Finally, 
miR-122 targets the transcription factor RUNX2, which functions independent of 
Snail1/2 in mediating EMT 76,77 and should be investigated in the developing heart in 
future studies.   
 The presented study is constrained by only examining a T1D model, and currently 
the prevalence of pregestational T2D is on the rise.78 This is of particular interest as 
recent studies have revealed elevated levels of miR-122 in patients with obesity, insulin 
resistance and diabetic retinopathy, along with its already established roles as a 
biomarker for myocardial infarction and coronary artery disease.31,32,34,79-82 The reason 
for this upregulation remains to be determined, however there is an inverse association 
between miR-122 and leptin, which is deregulated in diabetic patients.83,84  
  In conclusion, the present study is the first to reveal the role of miR-122 in 
embryonic heart development, and provide novel insights into the mechanisms 
underlying pregestational diabetes-induced CHDs. We show that embryonic hearts from 
diabetic dams have elevated levels of primary and mature miR-122, and that this nucleic 
acid could be stabilized in the cytosol by increased expression of GLD2. miR-122 targets 
the 3’ UTR of many genes responsible for cardiogenesis, including Gata4, Hand2, Wnt1 
and Snail1/2, and specifically inhibits their expression ex vivo.  This epigenetic 
modulation impairs key developmental processes of cell proliferation, apoptosis, and 
epicardial EMT, mirroring the negative effects of high glucose. In addition, we utilized a 
LNA form of the experimental drug antimiR-122 to effectively reduce the incidence of 
pregestational diabetes-induced CHDs and restore cardiac function. AntimiR-122 
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treatment had no adverse effects on litter size, fetal liver histology, or heart development, 
and can be considered safe for studies on fetal mice. Currently, undergoing phase II 
clinical trials for the treatment of chronic hepatitis C infection, our study suggests that 
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Chapter 5  
5 Chapter 5  
5.1 Summary of Major Findings 
 The overall aim of this thesis was to explore the pathogenesis of pregestational 
diabetes-induced congenital heart defects (CHDs) and coronary artery malformations 
(CAMs), and investigate the efficacy and mechanisms behind two preventative strategies. 
Specifically, I studied the impact of elevated levels of eNOS uncoupling/oxidative stress 
and miR-122 during gestation on embryonic heart development in a model of 
streptozotocin-induced (STZ) pregestational diabetes in mice. Concurrently, we tested the 
efficacy of sapropterin and antimiR-122 pharmacotherapy on preventing a range of 
defects induced by pregestational diabetes. Altered gene expression, impaired protein 
activity and function, and deregulated cellular processes in embryos of diabetic dams 
resulted in morphological and functional congenital heart abnormalities at birth, which 
were reduced in incidence by both treatments. The experimental approaches used to carry 
out these experiments included histological analysis of heart structure, using a serial 
sectioning technique to accurately diagnose heart malformations. Next, we employed in 
vivo lineage tracing using transgenic mice to specifically map a group of cardiac 
progenitors. In addition, we performed ex vivo heart explant cultures to examine certain 
cellular processes under normal and high glucose conditions. Finally, we conducted 
immunostaining to identify certain cells, and molecular analysis of embryonic hearts via 
Western blotting or qPCR analysis.  
 Pregestational diabetes in the mother increases the risk of a CHD in the child by 
over 4-fold.1 In Chapter 2, I investigated the effects of maternal sapropterin treatment on 
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CHDs induced by pregestational diabetes in mice. To carry out this aim, C57BL/6 adult 
female mice were made diabetic via STZ administration, a model of pregestational 
diabetes previously employed in our lab. Mice were categorized as diabetic if non-fasting 
blood glucose measurements were above 11 mM. Pregnant diabetic dams steadily 
increased in hyperglycemia throughout gestation. The offspring of these mice were born 
in smaller litters, had a lower body weight, impaired cardiac function, and a spectrum of 
morphological anomalies, including both cardiac and neural tube defects. Daily 
sapropterin treatment throughout gestation did not impact the hyperglycemic state of the 
pregnant dams; however, it prevented a decrease in fetal weight, and improved the 
functional and morphological defects in the hearts of the offspring. Importantly, oral 
sapropterin treatment to diabetic dams significantly decreased the incidence of CHDs 
from 59.4% to 26.5%, and all major malformations, such as AVSD and DORV, were 
absent in the treatment group. A higher proportion of male offspring had CHDs, and 
sapropterin treatment was effective in lowering the incidence of CHDs in both sexes. 
Fetal hearts from diabetic dams had thinner ventricular free walls, and thicker aortic, 
pulmonary and mitral valves, indicating defects in myocardialization and valve 
remodeling, respectively. Sapropterin treatment recovered the thickness of ventricular 
compact myocardium, and improved cardiac valve remodeling. In addition, treatment 
with insulin to diabetic dams restored normal blood glucose levels and resulted in no any 
CHDs, indicating that malformations in the offspring of diabetic dams were due to 
hyperglycemia. To determine the mechanism of hyperglycemia-induced CHDs, 
cardiogenesis was examined at different time-points during embryonic development. 
Lineage tracing of cardiac progenitors using the SHF-specific Mef2ccre/+ transgenic 
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mouse and the global double fluorescent Cre reporter line Rosa26mTmG was conducted at 
E9.5 and E12.5. Analysis revealed a lower commitment of SHF progenitors to the OFT, 
endocardial cushions, and ventricular myocardium of the fetal heart. In fact, embryonic 
hearts from diabetic dams had a shortened OFT length at E10.5, along with less cell 
proliferation in both the OFT and ventricle, which was normalized with sapropterin 
treatment. Accordingly, gene expression analysis of E12.5 hearts demonstrated lower 
mRNA levels of key cardiac transcription factors, such as Gata4, Tbx5, Nkx2.5, Gata5, 
which were restored to normal with sapropterin treatment. Sapropterin treatment also 
restored the expression of dihydrofolate reductase (Dhfr), responsible for the conversion 
of BH2 to BH4. These cellular and molecular alterations, induced by pregestational 
diabetes, could be attributed to elevated levels of ROS, observed in E12.5 hearts of 
diabetic dams via DHE-probe. Sapropterin treatment reduced ROS to the same levels as 
L-NAME and superoxide dismutase pre-treatment to embryonic hearts from diabetic 
dams, indicating eNOS-derived superoxide production. Furthermore, analysis of eNOS 
dimerization via western blotting showed a loss of the functional eNOS dimer in E12.5 
hearts from diabetic dams, and re-coupling of the enzyme with sapropterin treatment. 
Overall, this study demonstrated the efficacy of the FDA-approved drug sapropterin 
(Kuvan®) at preventing pregestational diabetes-induced CHDs by restoring gene 
expression profiles, improving eNOS coupling, reducing ROS, and increasing cell 
proliferation. 
 The development of coronary vessels that perfuse the cardiac muscle occurs 
concurrently with heart development.1 This process is reliant on coordinated epicardial 
EMT and eNOS-derived NO, and missteps can result in CAMs.2 In fact, eNOS-/- mice 
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display hypoplastic coronary arteries and postnatal myocardial infarction.3 To this end, in 
Chapter 3, we examined the effects of sapropterin on coronary artery development in 
embryonic hearts of mice with pregestational maternal diabetes. This study was 
conducted using the same model of pregestational diabetes and sapropterin administration 
as Chapter 2. Treatment with sapropterin to mice with pregestational diabetes resulted in 
a lower incidence of CAMs in their offspring from 50.0% to 20.6%. Histological analysis 
revealed coronary arteries with marked decreases in luminal diameters, abundance and 
volumes in fetal hearts from diabetic dams. In addition, capillary density within the 
myocardium was lower in these hearts. Sapropterin treatment prevented diabetes-induced 
fetal hypoplastic coronary arteries and restored capillary density. One source of coronary 
artery progenitors is the epicardium. Epithelial cells delaminate and migrate into the 
myocardium, where they differentiate into vascular smooth muscle cells, fibroblasts and 
endothelial cells, the components of coronary arteries.2 As such, the epicardium of E12.5 
hearts from diabetic dams was examined, and fewer actively proliferating cells were 
noted. In addition, these hearts had a lower number of Wt1+ cells and higher expression 
of E-cadherin, indicating an impairment in epicardial EMT, which was returned to 
normal with sapropterin treatment. To further explore the behavior of epicardial-derived 
(EPDC) coronary artery progenitors, E12.5 embryonic hearts were explanted onto a 
collagen matrix and cultured ex vivo. Consequently, tetrahydrobiopterin, infused into the 
culture media, prevented the lower EPDC outgrowth and number under high glucose 
conditions. In a similar manner as Chapter 2, the mRNA levels of key molecular 
regulators of coronary artery development involved in EMT, differentiation, and growth, 
were examined. The expression of Hif-1, Snail1, Aldh1a2, -catenin and bFGF, was 
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lower with maternal diabetes and reestablished with sapropterin treatment. 
Mechanistically, these compromised molecular pathways and cellular processes can be 
attributed to increased oxidative stress in the ventricular myocardium of E12.5 hearts 
from diabetic dams. The increase in lipid peroxidation was attenuated with sapropterin 
treatment. Moreover, Akt and eNOS phosphorylation was lower in embryonic hearts 
from diabetic dams, and was returned to basal levels with sapropterin treatment. Taken 
together, this data demonstrated the therapeutic potential of the FDA-approved drug 
sapropterin at preventing pregestational diabetes-induced CAMs. This study also 
provides insight into factors contributing to altered coronary artery development, such as 
impaired Akt/eNOS activity and oxidative stress.  
 Thus far, in Chapter 2 and Chapter 3 of this thesis, oxidative stress and impaired 
eNOS-derived NO signaling was been investigated as a major driver of diabetic 
embryopathy. In addition to elevated oxidative stress, pregestational diabetes may alter 
maternal/fetal microRNA profiles, leading to the pathogenesis of CHDs.4,5 Recent 
clinical data indicates that miR-122 is elevated in patients with impaired glucose 
tolerance, insulin resistance and obesity, and is a biomarker for cardiovascular disease.6-9 
In Chapter 4, I studied the role of miR-122 in the pathogenesis of pregestational 
diabetes-induced CHDs. To achieve this goal, we implemented ex vivo and in vivo 
experimental approaches to determine the effect of miR-122 on heart development, and 
antimiR-122 pharmacotherapy on mitigating diabetes-induced CHDs in mice. Along with 
confirming higher levels of miR-122 in E12.5 hearts from diabetic dams, an upregulation 
of primary-miR-122 was also noted. As miR-122 functions to inhibit the expression of 
mRNA transcripts, the levels of key cardiogenic targets of miR-122 were examined by 
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qPCR. Genes critical for cell cycle progression, angiogenesis, and heart development, 
such as Cyclin D1, Snail1, Gata4 and Hand2, were downregulated in normal E10.5 hearts 
transfected with miR-122. Antagonism using antimiR-122 to hearts cultured in high 
glucose media restored normal expression of these genes. Furthermore, transfection of 
miR-122 to heart explants inhibited cell proliferation, increased apoptosis and inhibited 
epicardial EMT, to the same level as explants exposed to high glucose levels. The high 
glucose-induced deregulation of these cellular processes was prevented by antimiR-122 
transfection. Since these experiments suggest that elevated levels of miR-122 disturb key 
process of cardiac development, in vivo administration of antimiR-122 was tested for its 
effects on pregestational diabetes-induced CHDs. To this end, diabetes was induced in 
female C57BL/6 female mice using the same method as in Chapter 2 and 3; however, 
prior to breeding, diabetic mice were administered 10 mg/kg LNA antimiR-122 or 
scramble control, subcutaneously. Another dose was injected at E7.5, and heart 
morphology was examined at E18.5 following fetal echocardiography. The blood glucose 
levels of diabetic dams increased progressively throughout gestation, and neither LNA 
treatment had any effect on glycemic levels. An equal number of males and female 
offspring from scramble LNA-treated diabetic dams had CHDs, and antimiR-122 
treatment was more effective in reducing the incidence of CHDs in male offspring. No 
significant changes in offspring litter size was noted between groups. Further, antimiR-
122 treatment prevented cardiac dysfunction, measured through M-Mode analysis of LV 
ejection fraction and fractional shortening, in offspring of diabetic dams. A spectrum of 
CHDs was observed in offspring of scramble LNA-treated diabetic mice, which were 
consistent with the malformations observed in Chapter 2. In fact, the total ratio of 
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abnormal fetal hearts was stable, upwards of 50%, between this thesis and previous 
studies using the same model of pregestational diabetes.10 Notably, the incidence of 
CHDs in the offspring of diabetic dams was reduced from 55.6% to 23.0% by antimiR-
122 administration. Overall, this study is the first to reveal the role of miR-122 in the 
pathogenesis of pregestational diabetes-induced CHDs, and demonstrates the efficacy of 
in vivo antimiR-122 treatment at reducing the incidence of these cardiac malformations.  
 In summary, the results of this thesis highlight the potential protective effects of 
sapropterin and antimiR-122 treatment against pregestational diabetes-induced CHDs. 
We show that daily sapropterin therapy to diabetic dams inhibits oxidative stress and 
eNOS dysfunction in the embryonic heart, which regulates cardiogenic gene expression. 
This normalized impairment in cell proliferation and epicardial EMT, leading to normal 
heart and coronary artery development. Additionally, we showed that the incidence of 
CHDs in offspring of diabetic dams could be reduced via a miRNA-mediated 
mechanism. By relieving the repression of targets of miR-122, antimiR-122 treatment 
restored cellular processes of cell proliferation, apoptosis and epicardial EMT to normal 
levels, reducing the incidence of CHDs. A summary of findings from these studies is 




















Figure 5.1. The role of eNOS uncoupling/oxidative stress and miR-122 in the 
pathogenesis of pregestational diabetes-induced congenital heart defects. 
Pregestational diabetes leads to a concurrent increase in oxidative stress and miR-122 in 
the embryonic heart. This brings about eNOS uncoupling, leading to a reduction in many 
critical factors. Cell proliferation, apoptosis, and epicardial EMT are perturbed, and lead 
to CHDs. Treatment with sapropterin or antimiR-122 reduces the incidence of these 
malformations by regulating heart development, albeit through different mechanisms.  
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5.2 Study Limitations 
5.2.1 Justification of a Mouse Model of Pregestational Diabetes 
 Diabetes is a global health issue with a rapidly increasing prevalence, and is 
estimated to affect 693 million people by 2040.11 Currently, 40% of women with diabetes 
are of reproductive age.12 T1D is characterized by autoimmune destruction of pancreatic 
-cells, resulting in a lack of insulin production; whereas, T2D is the result of insulin 
resistance and usually has a later onset, but is much more prevalent.13 Biomedical 
research utilizes various experimental approaches to study diabetes. In animal models, 
diabetes can be induced via many techniques, including diet, drugs, surgery, or genetic 
alterations. A common, established method for the generation of a T1D model in rodents 
is STZ administration.14, 15 This chemical agent is a glucose analogue, which is taken up 
by pancreatic -cells via the glucose transporter 2 (GLUT2). STZ within the cell causes 
DNA damage, oxidative stress, and ultimately results in cell death.16 This depletion of 
pancreatic -cells and thereby insulin supply recapitulates T1D in humans. A benefit of 
using this model of diabetes is the relatively quick induction period, taking approximately 
7 days for the onset of hyperglycemia. In addition, this method is fairly cost-effective, 
and requires a simple high dose or multiple low doses of intraperitoneal injections. 
However, a drawback to this approach remains the potential off-target effects of STZ, 
such as carcinogenesis.17 Nevertheless, as seen in Chapters 2 and 3, insulin 
administration to STZ-induced diabetic dams did not result in CHDs or CAMs, 
suggesting that STZ does not impose any teratogenic effects on the heart. Another 
limitation of this model is that clinically, most women with pregestational diabetes are 
insulin resistant, meaning they have T2D.12 The pathogenesis of T2D has environmental 
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and lifestyle components, altering a patient’s metabolism.13 Although a T2D model may 
be more clinically relevant, effectively reproducing it without confounding variables, 
such as a high-fat diet or genetic modifications, remains difficult. In fact, previous 
experiments done in our lab indicate that mice on a prolonged period of high-fat diet 
rarely reach hyperglycemic levels needed to induce CHDs in their offspring. While T1D 
and T2D have systemic physiological differences, in this study, elevated levels of blood 
glucose was regarded as the primary factor behind diabetic embryopathy.18 Importantly, 
in the clinic, both types of diabetes in women confer an equal risk of having a child with 
a CHD.19 Therefore, by using a STZ-induced model of pregestational diabetes in this 
thesis, a consistently high rate of CHDs and CAMs were noted, which enabled testing the 
efficacy of two pharmacotherapies. 
5.2.2 Genetically Altered Mice 
 Mice represent a practical and appropriate model organism to study physiological 
concepts, understand human diseases, and develop potential therapies. Embryonic heart 
development and the genetic and molecular mechanisms leading to congenital heart 
disease in humans, have been extensively studied using mouse models.20 Cardiac 
anatomy and developmental pathways are very similar between humans and mice.21 
Sequencing of the mouse genome revealed approximately 99% homology of genes to the 
human genome.22 In addition, manipulation of the mouse genome is relatively simple, 
even more so now with the advances in CRISPR technology, allowing for endless 
possibilities in studying development and disease. One of these genetic engineering 
technologies utilized in Chapter 2 of this thesis was the Cre/loxP system, which enabled 
lineage tracing of SHF cardiac progenitors.23 Specifically, we used the anterior SHF-
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specific Mef2c-Cre transgenic mouse and the global double fluorescent Cre reporter line 
Rosa26mTmG to trace and characterize the development of SHF-derived cardiac structures, 
broadening our knowledge of heart development under pregestational diabetes.24 Along 
with the many benefits of using this technology, some possible limitations of the 
Cre/loxP system exist. The insertion of the Cre recombinase gene or the lox P sites into 
the mouse genome could alter expression of surrounding genes.25 In addition, 
endonuclease activity of Cre recombinase can have toxic effects.26 Although driven by a 
tissue-specific promoter, the expression of Cre can occur in unwanted tissues. For 
instance, in lineage tracing experiments, all descendants of the original cell expressing 
Cre will be labeled with the reporter. Moreover, the Mef2c-Cre transgene is considered a 
“leaky” Cre, as mesodermal cells in other organs can also be labeled. In fact, in these 
mice, full body expression of Cre recombinase has been noted when this transgene is 
inherited via females. To mitigate this, the Mef2c-Cre transgene remained on a single 
allele and was inherited as a single copy in male mice.27 In spite of the drawbacks, the 
ability to lineage trace the SHF using the Cre/loxP system in this thesis demonstrated a 
specific insult of diabetic pregnancy to SHF progenitors, directly contributing to the 
septal and OFT defects in fetal mice. 
5.2.3 Use of ex vivo Organ Culture Systems 
 In Chapters 3 and 4 of this thesis, embryonic hearts were explanted and grown ex 
vivo to delineate the effects of high glucose, tetrahydrobiopterin (BH4), miR-122 or 
antimiR-122 on many parameters intimately linked to heart development. Specifically, in 
Chapter 3, E12.5 heart ventricles from control dams were isolated in sterile conditions 
and explanted onto a collagen matrix to study epicardial EMT and migration of 
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epicardial-derived cells (EPDCs). This enabled us to determine the migratory capacity of 
coronary artery progenitors under conditions of high glucose and when exposed to BH4, 
providing support to our immunohistological data in vivo. Similarly, in Chapter 4, this 
EMT assay was performed; however, in addition to simulating a diabetic pregnancy ex 
vivo with high glucose, miR-122 and antimiR-122 were transfected into these explants. In 
addition, E10.5 hearts from non-diabetic dams were explanted onto plastic and exposed 
to the above conditions for gene expression, cell proliferation and cell death analysis. 
Limitations exist with using these types of organ culture systems. For instance, in the 
embryo, blood vessels supply cardiac progenitors with continuous nourishment and 
remove cellular waste products. This is not matched in experimental conditions as 
growing heart explants on top of a collagen matrix or plastic well does not effectively 
replicate the in vivo environment of the cells, and could result in an altered response. In 
addition, the biomechanical forces within the live embryo, including the shear stress on 
cells by blood flow, cannot be simulated in this ex vivo setting. Finally, in Chapter 4, 
miR-122 or antimiR-122 were delivered to embryonic heart explants using the JetPrime 
transfection reagent and buffer system. Although considered generally less toxic and 
more efficient method of delivery compared to electroporation, sonoporation or viral 
transduction, the incubation time and ratio of nucleic acid to transfection reagent must be 
carefully optimized. Despite these drawbacks, employing this organ culture system was 
critical to advance our understanding on the impact of high glucose, BH4, and miR-122 
on embryonic cardiovascular development, and support our in vivo findings.  
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5.3 Suggestions for Future Studies 
 This thesis investigated the pathogenesis of congenital abnormalities of the heart 
induced by pregestational maternal diabetes. We tested two clinically relevant 
pharmacotherapies and elucidated developmental pathways leading to a spectrum of 
cardiac and coronary artery defects.  However, further research is warranted regarding the 
effects of sapropterin and antimiR-122 on diabetic embryopathy.   
 All three chapters of this thesis investigate a model of T1D in mice. Indeed, both 
pregestational T1D and T2D diabetes in patients induce CHDs in newborns.19 However, 
T2D is more prevalent in the population, encompassing 90-95% of cases, and can be 
brought about by environmental factors, such as obesity, which can also impact fetal 
heart development.13 Future animal studies should try to model T2D and its metabolic 
complications, while testing therapeutics like sapropterin and antimiR-122 on fetal 
cardiovascular malformations. The FDA-approved drug sapropterin (Kuvan ) has an 
acceptable safety rating and with very minor adverse effects, and represents a viable 
option for pregnancies affected with T2D.28  
 This thesis examined the impact of two distinct treatments on diabetes-induced 
CHDs. Sapropterin and antimiR-122 decreased the incidence of CHDs from 59.4% to 
26.5%, and from 55.6% to 23.0%, respectively. As such, neither therapy had complete 
penetrance at preventing cardiac malformations. Although sapropterin prevented all 
major CHDs, such as AVSD, VSD, and DORV, minor defects like ASD, valve 
thickening and ventricle thinning were still present. Since sapropterin and antimiR-122 
function via distinct mechanisms on mitigating perturbations in heart development, as 
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demonstrated in this thesis, a combination of both agents may further reduce the 
incidence of CHDs and should be examined in future studies. Correspondingly, previous 
studies in the same model of diabetes have demonstrated the beneficial effects of N-
acetylcysteine (NAC) and maternal exercise on reducing the incidence of these defects by 
maintaining the oxidative balance within the embryonic heart.10, 29 Future studies should 
test attenuating elevations in oxidative stress and miR-122 by sapropterin, NAC or 
maternal exercise, and antimiR-122 together, and investigate possible synergistic effects 
at preventing CHDs induced by pregestational diabetes.   
 In Chapter 2, I performed lineage tracing experiments to map SHF progenitors 
using the anterior SHF-specific Mef2c-Cre transgenic mouse, as many of the CHDs 
present at birth were in structures originating from the SHF. All SHF-derived cells and 
structures were GFP+ and therefore easily identifiable, and our findings indicated a 
specific insult of diabetic pregnancy on these progenitors, which could account for the 
septal and OFT defects. However, the impact of sapropterin treatment on this group of 
cells in particular was not examined, and should be tested in future studies. Conversely, 
in Chapter 3, we observed pregestational diabetes-induced CAMs and demonstrated a 
deficiency in epicardial EMT as a causal factor, reversed by sapropterin treatment. 
Indeed, coronary artery progenitors delaminate from the epicardium via EMT and 
migrate into the myocardium where they differentiate into vascular smooth muscle cells 
and fibroblasts, forming vessels.2 However, lineage tracing experiments confirm that the 
sinus venosus and endocardium also contribute to the formation of these arteries.30 In 
fact, the majority of the coronary arteries that perfuse the septum are endocardial-
derived.30 Future studies should employ lineage tracing using the Apj-CreER and the 
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Nfatc1-Cre transgenic mice to map sinus venous and endocardial contributions to 
coronary arteries in the embryonic heart from diabetic dams, respectively.30 This analysis 
should be conducted with both sapropterin and antimiR-122 treatment. In Chapter 4, 
antimiR-122 is effective at restoring epicardial derived cell (EPDC) outgrowth and 
number ex vivo, however the efficacy of antimiR-122 treatment at reducing the incidence 
of CAMs should also be defined in vivo.  
 Cardiac and coronary artery malformations were the focus of this thesis. 
However, in Chapter 2, one extra-cardiac defect, exencephaly, was reported. It has been 
well documented that along with CHDs, neural tube defects in the offspring can result 
from gestational hyperglycemia.31-33 In fact, a study using a similar model of STZ-
induced diabetes noted a 3-fold increase in offspring neural tube defects in comparison to 
our study.32 The pathogenesis of these defects may differ from CHDs; however, 
sapropterin or antimiR-122 therapy should be tested on the formation of cranial structures 
during diabetic pregnancy. Similarly, in Chapter 3, the development of the coronary 
vasculature was analyzed; however, pregestational diabetes may have consequences on 
vessel development in other parts of the body. Mouse models of maternal diabetes have 
demonstrated hyperglycemia-induced vasculopathy in the yolk sac, with specific insult to 
vascular endothelial cells by oxidative stress.34 Although the role of eNOS has not been 
explored in these studies, sapropterin therapy may have potential in mitigating these 
vascular abnormalities.  
 Additionally, in Chapter 4, I demonstrated that in vivo treatment with antimiR-
122 reduced the incidence of CHDs in pregestational diabetes. This study utilized a 
pharmacological approach to correct a genetic irregularity. It would be of particular 
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interest to also determine if conditional knockout of miR-122 in the developing heart can 
reduce the incidence of CHDs induced by pregestational diabetes to the same extent. 
Using the Cre/loxP system, a floxed miR-122 could be excised by Cre recombinase in the 
diabetic embryonic heart driven by the cardiac-specific Nkx2.5 promoter. A complete 
knockout of miR-122 would not be ideal as it is necessary for liver homeostasis and 
could result in hepatocellular carcinoma.35 Finally, as discussed before, a T2D model 
may have greater relevance, especially as an extension of Chapter 4. In patients with 
obesity, insulin resistance, and diabetic retinopathy, elevated circulating levels of miR-
122 have been reported.6-9, 36 Therefore, plasma levels of miR-122 should be analyzed in 
both a T2D and STZ-induced model of diabetes. In addition, plasma samples from 
diabetic patients should be analyzed to confirm reported findings. As miR-122 plays an 
important role in cholesterol and fatty acid metabolism in the liver, and is a potential 
prognostic marker for adult cardiovascular disease, elucidating its deregulation in 
diabetes is imperative.37-40  
5.4 Conclusion 
 This thesis provides evidence for the critical roles of oxidative stress, eNOS and 
miR-122 in heart and coronary artery development in a mouse model of pregestational 
diabetes. Here, I demonstrate for the first time that pregestational diabetes impairs eNOS 
coupling and elevates levels of oxidative stress and miR-122, leading to functional and 
morphological cardiovascular anomalies in the offspring of diabetic dams. These 
malformations range in severity, and include ASDs, VSDs, OFT defects, ventricular 
myocardium defects, and hypoplastic coronary arteries. Additionally, I have shown that 
deficits in cardiogenic gene expression, enzyme activity, cell proliferation, and epicardial 
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EMT, induced by pregestational diabetes, contribute to the development of these defects. 
Importantly, this thesis exhibits the efficacy of two clinically relevant pharmacotherapies 
at regulating heart development disturbed by diabetic pregnancy. Treatment with 
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